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Al though beta-blockers are considered among first line 
antihypertensive agents, it is well recognized that not all 
patients respond to usual doses with an adequate drop in 
blood pressure. Beta-blockers have been reported to be less 
effective in blacks and the elderly although the reasons 
for the inadequate blood pressure response have not been 
determined with any certainty. 
Accordingly, the objectives of the study were to administer 
50 mg of IV atenolol to normotensive healthy black and 
white volunteers and to: 
i) document any ethnic differences in blood pressure 
heart rate and plasma renin activity responses; 
ii) assess the pharmacokinetics of atenolol in blacks and 
whites; 
ii) define the atenolol concentration effect relationship 
wi th respect to reduction in exercise HR in 
individuals in order to ascertain if any ethnic 
differences exist with respect to maximal effect or 
sensitivity to beta,-blockade. 
Sixteen normotensive subjects (8 black and 8 white) between 
the ages of 20 and 30 years participated in the study, 
which was placebo controlled, single blind and crossover in 
design. Blood was sampled at intervals for 36 hours after 
placebo or atenolol administration in order to measure 
atenolol concentrations (14 subjects) and . plasma renin 
activity (5 black and 5 white subjects). Supine and erect 
systolic and diastolic BP were measured at intervals after 
drug and placebo administration as was resting and exercise 
HR. The periodi c sub-maximal exercise entailed bicycle 
ergometry for 3 minutes, at a constant load predetermined 
to raise HR to at least 140 beats per minute in that 
individual. 
Initially, the pharmacodynamic data (BP, HR and PRA) was 
iv 
analyzed in isolation from concentration. Analysis of 
variance (ANOVA) was used to discern if the drug caused any 
effect relative to placebo at each time point of 
measurement, and if so whether the effect might differ 
between the races. The difference in area under the curve 
(AUC) from 0 to 12 hours after placebo and atenolol was 
employed as an alternative approach in assessing an 
individual or group's overall response to ' atenolol. 
Responses to atenolol were similar to those reported by 
other investigators. As expected atenolol had the greatest 
and most consistent effect on exercise tachycardia. The 
effects of atenolol on resting HR, systolic and diastolic 
BP were slower in onset and were influenced to a far 
greater extent b y factors other than treatment, leading to 
baseline noise in the measurements. The PRA showed great 
intra- and inter-individual variation. There were no marked 
racial differences in treatment response in the ANOVA time 
point analysis for any of the effects measured. However, 
using AUC differences, supine systolic BP was found to be 
lowered significantly less in black individuals compared to 
whi tes. Moreover, this supine systolic BP response in 
individuals showed a significant correlation with baseline 
PRA (r2=O.5782 , p<O.0107). Unfortunately, there were 
insufficient measurements to detect possible differences in 
the regression line between blacks and whites . 
The atenolol plasma-concentration time data was analyzed in 
14 volunteers, by model independent methods as well as by 
compartmental modelling using two and three compartment 
open pharmacokinetic models. The compartmental modelling 
involved the use of two alternative approaches: 
i) the standard two stage (STS) method where data from an 
individual was used to generate pharmacokinetic 
parameters for that individual by extended least 
squares (ELS) regression. The individual data was then 
grouped and the black and white groups compared. 
ii) NONMEM anal ysis of data from all volunteers was used 
v 
to give group parameter estimates with quantitation of 
inter- and intra-individual variation in parameters. 
Race as a possible factor affecting inter-individual 
parameter variation was evaluated. 
Model independent mean estimations of CL (17.4 L/hr) and Vss 
(126 L) were consistent with STS two compartment modelling 
( CL of 17.2 L/hr and V of 126 L). However, NONMEM analysis ss 
indicated that a three compartment model described the data 
better than a two compartment model. The three compartment 
NONMEM parameter estimations of CL and Vss were 13.6 L/hr 
and 151.6 L respectively. Although terminal elimination 
half-life was consistent with literature values, the model 
independent and two compartment CL and Vss values were 
larger than published values. The 3 compartment NONMEM CL 
value was much closer to reported values of 11-12 L/hr for 
healthy young volunteers. None of the methods showed any 
ethnic differences in the disposition of atenolol. 
The last stage of the study involved the fitting of 
pharmacodynamic models to the effect data (in individuals 
by ELS regression and in the group by NONMEM) with the 
pharmacokinetic parameters constrained to those from the 
best fit pharmacokinetic analysis. The linear, log-linear 
E~ and sigmoid E~ models were evaluated. Because of the 
inadequate design of the study in that too few measurements 
were carried out when effect was undergoing maximal change, 
the fitting of individual effect data was problematic. In 
11 of the 14 subjects the E~ or sigmoid E~ model gave a 
reasonable fit with no significant differences noted 
between blacks and whi tes 
Using NONMEM, t he sigmoid 
appropriate with estimated 
and slope (n) of 42.7 
in ei ther E~ or ICse values. 
E~ model appeared the mos t 
parameter values for E~, ICse 
bpm, 32.4 ng/ml and 0.783 
respectively. Race did not influence the inter-individual 
variation in either E~x or ICse to any significant degree. 
In conclusion, there was no significant ethnic difference 
vi 
in the pharmacokinetics of the drug nor was there any 
difference in the sensitivity of the beta,-receptors 
responsible for exercise tachycardia. In the light of the 
above, the finding of a significantly lower overall 
systolic BP response as measured by difference in AUC 
between placebo and atenolol in normotensive blacks when 
compared to whi t es was surprising. The difference needs to 
be confirmed by further studies in hypertensive patients. 
The utilization of NONMEM for pharmacokinetic-dynamic 
modelling and dose ranging studies with beta-blockers where 
effect variabil i ty is related across a continuum to factors 
such as PRA, is a potentially powerful tool in elucidating 
the mechanism of action of these agents as well as the 
factors predicting response variability across populations. 
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INTRODUCTION 
Since their introduction into clinical medicine in the mid-
1960s the beta-adrenoceptor blocking drugs have become the 
most commonly prescribed drugs for cardiovascular diseases 
including hypertension, angina pectoris and cardiac 
arrhythmias (Weiner 1985). Their efficacy as 
antihypertensive agents is evidenced by their having been 
considered first line drugs in mild to moderate 
hypertension in many countries, especially in Europe. In 
the USA they were slower to gain acceptance and were 
generally considered the second line of treatment following 
thiazide diuretics (Kaplan 1983, Thadani 1983). 
It is recognized that there are some patients who do not 
respond with an adequate fall in blood pressure when given 
usual antihypertensive doses of beta-blockers. Blacks and 
the elderly are amongst those reported to be less likely to 
respond to beta-blockade (Opie 1983, Thadani 1983). 
Since the first report of limited efficacy of propranolol 
in hypertensive Jamaicans (Humphreys & Delvin 1968) many 
other studies have pointed to a relatively poor anti-
hypertensive response to beta-blockers in blacks (Abson et 
al 1981, Richardson et al 1968, Seedat & Reddy 1971, Seedat 
1980, veterans Administration Cooperative Study Group on 
Antihypertensive Agents 1982a, 1982b, 1983). 
The South African black urban population appears to have a 
particularly high incidence of hypertension and this is 
associated with high morbidity and mortality (Seedat 1983). 
Wi th increasing urbanization the problem is likely to 
become ever greater. It is therefore necessary to have safe 
and relatively cheap agents which can effectively lower 
blood pressure. The apparent lack of efficacy seen wi th 
beta-blockers is thus an important issue. 
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Although beta-blockers have been in use for over 25 years 
their mode of antihypertensive action remains unclear. 
Since all beta-blockers, regardless of ancillary 
properties, lower blood pressure to the same extent, it is 
certain that the antihypertensive effect is some function 
of beta,-receptor blockade, albeit indirect and apparently 
delayed relative to chronotropic effects. On the other hand 
it has been claimed that there is no relationship between 
antihypertensive effect and either plasma concentration or 
beta,-receptor blockade as measured by reduction in exercise 
tachycardia (McDevitt 1979). There are thus a number of 
questions to be answered: 
i) How do beta-blockers lower blood pressure? 
ii) What is the relationship between concentration and 
antihypertensive effect? (There must be some 
relationship even if it is not direct). 
iii) Why is it that people do not all respond with an 
adequate fall in blood pressure? 
iv) Is the apparent poor response in the elderly and in 
blacks related to alterations in beta-receptor 
sensi ti vi ty or the intrinsic acti vi ty of the beta-
receptor system or is it due to pathophysiology at 
another level of blood pressure regulation? 
Accordingly, the objectives of the study were: 
1. To document any differences between black and white 
normotensive volunteers in blood pressure and heart 
rate responses to the administration of intravenous 
atenolol. 
2 . To define the atenolol concentration-effect 
relationship with respect to inhibition of exercise 
tachycardia in individual volunteers. 
3. To ascertain whether racial differences exist in the 
above relationship with regard to maximal response and 
sensitivity to beta- blockers. 
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CHAPTER 1 
AN OVERVIEW OF THE PHARMACODYNAMICS AND PHARMACOKINETICS 
OF BETA-BLOCKERS 
1.1. PHARMACODYNAMICS OF BETA-BLOCKERS 
Sir Henry Dale, among the first to study adrenergic 
blockade, recognized that adrenaline had· two distinct sets 
of actions, only one of which could be blocked with ergot 
(Dale 1906). However, it took more than 40 years before 
Ahlquist (1948) introduced the concept of alpha- and beta-
adrenergic receptors. 
It took a further 10 years before the first beta-adrenergic 
blocking agent, dichloro-isoproterenol was described, 
al though its clinical usefulness was limited by a high 
degree of intrinsic sympathomimetic acti vi ty (Powell & 
Slater 1958, Moran & Perkins 1958). Sir Jim Black's group 
conceived the idea of using beta-blockers to treat angina 
and introduced the first clinically relevant agent, 
pronethalol, which had to be withdrawn because of tumour 
production in mice (Black & Stephenson 1962, Dornhorst & 
Robinson 1962). Subsequently Black et al (1964) introduced 
propranolol which, to date, remains one of the most widely 
used beta-blockers. 
On the basis of differential responses to beta-agonists, 
Lands et al ( 1967) suggested subdividing beta-receptors 
into beta,- and beta2-receptors. This led to a search for 
and the introduction of a relatively cardioselective beta,-
blocker, practolol (Sandler & Clayton 1970). Since then, 
many beta-blocking agents have been developed and marketed. 
In the 1970s and 1980s they were amongst the most widely 
used drugs in cardiovascular medicine. 
1.1.1. Properties of Beta-blocking Drugs 
Although all beta-blockers are competitive inhibitors of 
the effects of catecholamines at beta-receptors they differ 
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with respect to ancillary properties such as selectivity 
for beta-receptor subtypes, intrinsic sympathomimetic 
activity and membrane stabilizing activity. 
They all have at least one asymmetric carbon atom and thus 
exist as pairs of optical isomers. Beta-blockade is a 
stereospecific effect and the laevorotatory (I) or (-) 
isomer is much more potent in this respect than the dextro-
rotatary (d) or (+) isomer. The (-) isomer of propranolol 
has 50 to 100 times the beta blocking capacity of the (+) 
isomer (Gibson 1974). Most beta-blockers are, however, 
marketed as racema tes wi th the exception of ( - ) timolol 
(Drayer 1986). 
Beta-blockers with relative selectivity (Table 1.1.) for 
blocking the cardiovascular effects of catecholamines were 
developed in an effort to minimise the risk of side effects 
on the bronchi, blood vessels and metabolism, associated 
wi th blockade of beta2-receptors (Cruikshank 1980, Shand 
1983). Clinically, the selective agents may be preferable 
in smokers and in diabetics where a diastolic pressor 
response could occur under non-selective blockade 
(Cruikshank 1980). 
A number of the beta-blockers show a measurable response in 
the absence of an agonist, indicating that they are partial 
agonists (Table 1.1.). This property is termed intrinsic 
sympathomimetic activity (ISA) or partial agonist activity 
(PAA). The clinical relevance of ISA has been much debated 
(Opie 1983, Thadani 1983, Shand 1983) but the suggestion 
that ISA conveys protection in heart failure and asthma has 
not been conclusively proved (Shand 1983). Agents with ISA 
cause less resting bradycardia, less reduction in cardiac 
output and have a flatter dose response curve (Harry et al 
1979, Shand 1983). This is true in both normotensive and 
hypertensive patients and applies irrespective of the 
cardioselecti vi ty of the blockers (Svendsen et al 1979, 
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Svendsen et al 1981, Svendsen et al 1985). Assessment of 
concentration response relationships of beta-blockers with 
ISA in vivo is complicated. The concentration of endogenous 
agonist present is variable and generally unknown and, 
particularly at low concentrations, will have a marked 
influence on the degree of beta blockade. 
Many of the beta blockers possess 




1 • 1 • ) , wi th 
isomers being equipotent in 
1983, Shand 1983, Wood 1984). 
this respect (Breckenridge 
This effect of slowing the 
rate of rise of the intracardiac action potential requires 
propranolol concentrations well above those associated with 
substantial beta-blockade (Wood 1984). At therapeutic doses 
used in angina and hypertension this effect is thought to 
be clinically unimportant. 
Table 1.1. Pharmacodynamic properties of beta blockers. 
(Adapted from Shand 1983, Wood 1984). 
BETA,- ISA MSA 
SELECTIVITY 
Acebutolol + + + 
Alprenolol 0 + + 
Atenolol + 0 0 
Carteolol 0 + 0 
Metoprolol + 0 0 
Nadolol 0 0 0 
Oxprenolol 0 + + 
Penbutolol 0 0 + 
Pindolol 0 + ± 
Practolol + + 0 
Propranolol 0 0 + 
Sotalol 0 0 0 
Timolol 0 0 0 
It is general ly believed that in the treatment of 
hypertension and angina all beta-blockers are equally 
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effective regardless of which of these ancillary 
characteristics they possess (Breckenridge 1983, Opie 1983, 
Prichard 1974, Shand 1983, Wood 1984). However, Cruikshank 
( 1980) reported that cardio-selecti ve beta-blockers may 
have a slightly greater effect in lowering diastolic blood 
pressure than non-selective agents. 
Atenolol is a relatively cardioselective beta-blocker with 
no ISA or MSA (Harry 1977) (Table 1.1.). It is marketed as 
the racemate. 
1 . 1 .2. Cardiovascular and Haemodynamic Effects of Beta-
blockers 
The most important pharmacodynamic effects of beta-
adrenergic blocking drugs involve the cardiovascular 
system. They have negative inotropic, as well as negative 
chronotropic effects (Weiner 1985), affect cardiac 
conduction and are antiarrhythmic (Pimenta & Pereira· 1986). 
Rather surprisingly, they also lower blood pressure. 
The negative inotropic action together with the reduction 
in heart rate leads to a reduction in cardiac output 
(Ulrych et al 1968). This results in a beneficial 
influence on angina (Gibson 1974, Opie 1983, Prichard 1974) 
and may be implicated in the antihypertensive action 
(1.1.2 . 2.3). 
1.1.2.1. Effect on Heart Rate 
In normal subjects heart rate is determined by the balance 
between sympathetic stimulation and para-sympathetic 
inhibition (Guyton 1986) superimposed on intrinsic heart 
rate. Intrinsic heart rate is the rate devoid of any 
autonomic influences. This can be assessed after the 
autonomic influences have been removed with atropine and 
propranolol (Jose 1966). It is altered by disease states 
such as cardiac disease, thyrotoxicosis and pyrexia (Jose 
1966) . 
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The effect of a beta-blocker on heart rate is therefore not 
simply related to the concentration of the drug at the 
chronotropic beta receptors. Assessment must take into 
account the background influences including the autonomic 
tone (both sympathetic and parasympathetic) (Joubert et al 
1988), other reflex mechanisms (Shand 1983), 
cardioselectivity (Brown et al 1983) or ISA of the beta-
blocker (Svendsen et al 1979), underlying disease states 
and even the age of the subject (Jose 1966). 
1.1.2.1.1. Resting Heart Rate 
In the supine position at rest, the parasympathetic system 
is dominant (McDevitt 1977, Robinson et al 1966). Under 
these circumstances beta-blockers have less effect than 
during sympathetic stimulation. 
Beta-blockers lower resting supine heart rate in both 
volunteers (Fuller & Vallance 1982, Maling et al 1979) and 
patients (McDevitt 1977) to a variable degree depending on 
the dose, the initial heart rate (Gibson 1974) and the 
degree of ISA of the particular agent used (Carruthers & 
Twum-Barima 1981). The greater the degree of ISA the 
smaller the reduction in resting heart rate (Svendsen et al 
1985). Resting heart rate is therefore not a sui table 
parameter for estimation of beta-blockade (McDevitt 1979). 
untreated hypertensive patients and volunteers show intra-
subject variability in heart rate when measured over 24 
hours, with the lowest levels during sleep (Mancia et al 
1984). Beta-blockers, whilst reducing heart rate, do not 
alter the relative 24-hour variability (Mancia et al 1984). 
1.1.2.1.2. Stimulated Heart Rate 
Tachycardia evoked by various stimuli including exercise is 
mediated by increased sympathetic activity as well as 
parasympathetic withdrawal (Gibson 1974, Guyton 1986). The 
contribution of beta-blockers to reduction in tachycardia 
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would therefore be expected to be greater than that seen in 
the resting situation. 
In both patients and volunteers, beta-blockers reduce the 
magnitude of the increases in heart rate induced by 
isoprenaline administration (infusions and bolus doses), 
exercise, orthostasis, tilt, Valsalva's manoeuvre and 
anxiety (Gibson 1974, McDevitt 1977, Shand 1983, Svendsen 
et al 1981). 
The cardioselective beta-blockers inhibit isoprenaline 
induced tachycardia less than the nonselective agents, 
possibly because isoprenaline may have a direct cardiac 
beta2-mediated effect or because it causes an indirect 
reflex response due to vasodilatation (Brown et al 1983, 
McDevitt 1977, Perucca et al 1981, Shand 1983). The mode of 
isoprenaline administration (bolus injection versus 
continuous infusion) has been found to elicit contrasting 
effects on vagal reflexes (Arnold & McDevitt 1986). This 
may affect isoprenaline dose ratio displacement curves in 
the presence of beta-blockers. 
Agents with ISA ego pindolol show little influence under 
moderate sympathetic stimulation such as that induced by 
orthostasis (Carruthers & Twum-Barima 1981). 
The most consistent effect of beta-blockers on HR is on 
exercise tachycardia since this results largely from beta,-
receptor stimulation (Brown et al 1983, Hager et al 1981, 
Robinson et al 1966). Under these circumstances of high 
adrenergic stimulation the differences seen at lower levels 
of sympathetic stimulation between agents with and without 
ISA, largely disappear (Svendsen et al 1981, Svendsen et al 
1985). 
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1.1.2.2. Effect on Blood Pressure 
The ability of beta-blockers to reduce blood pressure (BP), 
although not anticipated, was discovered early in the 
development of these agents (Prichard 1964a, Prichard & 
Gillam 1964b, Prichard 1966). During long term therapy,all 
beta-blockers, irrespective of cardio-selectivity, ISA or 
MSA, have been found to lower blood pressure without 
causing postural hypoten~ion (Harry et al 1979, Opie 1983, 
Prichard 1966, Prichard & Gillam 1969, Thadani 1983, 
Simpson 1974). 
1.1.2.2.1. Acute Effect on Blood Pressure 
1.1.2.2.1.1. Intravenous Administration 
It was initially believed that intravenous (IV) 
administration of beta-blockers had no effect on blood 
pressure in either normotensive or hypertensive individuals 
(Mason & Winer 1976, Prichard 1964a, Prichard 1966, Ulrych 
et al 1968, Buhler et al 1975a). 
Even in a more recent series of studies using seven beta-
blockers with different ancillary properties in heal thy 
volunteers and patients with ischaemic heart disease, only 
exercise systolic BP was significantly reduced, with no 
effects on resting blood pressure observed (Svendsen et al 
1979, Svendsen et al 1981, Svendsen et al 1985). Effects 
were, however, only followed for at most an hour after the 
last dose. 
It has now been clearly shown that IV administration does 
affect BP in volunteers (Fagan et al 1982a, Fitzgerald et 
al 1978, Wilson et al 1982) and hypertensive patients 
(Okubo et al 1981, Shinebourne et al 1967). The effects on 
systolic post-exercise BP are most marked but resting 
systolic and, to a lesser extent, resting diastolic BP are 
also decreased. The effects depend on dose and are time-
lagged relative to the effects on HR (See 1.3.2.2.) . 
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The magnitude of change appears to be somewhat greater in 
hypertensive patients than in normotensive subjects. 
Shinebourne et al (1967) , recording intra-arterial 
pressure, found that systolic BP fell more than diastolic 
BP after propranolol (0.1 mg/kg) in hypertensive patients 
at rest, on standing and on exercise. The magnitude of 
these changes was greater in these hypertensive patients 
than in normotensive angina patients subjected to the same 
procedures. Okubo et al (1981) also found differential 
effects after pindolol (0 . 002 mg/kg) with no change in BP 
in normotensive subjects but a significant fall in 
hypertensive subjects . 
The reasons for the initial reports of lack of effect in 
both volunteers and patients may have been: 
i) the relatively small doses administered; 
ii) the short period of observation (under one hour after 
dose) thus possibly missing the time-lagged 
hypotensive effect (see 1.3.2.2. below); 
iii) many studies only report differences that reach 
statistical significance. 
1.1.2.2.1.2. Acute Oral Administration 
Post-exercise blood pressure 
A significant reduction in post-exercise systolic blood 
pressure has been shown with single oral doses of 
bisoprolol (Leopold et al 1986), carteolol (Stoll et al 
1981 ) , metoprolol (Leopold et al 1986) , penbutolol 
(Giudicelli et al 1977) and propranolol (Leopold et al 
1986). Much smaller effects were seen on diastolic BP. 
Similar results on exercise systolic pressure were seen 
wi th pindolol (7 . 5 
propranolol (78 mg) 









Single dose or short term oral beta-blocker administration 
has inconsistent effects on resting blood pressure. 
o I Conner et al (1985) reported no consistent effects on 
resting or standing systolic and diastolic pressure in 
volunteers given oral atenolol in doses up to 100 mg. 
However, a few single dose studies in volunteers have shown 
significant changes in resting systolic pressure but 
smaller changes in diastolic pressure using pindolol (5, 10 
and 20 mg) (Jennings et al 1979) and propranolol (80 mg) 
(Giudicelli et al 1977) . Although a dose of 20 mg 
penbutolol caused no significant reduction in systolic BP 
(Giudicelli et al 1977) higher doses (25, 50, 100 mg) 
significantly reduced systolic BP with lesser effects on 
diastolic BP (Jun et al 1979). 
In a double blind placebo controlled study of 3 days of 
atenolol treatment (100 mg per day), resting mean arterial 
pressure and systolic pressure were significantly lower 5 
hours after the dose (Fuller & Vallance 1982). Three days 
treatment with oral atenolol (50 mg per day) lowered 
resting and exercise systolic blood pressure (Hespel et al 
1986). Thus with slightly more prolonged treatment a 
similar pattern of greater influence on systolic pressure 
compared with d iastolic pressure was seen. 
In contrast to the above reports, two studies in healthy 
volunteers demonstrated clear cut changes in both systolic 
and diastolic BP at rest (Fagan et al 1982a, Maling et al 
1979). Single oral doses of atenolol (100 mg) and 
propranolol (200 mg) caused significant reductions in 
resting supine systolic and diastolic blood pressures 
(Maling et al 1979). Fagan et al (1982a) showed that a 
single 80 mg oral dose of propranolol reduced systolic, 
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diastolic and mean arterial pressure by 10% three hours 
after the dose. 
In mild to moderately hypertensive patients, single oral 
doses of propranolol (40-320 mg) decreased standing and 
supine systolic and diastolic BP by 6-13% (Fagan et al 
1982b). In another study using single 80 mg doses of 
propranolol a significant reduction in systolic but not 
diastolic BP was produced (Leenen et al 1982). 
Similarly, metoprolol (single 100 mg doses) administered to 
hypertensive subjects caused significant reductions in both 
systolic and diastolic BP (Myers & Thiessen 1980). 
However, with smaller doses (50 and 80 mg) only systolic BP 
was significantly reduced (Bengtsson et al 1975, Collste et 
al 1980). 
In only one s t udy in hypertensives who received 100 mg 
atenolol, was a significant reduction of diastolic BP found 
without a corresponding significant effect on systolic BP 
(Holtzman et a l 1986). 
In summary then, as with IV administration, single oral 
doses of beta-blockers in patients and volunteers have 
produced relatively inconsistent effects on resting blood 
pressure. Effects on resting systolic pressure are more 
prominent than effects on diastolic BP but both are more 
pronounced wi th higher doses. Exercise systolic BP is 
generally reduced to a significant extent. 
1.1.2.2.2. Chronic Treatment Effect on Blood Pressure 
Numerous studies including open label, single blind and 
double blind placebo controlled designs, attest to the 
clinical efficacy of long term administration of beta-
blockers in lowering systolic and diastolic BP. The use of 
these drugs in hypertension has been reviewed by various 
authors including McDevitt ( 1979) , Prichard ( 1 966) , 
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Prichard (1979), Robertson (1983), Seedat (1975), Simpson 
(1974), Thadani (1983). 
In the so-called stepped-care approach to hypertension 
(Hypertension Detection and Follow up Program Cooperative 
Group 1979a, 1979b) which became very popular in the 1980s, 
either beta-blockers or thiazide diuretics were recommended 
as the first step, the beta-blockers being more popular in 
Europe than in America (Moser et al 1977, Moser 1983) . 
A review of t he literature regarding the hypotensive 
efficacy of beta-blockade reveals that the criteria by 
which efficacy is assessed differ among studies, making 
fair comparisons difficult. Most studies use one or more of 
the following assessment methods: 
i) the fall i n BP expressed as a percentage of the 
baseline value; 
ii) a significant fall in systolic and diastolic BP 
compared to pretreatment 
iii) achievement of goal 
diastolic BP of 90 or 95 
mm Hg fall. 
or placebo values; 
blood pressures ego 
mm Hg; and at least a 5 
Depending on which method is used different conclusions 
could be drawn. Method i) is the least stringent and any 
percentage fall could be construed as a positive result. 
Wi th method ii) if numbers in the study are small the 
chances of finding positive results will be reduced due to 
inter-patient variabili ty. The use of method iii) would 
give better results in patients who start off at relatively 
lower blood pressures. To illustrate this, in a study of 
15 patients on long term metoprolol (Rasmussen & Rasmussen 
1979) falls of 11 and 8 % in systolic and diastolic BP 
respectively were found, constituting a statistically 
significant result . However 8 (53%) of the patients were 
actually considered to be non-responders because their 
diastolic BP did not drop below 95 mm Hg. 
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In many of t he original trials frequently quoted as 
demonstrating the potent antihypertensive effects of beta-
blockers, efficacy criteria and trial design were 
inadequate. In the often cited, first relatively · large 
series of patients reported by Prichard & Gillam (1969) a 
claim of 84% response was made. However, only 14% of 
patients were on mono therapy and goal diastolic BP appears 
to have been 100 mm Hg. In another study, while propranolol 
reduced BP in 16 patients (84%,) 7 of these did not achieve 
diastolic pressures below 95 mm Hg (Frohlich et al 1968). 
Similarly, Paterson & Dollery (1966) in a crossover study 
reported that 240 mg propranolol lowered BP on average 
although it was slightly less effective than 50 mg 
hydrochlorothiazide. However, average diastolic BP did not 
fall below 100 mm Hg with either treatment. 
A review of relatively large, well designed studies reveals 
that monotherapy with beta-blockers appears to reduce blood 
pressure in 50-60% of patients with mild-to-moderate 
hypertension with the magnitude of the reduction being in 
the range of 10-24 and 8-14 mm Hg for systolic and 
diastolic pressures respectively (Tarazi & Dustan 1972, 
Thadani 1983, Veterans Administration Cooperative Study 
Group on Antihypertensive Agents (VACSG) 1977, 1982a, 
1982b, 1983). 
The dose response curve for blood pressure reduction is 
relatively fla t with little to be gained from resorting to 
very large doses (See 1.3 . 1.2.) although some investigators 
claim a biphas i c response (Esler et al 1977, Hollifield et 
a11976). 
Notwithstanding their widespread use, the extensive 
research conducted and literature available on these 
agents, a number of inter-related questions have been 
extensively debated and remain essentially unanswered. 
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These include: 
i) What is the mode of the antihypertensive action of 
beta-blockers? 
ii) Why do some people not respond to beta-blockers? 
iii) What is the time course of hypotensive actions? 
iv) Why is there apparently no relationship between 
concentration and the antihypertensive action? 
These issues will be discussed in the following sections. 
1.1.2.2.3. Mode of Hypotensive Action 
Since all beta-blockers, regardless of ancillary 
properties, appear to lower blood pressure to about the 
same extent when used long term (Harry et al 1979, Vaughan 
Williams et al 1980) the hypotensive effect must be the 
consequence of blockade of beta,-receptors albeit indirect 
and delayed relative to effects on heart rate (Connell 
1986, Tarazi & Dustan 1972). 
The hypotensive mechanism has been much debated (Connell 
1986, Lowenthal et al 1984, Man in I t Veld & Schalekamp 
1983, Opie 1983, Prichard 1979, Robertson 1983, Seedat 
1975, Simpson 1974, Thadani 1983). The following 
possibili ties have been proposed but none are entirely 
satisfactory: 
i) resetting of baroreceptors (Prichard & Gillam 1964b)i 
ii) fall in cardiac output (Frohlich et al 1968, Tarazi & 
Dustan 1972); 
iii) suppression of renin release, activity and/or 
concentration (Buhler et al 1972); 
iv) interference with central sympathetic outflow in the 
vasomotor centre (Birkenhager et al 1977); 
v) blockade of presynaptic beta-receptors thereby 
preventing neurotransmitter release (Langer 1977). 
The first proposal is difficult to prove or refute. It 
suggests a long term adaptive regulatory response. Acute 
administration of oral propranolol and atenolol to normal 
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volunteers can cause 'resetting' of the baroreceptors 
(Deering et al 1988). Exactly how this relates to long term 
blood pressure reduction has not been elucidated. 
Considering the second hypothesis, it has been shown that 
the inverse correlation between changes in cardiac output 
and vascular resistance, on long term beta-blocker therapy 
is shifted to a lower level of vascular resistance for a 
given cardiac output (Man in't Veld & Schalekamp 1983). Yet 
the beta blockers with ISA when given acutely, cause a much 
smaller reduction in cardiac output than those without ISA 
(Svendsen et a l 1979, Svendsen et al 1981, Svendsen et al 
1985) despite causing similar reductions in BP. Also the 
reduction in cardiac output by selective beta-blockers is 
not temporally related to the fall in BP (Tarazi & Dustan 
1972). It is therefore difficult to envisage exactly how 
the reduction in cardiac output could be at the core of the 
hypotensive action. 
Plasma renin activity is at least partially controlled by 
beta,-receptors with beta2-receptors playing a negligible 
role (Hespel et al 1986). A cardinal role for renin 
suppression i n beta-blocker hypotension has many 
protagonists. The original theory by Laragh et al (1972, 
1973) that essential hypertension can be divided into 
subtypes according to renin and other hormone profiling is 
supported by, amongst others, the large study of Buhler et 
al (1975a). This study showed a clearly different pattern 
of response to antihypertensive treatment (beta-blockers 
and diuretics) dependent on the renin-sodium index; those 
with a high index showed an excellent response (85%) to 
beta-blockade, those with normal renin levels a good but 
less consistent response whilst those with low renin-sodium 
index little or no response. The opposite pattern was 
evident with diuretics. The patients with a poor response 
and low renin-sodium index were generally older and had 
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higher diastolic pressures than those who showed a good 
response (See 1.1 .2.2.4.2 . ). 
There are a number of other studies which support a 
relationship between blood pressure reduction by beta-
blockers and basal plasma renin activity (PRA) (Volpe et al 
1983, Von Bahr et al 1976, Weber et al 1980) and plasma 
renin concentration (Amery et al 1977a). However, the 
extent of reduction of diastolic pressure by beta-blockade 
could not be related to the degree of PRA suppression 
(Holland & Fairchild 1982, Lehtonen et al 1977, Pedersen et 
al 1981, Salvetti et al 1977). 
All beta,-receptor blockers decrease plasma renin activity 
on exercise (Buhler et al 1975a) whereas only those without 
ISA have a significant effect on basal plasma renin 
activity (Buhler et al 1975b, Lijnen et al 1979, Stokes et 
al 1974, Traub et al 1980). This is used as an argument 
against the renin suppression theory (Stokes et al 1974) 
as all beta-blockers lower blood pressure to a similar 
extent . 
Hollifield et al (1976) proposed a dual mechanism of 
action: a renin associated, low to moderate dose 
antihypertensive action and a high-dose, renin-independent 
action which might involve central effects. They showed 
that in both high and low renin hypertensive patients 
significant falls in BP unassociated with any changes in 
PRA occurred at doses above 160 mg of propranolol. 
The argument against the beta-blockers having a central 
effect to limi t sympathetic outflow from the vasomotor 
centre is that the accessibili ty of the various beta-
blockers to the CNS bears no relationship to either the 
onset or magnitude of the hypotensive response (Man in't 
Veld & Schalekamp 1983). The acute haemodynamic effects of 
IV atenolol ( limited CNS access) and metoprolol in 
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anaesthetized cats were found to be identical although 
metoprolol concentrations in CSF were 6-9 fold those of 
atenolol (Van Zwieten & Timmermans 1979). 
The existence of presynaptic beta-receptors, which when 
stimulated lead to noradrenaline release, has been 






this way. Blockade 
facilitate 
of these 
presynaptic receptors could conceivably reduce 
noradrenaline release on sympathetic stimulation, reduce 
vascular resistance and thus lower blood pressure (Man in't 
Veld & Schalekamp 1983). 
The answer, to what the hypotensive mode of action of beta-
blockers really is, probably lies in some complex 
combination of some or all of the above effects, 
particularly the sympathetic cardiovascular actions and 
renin-angiotensin fluid balance mechanisms interacting with 
the complex pathophysiology maintaining raised BP in 
hypertensive individuals. 
1 . 1 .2.2.4. Poor Response to the Hypotensive Effects of 
Beta-blockade 
It was recognized quite early in the development of the 
beta-blockers that there are hypertensive patients who 
clearly do not respond with any fall in BP upon 
administration of beta-blockers alone, even in large doses. 
Patient groups who are reportedly less likely to respond to 
beta-blockers are blacks (Humphreys & Delvin 1968, Seedat 
& Reddy 1971, VACSG 1983) the elderly (Buhler et al 1975a) 
and patients with low basal PRA (Buhler et al 1972, Buhler 
et al 1975a, Distler et al 1978, Weber et al 1980). 
Much debate on the reasons for a poor response to beta-
blockers has centred on the renin status of patients. There 
is a reasonable amount of evidence that patients with low 
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renin levels wi ll respond better to diuretic therapy and 
calcium channel blockers than to beta-blockers and 
angiotensin converting enzyme inhibitors while the opposite 
pattern of efficacy is found in high renin patients (Buhler 
et al 1975a, M'Buyamba-Kabanga et al 1986, Serlin et al 
1980, Weber et al 1980). The higher incidence of so-called 
'low renin hypertension' in blacks (Cruikshank & Beevers 
1982) and the elderly (Buhler et al 1975a) seems to bear 
out the predictive role of renin status (see 1.1.2.2.3. 
above). The situation is less clear, however, in patients 
with intermediate renin activity and this may account for 
some of the conflicting results reported. 
1.1.2.2.4.1. Poor Response in Blacks 
Since the initial report by Humphreys and Delvin (1968) 
that propranolol was ineffective in hypertensive Jamaicans 
a number of other reports have suggested that beta-blockers 
are relatively ineffective in lowering blood pressure in 
blacks (Abson et al 1981, Hollifield et al 1978, Seedat & 
Reddy 1971, Seedat 1980, Richardson et al 1968). 
These studies can be criticised on a number of grounds, 
including small numbers of patients and a relatively high 
pre-treatment diastolic BP. In the study of 25 patients 
where Seedat and Reddy (1971) showed a better response to 
propranolol in Indians than Blacks, pre-treatment diastolic 
BP was high, on average 136 mm Hg. This was also the case 
in the trials of Humphreys & Delvin (1968) and Abson et al 
(1981 ). Similar poor response rates (20-30%) have been 
found in other studies where patients who were presumably 
white had pre-treatment diastolic blood pressures above 110 
mm Hg (Frohlich et al 1968, Paterson & Dollery 1966). 
Studies in mild hypertension in black patients, comparing 
the efficacy o f beta-blockers with diuretics, clearly show 
that diuretics are more effective than beta-blockers in 
lowering BP (Grell et al 1984, Moser & Lunn 1981, 
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Richardson et al 1968, Seedat 1980). This could be due to 
better efficacy of the diuretic and not necessarily poorer 
response to the beta-blocker. In one of the above 
comparative studies (Grell et al 1984) as well as other 
studies using only beta-blockers, a significant drop in BP 
in blacks was found (Oli 1982, Seedat & stewart-Wynne 
1972) . 
Beta-blockers could be termed mild hypotensive agents while 
diuretics are relatively potent blood pressure lowering 
agents in all patients. 
The best evidence for a racial difference in response comes 
from studies involving both whites and blacks. The Veterans 
Administration cooperative study Group on Hypertensive 
Agents (1982a, 1982b) showed that overall (blacks + whites) 
hydrochlorothiazide (HCTZ) was more effective than 
propranolol in controlling BP (65.5% vs 52.8%) with HCTZ 
having a greater effect on systolic BP. This pattern was 
also seen when blacks and whites were considered 
separately. However, although the difference was not 
statistically significant, blacks showed a greater response 
than whites to HCTZ whilst whites showed a better response 
to propranolol than blacks. In another study nadolol was 
marginally more effective overall than bendroflumethiazide 
(49% vs 46%) (VACSG 1983). When whites and blacks were 
considered separately an equivalent response rate to 
diuretic was seen (46% in each) but more whites than blacks 
responded to nadolol (77% vs 31%). In a much smaller trial 
by Weber et al (1980) a greater response to diuretics was 
found in black than in white patients. 
There is therefore some evidence that black patients with 
mild to moderate hypertension respond better than whites to 
diuretics with whites responding better to beta-blockers 
than blacks. The differences are, however, not dramatic. 
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A few attempts have been made to find the cause of the 
apparent racial difference in response to beta-blockers by 
looking more closely at cardiac beta-receptor sensitivity. 
In healthy males, a significantly lower Emax/ED50 was found 
in whites compared with blacks when the ·effect of the beta-
agonist, isoprenaline, on heart rate was assessed (Rutledge 
et al 1989). The authors caution however, that the mode of 
isoprenaline administration (bolus injection) leads to 
vagal withdrawal which may be subject to racial 
differences. 
Although venter & Joubert (1982, 1984a) initially claimed 
that black volunteers were less responsive than whites to 
the effects of beta blockade on exercise tachycardia they 
have subsequently demonstrated this to be a methodological 
artefact (Joubert et al 1988) due to ethnic differences in 
intrinsic heart rate and vagal withdrawal (Venter et al 
1984b, Venter et al 1986). 
Assessment of the beta-adrenergic pathway using 
isoprenaline stimulated cAMP production by lymphocytes has 
yielded conflicting results. Two reports indicated 
significantly higher cAMP production in blacks than in 
whites (Venter et al 1985, Rutledge et al 1990) although a 
third study reported lower cAMP levels in blacks than in 
whites (Stein et al 1987). Beta-receptor isotherm binding 
studies found no differences in B , sites per cell or kd max 
suggesting that if there was a racial difference it was 
probably distal to the receptor (Rutledge et al 1990). 
These studies were conducted in normotensive volunteers and 
involved the beta2-receptor. It is therefore difficult to 
extrapolate these findings to hypertensive patients where 
the antihypertensive effect is assumed to be a beta-
1 
receptor mediated effect. 
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A much better case can be made for differences in the 
pathophysiology of hypertension in blacks and whites. In 
untreated hypertensives the percentage of black patients 
wi th volume expansion and low renin acti vi ty was double 
that in whites, whilst a higher percentage of whites were 
volume contracted with high plasma renin activity (Chrysant 
et al 1979). Racial differences in the pathophysiology and 
epidemiology of hypertension have been extensively reviewed 
by Aderounmu (1981) and M'Buyamba-Kabanga (1986). Evidence 
for differences include: 
i) differences in response to antihypertensive drugs 
including diuretics, beta- blockers and 
angiotensin converting enzyme inhibitors; 
ii) differences in complications with stroke and 
renal failure being much more common in blacks as 
opposed to ischaemic heart disease in whites; 
iii) physiologi cal differences in plasma and intra-
cellular electrolytes and transmembrane fluxes, 
plasma renin activity, urinary kallikrein 
activity and plasma volume. 
The above differences may be due to different environmental 
(socio- economic) factors overlaying the pathophysiology of 
hypertension, influencing the expression of the disease. 
It has been suggested that the primary pathophysiological 
abnormali ty in essential hypertension is an increase in 
peripheral resistance (Rosendorff 1988) with two different 
mechanisms responsible for long term vasoconstriction 
identified (Laragh 1987) . One mechanism is renin 
independent, requiring sodium retention and seems to be 
related to abnormal membrane transport of calcium and is 
clinically identified by low plasma renin and ionised 
calcium. The second is renin dependent and may involve an 
increase in cytosolic calcium (Laragh 1987) . 
23 
In most black hypertensive patients the first mechanism 
appears to be operative and can be corrected by sodium 
depletion, calcium channel blockade or blockade of 
heightened sympathetic acti vi ty at the blood vessels by 
central adrenolytics or alpha-blockers (Rosendorff 1988). 
The second situation (more common in whites) would be 
expected to respond well to drugs which act on the renin-
angiotensin system ego beta-blockers and angiotensin-
converting enzyme inhibitors. 
There are suggestions that the racial difference in blood 
pressure response to beta-blockers may be less with beta-
blockers with high ISA such as pindolol (Hall & Kong 1991) 
as well as the combined alpha and beta-blocker labetalol 
(Cubberley 1985, Flamenbaum et al 1985). 
The efficacy in blacks, of drugs such as labetalol which 
also have alpha- blocking properties fit in with the above 
I 
theories of renin independent mechanisms maintaining raised 
BP in blacks while renin sensitive mechanisms are operative 
in most whites. 
The question of where those beta-blockers with strong ISA 
such as pindolol, fit into the picture, remains unanswered. 
These agents although reducing BP, do not reduce plasma 
renin activity. In a review of the effects of 10 different 
beta-blockers on basal haemodynamics in hypertensive 
patients it was concluded that all beta-blockers cause a 
shift in vascular resistance to a lower level which is 
always accompanied by a reduction in blood pressure during 
chronic therapy (Man in 't Veld & Schalekamp 1983). 
However, the acute response is based on a reflex response 
to cardiodepression which appears to differ depending on 
the level of ISA. Beta-blockers with strong ISA reduce BP 
in the face of a reduction of total peripheral resistance 
below pre-treatment levels without a net change in cardiac 
output , those with moderate ISA reduce BP without a net 
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change in total peripheral resistance but cause moderate 
cardiodepression while those without ISA cause gross 
cardiac depression with an elevated peripheral resistance 
above pre-treatment levels (Man in I t Veld & Schalekamp 
1983). If the possession of ISA improves the hypotensive 
efficacy of beta-blockers in otherwise poor responders it 
may be the cardiodepressi ve effects possessed by those 
without ISA ego propranolol and atenolol amongst others, 
which somehow negate the hypotensive effects common to all 
beta-blockers. 
Beta-blockers without ISA (atenolol, propranolol, nadolol) 
were used in most of the studies suggesting a reduced 
hypotensive efficacy in blacks. Only one study comparing 
the acute haemodynamic effects in hypertensive Africans, of 
a beta blocker without ISA (propranolol 100 mg) and one 
with ISA (pindolol 20 mg) appears to have been done (Salako 
et al 1979). As expected the two beta-blockers differed in 
their effect on resting heart rate. Pindolol however, had 
a greater effect in reducing resting systolic BP than 
propranolol despite an almost identical reduction in 
exercise heart rate (Salako et al 1979). The relevance of 
this acute dose difference to long term BP reduction is 
uncertain. At this stage there appears to be very little 
evidence to support or refute the claim of better efficacy 
of beta-blockers with ISA in blacks. More studies need to 
be done to examine the effect of ISA on BP response in 
black hypertensives. 
1.1.2.2.4.2. Poor Response in the Elderly. 
A number of studies claim a reduced blood pressure response 
in elderly patients compared with younger patients (Buhler 
et al 1975a, Rasmussen & Rasmussen 1979). This poor 
response may be related to : 
i} reduced adrenoceptor sensitivity with age (Dillon 
et al 1980, Klein et al 1986, Vestal et al 1979); 
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ii) alterations in sodium excretion resulting in 
increased total body sodium and extracellular 
fluid volume . These changes are particularly 
prominent in patients with moderate myocardial 
insufficiency (Weiner 1985) which is more likely 
to occur in the elderly; 
iii) age related reductions in renin status (Buhler et 
al 1975); 
i v) higher pressures in the elderly (Buhler et al 
1975a). 
The evidence for reduced beta-receptor sensitivity is based 
on studies using the agonist, isoprenaline. Dillon et al 
(1980) showed a decreased maximal response and a 
displacement to the right of the dose response curve of 
isoprenaline stimulated cAMP production from the 
lymphocytes of the elderly. In two studies, the doses of 
isoprenaline required to raise heart rate by a given 
amount were significantly greater in elderly people 
compared with young volunteers (Klein et al 1986, Vestal et 
al 1979). In the one study the sensitivity to propranolol 
also appeared to be reduced, with an age related increase 
in the apparent dissociation constant (Vestal et al 1979). 
This contrasts with a study where timolol binding to 
cardiac beta-receptors has been shown to be unaltered by 
age (Klein et al 1986). These studies suggest a reduction 
in post-synaptic receptor sensitivity to agonists and 
antagonists. 
In the elderly, BP is generally higher than in younger 
people and there is a higher incidence of low PRA possibly 
due to volume expansion . Points ii) to iv) are thus inter-
related. Volume expansion could result in higher pressures 
and both higher pressures and volume expansion suppress 
renin . 
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There is evidence that failure to respond to beta-blockers 
wi th a drop in BP may be due to fluid retention. This 
possibility is strengthened by the appreciable fall in BP 
seen in non-responders to beta-blockers when a diuretic is 
added (Baber & Dawes 1979). This may be related to the 
opposite effects of the two classes of drugs on 
extracellular fluid volume (ECV). Rasmussen & Rasmussen 
(1979) showed t hat non-responders to metoprolol showed a 
significant 5% increase in ECV on metoprolol treatment 
whilst responders showed a non-significant 1% increase with 
no change in plasma volume in either group. The addition of 
a diuretic to metoprolol in the non-responders reduced the 
BP as well as t he ECV . The non-responders were on average 
20 years older than the responders. 
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1.2. PHARMACOKINETICS OF BETA BLOCKERS 
The pharmacokinetics of a drug are determined to a large 
extent by its lipid solubility or polarity which is a 
consequence of its chemical structure. The lipid solubility 
determines its route(s) of clearance from the body as well 
as its penetration into tissue. While tissue penetration 
influences the intensity of effects, clearance will affect 
the duration of action . 
The beta-blockers vary widely in their lipid solubility 
(Hinderling et al 1984) and thus in volumes of 
distribution, routes of clearance and elimination. The more 
lipid soluble, less polar agents are generally extensively 
metabolised by the liver, are more highly bound to serum 
protein, have larger volumes of distribution, more rapid 
clearance and thus shorter half-lives (Ochs et al 1985, 
Regardh 1982) (See Table 1.2). The pharmacokinetics of 
beta-blockers have been reviewed by Regardh (1982), Riddell 
et al (1987) and Ritschel (1980). 
The pharmacokinetics of atenolol (one of the least lipid 
soluble beta-blockers) as well as those of the lipid 
soluble agent, propranolol, will be discussed in more 
detail. Propranolol is of interest because it has been used 
in many of the studies relating concentration to effect 
(see 1.3. below) and its kinetics contrast in many respects 
with those of atenolol. 
1.2.1. The Pharmacokinetics of Propranolol 
1.2.1.1. Absorption and Bioavailability 
Propranolol, although well absorbed after oral 
administration, undergoes extensive pre-systemic (first 
pass) metabolism resulting in a variable and relatively low 
bioavailabili ty (~30%) . At low single doses « 30 mg) 
bioavailability is very low but when the removal process 
Table 1.2. Pharmacokinetic characteristics of some beta-blockers. The drugs are listed in 
increasing order of polarity. (After Regardh 1982, Riddell et al 1987). 
DRUGS F t!a 
(minutes) 
Propranolol .3 5-10 
Alprenolol · 1 5-10 
I Oxprenolol · 3 20 
Metoprolol .5 5-10 
Timolol .5 5-10 
Pindolol . 5-1 5-10 
Sotalol · 9 -
Nadolol .3-.5 -
Atenolol .5 20-30 
F = bioavailability 
t!a = half-life of distribution 
V = volume of distribution 
-
V Serum CL 
(L/kg) Protein (L/kg/hr) 
Binding (%) 
3.6 93 1 .0 
3.3 85 1 .2 
1 .2 80 0.4 
5.0 10 1 .0 
2.0 10 0.4 
1 . 2 50 0.4 
1 .4 0 0.16 
1 .9 30 0.10 
0.7 5 0.10 
CL = total clearance 




























becomes saturated at higher doses a larger fraction of the 
oral dose reaches the systemic circulation (Nies & Shand 
1975). At steady state during 6 hourly dosing drug 
concentrations are essentially proportional to dose 
although hepatic extraction is still relatively high with 
only 20 to 50% of the dose reaching the systemic 
circulation (Nies & Shand 1975). 
The extent of first pass metabolism is dependent on many 
factors (Riddell et al 1987, Routledge & Shand 1979) 
including dose, route and frequency of administration 
(Coelho et al 1983, Woods et al 1979). Since propranolol 
is a high extraction ratio drug, the bioavailability can be 
altered by changes in blood flow~ concurrent food intake 
(Olanoff et al 1986, Routledge & Shand 1979) and other 
drugs which inhibit or induce enzymes. Propranolol itself 
reduces liver blood flow by reducing cardiac output and 
consequently can reduce its own elimination (Nies & Shand 
1975). A 10-20 fold inter-individual variation in plasma 
concentration has been found in patients on the same dose 
(Esler et al 1977, Lehtonen et al 1977, Nies & Shand 1975, 
Serlin et al 1980). 
1.2.1.2. Distribution 
Propranolol has a relatively large volume of distribution 
and is rapidly distributed from the blood into various 
tissues including the brain (Riddell et al 1987). 
As a basic drug, propranolol binds extensively (90-94%) to 
a,-acid glycoprotein and to albumin (Riddell et al 1987). 
The extent of binding is highly variable (Steinberg & 
Bilezikian 1983) and can be altered by many condi tions. 
This can influence the pharmacokinetics by changing 
distribution volume and altering half-life. The 
pharmacodynamics can also alter because it is essentially 
the free fraction which is active. 
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In inflammatory conditions where o,-acid glycoprotein is 
raised increased binding of propranolol can occur (Regardh 
1982). In one study a significantly higher degree of 
protein binding was demonstrated in hypertensive subjects 
compared with normotensive volunteers (McDevitt et al 
1976) . 
1.2.1.3. Metabolism and Elimination 
Propranolol is extensively metabolised by the liver to both 
inactive and active metabolites which include 4-
hydroxypropranolol. In single dose studies where effects 
are measured shortly after oral dosing this metabolite may 
contribute to effect but because it has a shorter half-life 
than propranolol, effects seen at 6 hours are due mainly to 
propranolol (Nies & Shand 1975). In hypertensive patients 
on chronic therapy relatively low levels of 4-
hydroxypropranolol have been found and it is unlikely that 
this metabolite contributes greatly to effect at steady 
state (Chidsey et al 1976, Wong et a~ 1979). 
The oxidation of some beta blockers eg. metoprolol and 
timolol appear to be related to debrisoquine phenotype 
(Dayer et al 1985, Lennard et al 1986) which could account 
for some racial differences (Iyun et al 1986). Al though 
propranolol also undergoes oxidation, its metabolism has 
been found to be unaffected by debrisoquine phenotype 
(Lennard et al 1986). 
Bioavailability, protein binding and clearance are altered 
by liver disease, necessi tating dose reduction (Regardh 
1982). 
There is a very wide inter- and intra-individual spread of 
propranolol concentration to dose ratios (Esler et al 1977 , 
Hitzenberger 1979, Lehtonen et al 1977). This is the result 
of variation in bioavailability, serum protein binding and 
extent of metabolism including production of active 
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metaboli tes. Defining concentration effect relationships 
for propranolol is complicated by this pharmacokinetic 
variability. 
1.2.2. Pharmacokinetics of Atenolol 
1.2.2.1. Absorption and Bioavailability 
The oral bioavailability of atenolol is approximately 50% 
(Brown et al 1976, Conway et al 1976, Kirch et al 1981, 
Mason et al 1979, Wan et al 1979). Bioavailabili ty is 
unaffected by dose up to at least 600 mg (Kirch & Gorg 
1982). Unlike propranolol, atenolol dose and concentration 
are linearly related (Amery et al 1977b, Ishizaki et al 
1983, Mason & Winer 1976, Shanks et al 1977). In contrast 
to dogs where absorption is complete, man, rats, mice, 
rabbi ts and rhesus monkeys absorb atenolol incompletely 
after oral administration (Reeves et al 1978a, Reeves et al 
1978b). Using radiolabelled atenolol, Reeves at al (1978b) 
showed that after oral dosing 47% of the dose was recovered 
from urine and 53% from faeces in contrast to 88% urinary 
and 10% faecal recovery after IV dosing. This study 
confirmed that the incomplete urinary recovery after oral 
dosing seen in earlier studies (Brown et al 1976, Conway et 
al 1976, McAinsh 1977) was due to incomplete absorption and 
not to extensive first pass metabolism as with propranolol. 
Peak levels occur 2-4 hours after oral administration with 
an approximately 4- 10 fold inter- individual variation 
(Amery et al 1977a, Ishizaki et al 1983, McAinsh et al 
1980). Administration of atenolol with food reduces the AUC 
by about 20% (Melander et al 1979). Hypothyroid patients 
have a lower maximum atenolol concentration and AUC after 
oral administration than after correction of the 
hypothyroidism (Levesque et al 1990) implying reduced 
bioavailability in this condition . 
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1.2.2.2. Distribution 
Any variation in serum protein binding of atenolol is not 
likely to alter effect dramatically since serum protein 
binding is less than 5%. 
The plasma concentration-time decay can be described by a 
two or three exponential expression reflecting a two or 
three compartment open model. 
studies in which the distribution characteristics of 
atenolol have been investigated are summarised in Table 
1.3. When doses were small (5-10 mg) the two compartment 
model appeared to be most appropriate probably because 
serum/plasma levels declined to below the assay detection 
limits of 10-20 ng/ml before the slow terminal elimination 
phase became evident (Buck et al 1989, Kirch et al 1981, 
Rubin et al 1982). In studies where larger IV doses (50 mg 
or greater) were used a 3 compartment model appeared to fit 
best for most individuals (Mason et al 1979) since levels 
of atenolol were detectable at 24 hours or longer after 
administration. This would account for the shorter half-
lives reported with lower IV doses as compared with 50 mg 
IV doses (Rubin et al 1982) and oral doses of 100 mg or 
more. This methodological explanation is more likely than 
the suggestion that a saturable non-glomerular elimination 
pathway is operative and becomes saturated at doses above 
10 mg (Rubin et al 1982). 
Atenolol is rap idly distributed to extra-vascular tissue 
(half-life of about 20 minutes) (Buck et al 1989). The 
volume of the central compartment has been calculated as 
between 12 and 20 Ii tres with that of the peripheral 




Atenolol is mainly eliminated unchanged by the kidneys with 
less than 10% being metabolised (Reeves et al 1978b). The 
influence of metabolites (active or inactive) is the~efore 
negligible in terms of the dose-concentration-effect 
relationship. 
Although one study showed that age did not appear to alter 
atenolol disposition dramatically (Rubin et al 1982) 
another study showed a significantly increased AUC 
associated with decreased clearance in elderly hypertensive 
subjects compared with healthy young volunteers (Rigby et 
al 1985). A number of studies show atenolol plasma levels 
and clearance correlate closely with creatinine clearance 
(Amery et al 1977a, Ishizaki et al 1983). Impaired renal 
function can substantially reduce the clearance of atenolol 
and the elimination half life is prolonged from 6 to more 
than 100 hours in anephric patients (McAinsh et al 1980). 
Dose or dose interval adjustment is necessary in severe 
renal failure (McAinsh et al 1980a, Regardh 1982). 
Not surprisingly, neither clearance nor pharmacodynamics of 
atenolol are related to debrisoquine oxidation phenotype 
(Dayer et al 1985, Lennard et al 1986, Lewis et al 1985). 
Atenolol's clearance is dependent only on renal function 
and therefore plasma levels show little intra-individual 
variation and relatively small inter-individual variations 
(Ishizaki et a l 1983). 
Table 1.3. Pharmacokinetic parameters of atenolol after IV dosing. 
References No of Dose V CL 
Patients (mg) (L/kg) (L/hr) 
Reeves et al 2 5 76.00 5.85 
1978b (L) 
Kirch et al 1981 7 5 1 .20 9.00 
Buck et al 1989 7 (young) 0.1 0.83 0.15 
(mg/kg) (L/hr/kg) 
Wan et al 1979 6 (young) 50 - 9-14 
Rubin et al 1982 7 (young) 10 0.55 12.18 
7 (elderly) 10 0.75 9.78 
Brown et al 1976 4 10,20, 51 .2 5.8 
50 & 80 (L) 
Kirch et al 1981 7-normal GFR 5 1 .2 9.0 
8-moderate .J. 5 - 4.2 
! 
4-pre-uraemic 5 0.9 1 .5 





























1.3. DOSE-CONCENTRATION-EFFECT RELATIONSHIPS OF BETA-
BLOCKERS 
1.3.1. Dose-effect Relationship 
The steepness of the dose-effect relationship depends on 
which effects of beta-blockers are under consideration. 
1.3.1.1. Negative Chronotropic Effects 
Resting bradycardia is dose dependent for all those beta-
blockers without ISA. However, with pindolol, reduction in 
resting heart rate has been shown to be inversely related 
to dose when assessed 1 to 3 hours after dose but is 
reversed at 24 hours post dose (Jennings et al 1979). 
In volunteers, a linear relationship between dose and 
inhibition of exercise tachycardia has been demonstrated 
for atenolol (up to 200 mg), metoprolol (up to 400 mg), 
sotalol (up to 400 mg) (Harron et al 1981, Shanks et al 
1977) and timolol (up to 25 mg) (Singh et al 1980). 
Exercise tachycardia was increasingly reduced with 
increasing doses of metoprolol from 25 to 100 mg and 
propranolol 20 to 120 mg but pindolol increased effects 
only from 2.5 to 5 mg with minimal further increases at 
higher doses (Gugler et al 1980). The magnitude of maximal 
inhibition of exercise tachycardia was also less with 
pindolol (25%) than with the other two drugs (30%). 
In a large volunteer study of the influence of varying 
dosage regimens of propranolol on exercise tachycardia, the 
degree of beta-blockade at the daily minimum propranolol 
level (trough) was related to total daily dose and not to 
dose frequency (Mullane et al 1982). Regardless of how the 
daily dose was divided (twice or four times daily) an 
equivalent degree of inhibition of exercise tachycardia was 
observed before the morning dose with equivalent daily 
doses. 
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1.3.1.2. Hypotensive Effects 
The dose response curve for BP reduction appears to be less 
steep than that for heart rate. In responders little 
further reduct i on in BP was seen over 200 mg metoprolol 
(Collste et al 1980), 75-100 mg atenolol (Douglas-Jones & 
Cruikshank 1976, Ishizaki et al 1983, Myers et al 1976, 
Amery et al 1977a) and 80 mg propranolol (Leenen et al 
1982, Serlin et al 1980) although resting bradycardia 
increased with higher doses. 
In one study, although BP reduction was more pronounced 
wi th increasing doses of propranolol neither mean dose 
(160 to 480 mg/day) nor concentration (98 to 215 ng/ml) 
could be . correlated with mean decrease in BP (Lehtonen et 
al 1977). The reason could be that dose and concentration 
were near maximal. 
It has been suggested that there may be a difference in the 
dose response curves of systolic and diastolic BP. Amery et 
al (1977b) showed a maximal effect on systolic BP at doses 
of 150 mg atenolol with no further significant decrease 
with doses of 300 mg and even 600 mg in some patients. 
Diastolic, BP however, decreased successively with 
increments up to a total of 300 mg per day. This suggests 
different mechanisms may be involved. 
There is some controversy as to whether there might be a 
biphasic BP response (Esler et al 1977, Hollifield et al 
1976) and whether BP can be effectively lowered in patients 
who do not respond to low doses of propranolol by using 
large doses (M'Buyamba-Kabanga 1986, Seedat & Reddy 1971). 
This is of academic interest only because side effects 
including bradycardia limit the use of very large doses. 
1.3.1.3. Plasma Renin Activity 
Renin suppression appears to occur at lower doses than are 
usually needed for BP reduction (Prichard 1979). Ishizaki 
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et al (1983) showed that renin suppression was maximal at 
doses of 25 mg of atenolol daily, which in most patients 
had little effect on BP. Similarly 40 mg propranolol 
induced maximal suppression of supine and furosemide 
stimulated renin levels and 60% suppression of standing 
renin levels whilst BP decreases were seen at doses from 
40-160 mg daily (Leonetti et al 1975). 
1.3.2. Time Course of Action 
1.3.2.1. Negative Chronotropic Effects 
In most studies, the time course of inhibition of exercise 
tachycardia by beta-blockers is the same as that of plasma 
concentrations. After IV administration maximal reduction 
of exercise tachycardia is seen 
assessment, 5-15 minutes after 
at the first point of 
doses of timolol and 
propranolol (Achong et al 1976). When beta-blockers are 
administered orally, the peak effects on inhibition of 
exercise tachycardia usually occur at approximately the 
same time as the peak concentrations. This has been found 
with propranolol (Giudicelli et al 1977) metoprolol 
(Wieselgren et al 1989), and pindolol (Jennings et al 
1979). 
Penbutolol appears to be an exception, with a delay of 
about 1 hour to peak chronotropic effects (Brockmeier et al 
1988, Giudicel l i et al 1977). This may be the result of the 
production of unknown active metabolites (Brockmeier et al 
1988). 
Achong et al (1976) have shown that the time course of the 
negative inotropic and chronotropic responses to timolol 
and propranolol are identical. 
1.3.2.2. Hypotensive Effects 
The time of onset and the time to development of maximal 
antihypertensive effects have been the subject of much 
controversy. Many publications, especially the earlier 
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ones, claimed that the hypotensive action was slow in onset 
requiring dose titration and weeks to months for maximal 
effects to develop (M'Buyamba-Kabanga et al 1986, Prichard 
1964a, Prichard & Gillam 1964b, Prichard & Gillam 1966, 
Prichard & Gillam 1969, Tarazi& Dustan 1972). Since most 
of these studies increased doses at intervals (usually two 
weeks) and the patients were only monitored at these 
intervals it is not clear whether it was dose or time which 
was responsible for the observed increase in effects. Very 
few single dose studies in the 1960s and early 1970s 
assessed blood pressure responses. 
The development of the hypotensive effect of beta-blockers 
is time-lagged by hours when compared with negative 
inotropic and chronotropic effects and with blood levels. 
In the early studies the hypotensive effects of single 
doses were probably missed since attention was focused on 
the time course of heart rate effects. 
1.3.2.2.1. Intravenous Administration 
In volunteers, bolus IV doses of propranolol (0.2 mg/kg) 
modestly decreased resting systolic, diastolic and mean 
arterial pressure at 3 to 6 hours after the dose (Fagan et 
al 1982a). A study with atenolol (10 mg) showed different 
time courses for systolic and diastolic BP (Fitzgerald et 
al 1978). Systolic BP was reduced from 15 minutes to 8 
hours post dosing whilst diastolic BP was significantly 
decreased only from 4 up to 24 hours after the IV dose. 
1.3.2.2.2. Oral Administration 
There is now much evidence that effects on BP are seen 
after the first oral dose or at least within a few days, 
w( th the effec t on systolic BP preceding that on diastolic 
pressure. It has been suggested that the extent of the 
initial effect is dose dependent; the bigger the starting 
dose the quicker the onset of effect (Pedersen et al 1981). 
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Normotensive Volunteers 
In volunteers, single oral doses of both atenolol (100 mg) 
and propranolol (200 mg) caused significant reductions in 
resting supine systolic and diastolic blood pressures with 
the fall beginning 1 hour after administration and 
remaining below control values for 24 hours (Maling et al 
1979). Peak effects were seen between 2-4 hours and 6-8 
hours with propranolol and atenolol respectively. Fagan et 
al (1982a) showed that a single 80 mg oral dose of 
propranolol reduced systolic, diastolic and mean arterial 
pressure by 10%, three hours after the dose. 
Oral pindolol ( 5 , 1 0, and 20 mg) given to normotens i ve 
volunteers reduced resting systolic blood pressure with 
peak effects occurring between 1 and 3 hours post-dose 
(Jennings et a l 1979). The effects of the two lower doses 
had worn off by 7 hours. 
Hypertensive Patients 
In hypertensive patients given single doses of propranolol 
(Fagan et al 1982b, Leenen et al 1982), effects on BP were 
seen wi thin 6 hours. In the first study these effects 
increased wi th further dosing and appeared to parallel 
propranolol cumulation; at 3 days 89-92% of the total 
effects seen at 6 days were observed (Fagan et al 1982a). 
Collste et al (1980) found that single doses of metoprolol 
produced falls in systolic and diastolic pressures of 57% 
and 23% of those seen with long term therapy with 
relatively greater effect seen on systolic BP. In another 
study single oral doses of metoprolol (50 and 80 mg) given 
to hypertensive patients decreased systolic BP within half 
an hour of administration with no effect observed on 
diastolic BP up to 6 hours post dose (Bengtsson et al 
1975). 
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A single 100 mg dose of atenolol decreased supine BP in 
hypertensives producing a maximum decrease of 17 mm Hg at 
6 hours and o f 11 mm Hg at 10 hours for systolic and 
diastolic BP respectively (Leonetti et al 1980). In another 
study, oral atenolol (200 mg) caused a significant 
reduction in systolic pressure from 45 minutes onwards with 
a return to normal by 24 hours (Fitzgerald et al 1978). In 
contrast, reduction of diastolic pressure was only evident 
from 3-4 hours after oral dosing but persisted up to 24 
hours after dosing. Curiously, in the same study, the time 
courses of effects of intravenously administered atenolol 
(10 mg) on both systolic and diastolic BP, closely 
paralleled those of oral dosing. 
In a long term study in 15 patients who carried out horne BP 
measurements, the major fall in BP occurred 24-48 hours 
after initiation of treatment with 200 mg atenolol three 
times daily (Amery et al 1977b). In another study of 
atenolol the first 100 mg dose caused a prompt (3 hours) 
and prolonged (up to 24 hours) reduction of supine and 
standing systolic and diastolic BP (Leonetti et al 1980). 
The extent and time course of the effects were not altered 
by repeated daily (100 mg) dosing for two weeks. 
Many studies have shown that, in responders to beta-
blockers, effects that were seen at the first assessment 
viz. one week (Harry et al 1979) two weeks (Marshall et al 
1977, Myers et al 1976, Serlin et al 1980) or 3 weeks 
(Paterson & Dol lery 1966) were not significantly different 
from those seen at later times. 
1.3.2.3. Tremor olytic Actions 
The tremorolyt i c actions of beta-blockers although mediated 
mostly by beta2-blockade are interesting in that the time 
course of onset of effect is delayed with respect to that 
of heart rate although off set rates are similar. Abila et 
al (1985) conducted a very interesting experiment using 
three beta-blockers wi th different kinetic and dynamic 
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characteristics. They showed significantly greater rate 
constants for onset of cardiac effects than for 
tremorolytic effects, irrespective of the magnitude of the 
effects seen. Differences in the rate constants for the 
three drugs within the heart rate and tremor responses were 
not however, significant. The authors concluded that the 
delay in tremorolytic actions was possibly due to the beta-
receptors being located in a relatively inaccessible 
compartment rather than to rate-limiting post receptor 
events. 
1 . 3.3. Concentration-Effect Relationships of Beta-blockers 
1.3.3.1. Negat i ve Chronotropic Effects 
1.3.3.1.1. Resting Bradycardia 
A linear relationship between reduction in resting heart 
rate and the log of metoprolol plasma concentration within 
the range of 20-100 ng/ml has been demonstrated (Bengtsson 
et al 1975). 
Maximal resting heart rate responses to propranolol occur 
at concentrations of 100 ng/ml (Lehtonen et al 1977). 
Significantly greater effects on inhibi tion of resting 
heart rate occurred at pindolol concentrations above 20 
ng/ml compared with below 20 ng/ml but little further 
inhibition was seen in the range 21-160 ng/ml (Jennings et 
a11979). 
other studies showed a poor relationship between 
propranolol (Hager et al 1981 , Hi tzenberger 1979) 
penbutolol (Jun et al 1979) and oxprenolol (Hitzenberger 
1979) concentrations and changes in resting heart rate. 
1.3.3.1.2. Inhibition of Exercise Tachycardia 
Many studies, both acute and chronic have found a linear 
relationship between inhibition of exercise tachycardia and 
the log of plasma concentration of various beta blockers, 
including atenolol (Amery et al 1977b, McAinsh 1977, Shanks 
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et al 1977), acebutolol (Quarterman et al 1979, Woods et al 
1979), alprenol ol (Ab~ad et al 1974), bisoprolol (Leopold 
et al 1986), metoprolol (Woods et al 1979), oxprenolol 
(Mason & Winer 1976) penbutolol (Muller et al 1979), 
propranolol (Coelho et al 1983, Coltart & Shand 1970, Hager 
et al 1981, McAinsh et al 1978, McDevitt & Shand 1975, 
Mullane et al 1982, Van den Brink et al 1980, Woods et al 
1979), nadolol and pindolol (Kostis et al 1984). 
Fujimura et al (1990) demonstrated a greater reduction of 
exercise tachycardia with morning oral dosing of 
propranolol than with evening dosing. They ascribed this to 
diurnal variation in plasma concentrations of propanolol 
resulting from an increased absorption rate in the morning. 
They found no difference between the morning and evening 
regression l i nes relating percentage reduction in 
tachycardia to the log of plasma propranolol 
concentrations. 
A linear relationship between propranolol plasma 
concentration (up to 300 ng/ml) and reduction in exercise 
tachycardia has also been demonstrated (Serlin et al 1980). 
A similar linear relationship has been found for timolol 
plasma levels and percentage reduction in exercise 
tachycardia (Singh et al 1980). 
The concentrations at which effects reach a plateau show 
inter-individual and inter-study variation, probably 
because of differences in the extent of sympathetic 
stimulation el i cited by differing exercise protocols. Hager 
et al (1981) found inhibition of exercise tachycardia to 
plateau at propranolol concentrations of 200 ng/ml in 4 of 
7 subjects whilst in the other 3 no plateau was 
demonstrated up to 450 ng/ml. Serlin et al (1980) also 
found plateau effects above 300 ng/ml of propranolol. On 
the other hand, inhibition of exercise tachycardia has been 
reported to be maximal at propranolol concentrations of 80 
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to 100 ng/ml (Chidsey et al 1976, Mullane et al 1982, Nies 
& Shand 1975). 
Chidsey et a l (1976) found an IC~ of 8 ng/ml for 
propranolol inh ibition of exercise tachycardia at maximal 
exercise indicating a relatively flat dose response curve. 
The ICso was 5 ng/ml and 3 ng/ml for moderate and mild 
exercise respectively (Chidsey et al 1976). (See 2.2.2.) 
Coltart and Shand (1970) reported that for a given maximal 
effect on exercise tachycardia, higher concentrations (> 
100 ng/ml) of propranolol are required after single dose IV 
administration than after oral administration (40 ng/ml). 
They ascribe the difference in response to a contribution 
by active metabolites formed after oral but not after IV 
administration. Since measurements were made 1.5 hours 
after dosing, active metabolites may well have contributed 
to the effect. (See 1.2. 1 .3. ) 
1.3.3.1.3. Inhibition of Isoprenaline Induced Tachycardia 
A straight line relationship between log of mean plasma 
concentration of propranolol and the dose ratio of 
isoprenaline i n the presence and absence of propranolol has 
been found (Coltart & Shand 1970, Zacest & Koch Weser 
1972). 
Hager et al (1981) have also reported a good relationship 
between isoprenaline dose ratio minus 1 (DR-1) and serum 
propranolol concent1;"ations after chronic oral treatment 
with doses from 10 to 160 mg four times daily. This was 
also found after intravenous administration of propranolol 
with concentrations between 5 and 200 ng/ml (McDevitt & 
Shand 1975). A higher dose ratio was found by Shepherd et 
al (1991) than by McDevitt and Shand (1975) (22 versus 13). 
In a study where subjects were given much smaller doses by 
intravenous i n fusion, McDevitt et al (1976) found a 
44 
relatively poor relationship between total 
plasma concentrations (range of 22 to 50 
propranolol 
ng/ml) and 
isoprenaline DR-1. However, an excellent correlation 
between efficacy and free drug concentration was found. 
They concluded that the effects of propranolol are a 
function of free drug concentration according to the 
classical receptor theory of drug antagonism (See 2.2.2.). 
When beta-blockade due to a small IV dose of timolol (0.25 
mg) was assessed by determining the dose ratios of 
isoprenaline required to raise heart rate by 25 
beats/minute a linear relationship between log of timolol 
concentration and log (DR-1) was found (Kaila et al 1991). 
The isoprenaline DRs and the pA2 (below 1 ng/ml) values for 
timolol are consistent in various studies (Achong et al 
1976, Kaila et al 1991, Klein et al 1986) and indicate that 
the isoprenaline increased heart rate is extremely 
sensitive to timolol blockade. 
1.3.3.2. Hypotensive Effects 
Poor relationships between plasma concentration and fall in 
BP have been demonstrated for atenolol (Amery et al 1977b, 
Ishizaki et al 1983), carteolol (Giles et al 1984), 
propranolol (Hitzenberger 1979, Krediet et al 1980, 
Lehtonen et al 1977, Serlin et al 1980), metoprolol 
(Bengtsson et al 1975) and oxprenolol (Hitzenberger 1979, 
Myers & Thiessen 1980, Marshall et al 1977). 
When Amery et al (1977b) divided their patients into 3 
equal groups according to the hypotensive response to daily 
doses of 300 mg of atenolol, they found no differences 
between the groups with respect to beta-blockade (exercise 
tachycardia) or morning blood levels of a tenolol which 
could account for the variability in response. 
Most of the above authors concluded that the wide inter-
patient variabi lity in hypotensive response is unrelated to 
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plasma concentrations or degree of beta-blockade as 
assessed by reductions in exercise tachycardia. 
Because there is a lag in the time course of the anti-
hypertensive effects relative to chronotropic effects it is 
not surprising that the log-linear relationship found for 
concentration and negative chronotropic effects (See 
1.3.3.1.2. above) should be inappropriate for BP. 
Two other factors which may complicate the relationship 
between concent ration and blood pressure response are the 
inclusion of non-responders and the disregard of maximal 
effects by many investigators. 
A few studies have demonstrated some correlation between 
concentration of beta blocker and blood pressure response. 
Although there was great inter-individual variability an 
average level of 120 ng/ml of propranolol was associated 
with a good response (Chidsey et al 1976, Hansson et al 
1974). Chidsey et al (1976) found significant effects on 
blood pressure at propranolol concentrations above 30 ng/ml 
which became progressively greater as the propranolol 
levels rose. They found a linear relationship between the 
log of propranolol concentration and percentage change in 
diastolic BP with no evidence of a plateau at the levels 
achieved in their patients. They concluded that much higher 
concentrations were necessary for BP reduction than for 
inhibition of exercise tachycardia and PRA. This conflicts 
with the idea that the dose response curve for BP is less 
steep than that for inhibition of exercise tachycardia (See 
1 .3 . 1 .2. above). A modest but statistically significant 
linear relationship between minimum nadolol plasma 
concentration ( 25 to 275 ng/ml) and fall in diastolic BP in 
responders (>5% from pre-treatment) has been reported 
(Duchin et al 1980). 
46 
A biphasic plasma propranolol concentration-hypotensive 
effect relationship has been demonstrated by another group 
of investigators (Esler et al 1977). They suggested an 
early antihypertensive effect at propranolol concentrations 
of 10 ng/ml (related to basal plasma renin activity) with 
the later effect above 30 ng/ml (unrelated to renin status) 
and a plateau above 100 ng/ml. Concentrations were however, 
unrelated to falls in PRA but appeared to be related to 
higher plasma noradrenaline levels, a higher cardiac output 
and heart rate. 
In a study investigating the 
metoprolol treatment on blood 
effects of 14 days of 
pressure, critical flash 
fusion and tremor, an Emax pharmacodynamic model was used to 
estimate values for the concentration giving 50% of maximal 
effect (ICso ) and the ratio of Emax to drug free baseline 
(Gengo et al 1985). Significantly different values for the 
different effects were found indicating distinct sites or 
mechanisms of action . The ICso for BP reduction was 49.2 
ng/ml and was between that found for the other two effects. 
1.3.3.3. Plasma Renin Activity 
One study with propranolol has shown a maximal effect on 
PRA at concentrations of 10 ng/ml to 30 ng/ml (Esler et al 
1977). In another study, maximal effects on both supine and 
standing PRA were seen at 100 ng/ml of propranolol with an 
IC so of 11 ng/ml, which closely resembled effects on heart 
rate (Chidsey et al 1976). 
1.3.3.4. Anti-anginal Efficacy 
As with hypertensive patients, patients with angina can 
also be categorised into responders and non'-responders to 
beta-blockers (Johnsson & Regardh 1976). A significant 
reduction in anginal episodes in responders was 
consistently obtained with propranolol serum levels above 
30 ng/ml (Alderman et al 1975, Johnsson & Regardh 1976, 
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Pine et al 1975) whilst in non-responders much higher 
levels were wi t hout effect. 
1.3.3.5. Myocardial Contractility 
Corbo et al (1989) found that the pharmacokinetic-dynamic 
relationship for propranolol on myocardial contractility 
differed between normotensive and spontaneously 
hypertensive rabbits. There were no differences in 
pharmacokinetic parameters of propranolol between the two 
groups of rabbits including the elimination rate constant 
from the effect compartment (keD of 2.78 hr-1 ) (See 
2.3.2.4.). However, using the sigmoid Emax model, ICSD 
values of 12.7 and 6.9 ng/ml and slopes of 7 and 3 were 
obtained for the normotensive and hypertensive groups 
respectively suggesting altered sensitivity to propranolol 
in hypertension. 
1.3.3.6. Antiarrhythmic Actions 
Antiarrhythmic effects in patients who respond to 
propranolol have been demonstrated at concentrations of 40-
85 ng/ml whilst concentrations of 20-700 ng/ml were 
ineffective in non-responders (Coltart et al 1971). 
1.3.3.7. Central Nervous System Actions 
Changes in psychomotor function as measured by flash fusion 
frequency were found to be related to metoprolol serum 
levels, although these changes lagged behind the time 
course of metoprolol concentrations (Gengo et al 1985a). 
This time lag with a half-time of 29 minutes was thought to 
be the result of accumulation of an active metabolite, 
hydroxymetoprolol rather than a delay in CNS penetration. 
CHAPTER 2 
AN OVERVIEW OF THE DOSE-CONCENTRATION-EFFECT RELATIONSHIP 
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CHAPTER 2 
AN OVERVIEW OF THE DOSE-CONCENTRATION-EFFECT RELATIONSHIP 
In order for any drug to bring about a desired therapeutic 
effect in a patient the drug must have the appropriate 
pharmacodynamic capability and it must reach its site of 
action in sufficient concentrations to elicit that effect. 
To achieve this the correct dosage regimen needs to be 
implemented . A thorough knowledge of the drug's pharmaco-
dynamics as well as its kinetics and the sensitivity and 
variation of the target population will allow more rational 
drug choice, dose design and thus therapeutic application 
of medicines. 
In the case of the beta-blockers although much is known 
about their pharmacodynamic effects their mode of anti-
hypertensive action still eludes us. It is also far from 
clear why beta-blockers are ineffective in lowering BP in 
some patients. New, more sophisticated, computer based data 
analysis techniques are assisting in the elucidation of 
more subtle i n terindi vidual differences in kinetics and 
dynamics. This chapter gives a background to the develop-
ment and application of the pharmacokinetic and pharmaco-
dynamic techniques which have been utilised in the present 
study in an attempt to assess whether black and white 
normotensi ve volunteers differ in their sensi ti vi ty to 
atenolol. 
2.1. DOSE-CONCENTRATION-TIME RELATIONSHIPS 
PHARMACOKINETICS 
A brief review of some aspects of pharmacokinetic data 
analysis which are pertinent to this thesis will be given 
below. It should in no way be considered a comprehensive 
review. 
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2.1.1. Methods of Pharmacokinetic kssessment 
Certain pharmacokinetic parameters can be calculated 
without making as many assumptions as are made when 
compartmental models are used. It may therefore be useful 
to calculate these parameters using model dependent and 
model independent methods in order to confirm the applic-
ability of the particular model(s) chosen. 
2.1.1.1. Model Independent Assessment Methods 
Noncompartmental methods for the assessment of certain 
pharmacokinetic parameters based on statistical moment 
theory are enjoying i ncreasing utilization particularly in 
bioavailability studies . 
The time course of drug concentration in plasma can usually 
be regarded as a statistical distribution curve. The first 
three moments are: 
i) Area under the curve (AUC); 
ii) Mean residence time (MRT)i 
iii) Variance of the mean residence time (VRT). 
These moments can be calculated by numerical integration 
using the trapezoidal rule (Gibaldi & Perrier 1982) 
although only the zero moment (AUC) and first moment (MRT) 
are used due to unacceptable error in the computation of 
the second moment (VRT) (Gibaldi & Perrier 1982). 
In the usual single-dose pharmacokinetic study, estimation 
of AUC and Area-under- the-(first) - moment versus time curve 
(AUMC) is carr i ed out in two stages . First the AUC or AUMC 
from the time of administration to the last blood sampling 
time is calculated. This is then added to the AUC or AUMC 
from this last sample time extrapolated to infinity 
(Gibaldi & Perrier 1982 , Rowland & Tozer 1989). 
The following parameters relevant to intravenous 




iii) Volume of distribution 
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(See Methods 3 . 5.2.1. for equations). 
2.1.1.2. Model Dependent Compartmental Pharmacokinetic 
Assessment Methods. 
Models are heavily relied upon in much of the work carried 
out in pharmacokinetic and pharmacodynamic analyses. 
'Models' are s i mplified, mathematical forms, the constants 
(parameters) of which represent factors believed to be 
important in determining observations of either 
concentrations or effects of drugs (Holford & Sheiner 
1982). 
Rescigno & Beck (1987) have explicitly reviewed the 
limitations of modelling. Their definition of a model is a 
secondary system made with the purpose of verifying the 
validi ty of a hypothesis made on a primary system. In 
judging a simulator (a secondary system merely describing 
a primary system) only the closeness with which the 
simulator mimics the primary system need be assessed. 
However, in contrast to a simulator, when choosing a model 
three different points need to be judged: retrodiction, 
prediction and understanding (Rescigno & Beck 1987). 
The description of concentration time data by means of 
compartmental models is a commonly used approach. It 
represents the body as a system of compartments, with the 
assumption that the rate of transfer (intercompartmental 
clearance) between compartments and the rate of elimination 
from compartments is linear (Gibaldi & Perrier 1982). These 
compartments may have no physiologic or anatomic reality 
(see 2.3.2.3. below). However, this approach is useful in 
relation to pharmacodynamics in the context of obtaining 
good predictions of concentrations at times when effects 
and not concentrations are measured. Thus, whether atenolol 
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concentration time data fits a two or three compartment 
model better in a particular individual has no clinical 
relevance. Nevertheless, the better the description of the 
pharmacokinetic data the less the uncertainty in the 
pharmacokinetic-pharmacodynamic modelling. 
2.1.1.2.1. Nonlinear Least Squares Regression Analysis for 
Individual Patient Parameter Estimation 
In model dependent analysis of pharmacokinetic data (and 
pharmacodynamic data) the mathematical form of a model is 
fitted to the observed data by using nonlinear regression 
procedures. The most commonly used method is ordinary 
nonlinear least squares analysis (OLS) which assumes a 
constant variance model (Sheiner & Beal 1985). Many 
pharmacokineticists make use of weighted least squares 
(WLS) where ei t her some form of weighting (variance model) 
is assumed appropriate or different weightings require 
testing. 
The method of extended least squares (ELS) regression (Beal 
& Sheiner 1979) overcomes the problem in that the variance 
model is speci f ied explicitly rather than implicitly as in 
choosing weights for ordinary least squares regression 
(Peck et al 1984). Simulations have established that ELS 
regression behaves better when there is heteroscedasticity 
in the data (Sheiner & Beal 1985) as is usually the case 
with pharmacokinetic data. 
2.1.1.2.2. The Use of NONMEM for Population Pharmacokinetic 
Parameter Estimation 
Nonlinear Mixed Effect Modelling (NONMEM) is a technique 
developed to directly assess mean population pharmaco-
kinetic parameters, their quantitative relationship (fixed 
effects) to individual physiology (eg. body size, age, 
renal function etc. ) and their variability across 
popula tions (random effects and errors). It is ideally 
.sui ted for the analysis of data collected from a large 
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number of patients (few data points per individual), in a 
relati vely unstructured fashion in routine patient care 
(Sheiner et al 1977) . 
This method is also applicable to data arising from 
traditional experimental designs. When compared to a 
standard two stage (STS) method where each individual's 
data is fitted separately and the individual parameters are 
then combined, NONMEM's estimates are as good for mean 
parameters and residual variability (Grasela et al 1986, 
Sheiner & Beal 1981) but are better for interindividual 
variability. In a simulation study Sheiner & Beal (1981) 
demonstrated that the STS method consistently over-
estimates interindi vidual variability due to the added 
error from each individual estimation. 
In pharmacokinetic studies the estimate of interindividual 
variability by NONMEM although not biased is unacceptable 
in an absolute sense since it is highly imprecise (Grasela 
et al 1986). This is a consequence of the small number of 
subjects used in experimental studies. Additionally, they 
may not be representative of the population. 
However, in the context of the present study it was thought 
appropriate to test NONMEM against the STS method in an 
attempt to highlight any possible racial differences in 
kinetic handling and pharmacodynamic response. At the same 
time it is recognised that a small number of individuals 
would make it difficult to identify statistically 
significant differences with either method. 
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2.2. IN VITRO CONCENTRATION-EFFECT RELATIONSHIP AND 
RECEPTOR THEORY 
Most drug molecules exert their effects by interacting with 
functional macromolecular components of the ... organism, 
namely the receptors. The development of receptor theory 
began with the observations of Langley and Ehrlich in 1905 
and 1906. Langley suggested that drug cell combinations and 
hence drug actions were probably governed by the law of 
mass action. Clark developed this view in the 1920s and 
1930s and introduced many of the concepts still in use 
today. However, it was Ariens, Simonis 
(1964) who refined the theory, made it 
rigorous and examined the applicability 
experimental f i ndings (Tallarida 1984). 
2.2.1. Receptor Binding of Agonists 
and Van Rossum 
mathematically 
of theory to 
The original work involved indirect characterization of 
receptors by examining agonist and antagonist structure 
activity relat i onships, usually in carefully controlled in 
vitro isolated organ systems. In these isolated systems the 
concentration in the organ bath is assumed to be propor-
tional to that in the biophase with transport and 
distribution processes having minimal influence. Under 
these circumstances relatively simple dose-response 
relationships can be studied (Ariens et al 1964). The 
simple relationships described below underlie the more 
complex situation encountered when drugs are administered 
to patients. 
Recent progress in receptor identification and 
characterization has involved the extensive use of 
radiolabelled ligand binding techniques whereby drug 
binding propert ies of receptors are studied directly. The 
earlier assumptions have been confirmed for a number of 
drug-receptor systems (Bourne & Roberts 1987). The 
quantitative assessment of drug action can be considered 
analogous to enzyme substrate interactions and ligand 
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binding reactions. If an agonist is assumed to interact 
with a receptor in a reversible fashion and the resultant 
effect is proportional to the number of receptors occupied 
the following equation can be written: 
k, 
Drug (D) + Receptor (R) ~ DR ~ Effect 
k2 
The magnitude of the effect (E) can be expressed in the 
form of the Michaelis Menten equation: 




where [D] is the concentration of free drug and KD (equal to 
k,/k2 ) is the dissociation constant for the drug receptor 
complex. There is thus no effect when [D] = 0 and the 
effect is half-maximal when [D] = KD• 
In the case of an agonist the term intrinsic activity (a) 
refers to the relative ability of a compound to give rise 
to a particular effect in relation to the maximal effect 
(Emax) of the system (Ariens et al 1964). Thus: 




In the situation where two drugs (A and B) are competing 
for occupation of the same receptor and both drugs are 
agonists the combined effect (EAB ) can be described as 
follows: 
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EAB _____ ....:..(l __ -:-::-_ + ~ 
Emax ( [B]) ( KA) 1+ (1+.1&) ( KB ) 
1+ 1+ KB lAf KA [B] 
The combined effect is determined by the concentrations of 
the individual drugs ([A] and [B]), by their affinity for 
the receptor (1/K
A 
and 1/Ks) and by their intrinsic 
activities (0 and 8) (Ariens et al 1964). 
2.2.2. Receptor Binding of Antagonists 
If one of the drugs, B for example, is a competitive 
antagonist with no intrinsic activity (8 = 0), only 
affinity, then the right hand term above becomes zero and 
the equation for effect would be: 
The concentration of a competitive antagonist which 
diminishes by 50% the observed response to a fixed agonist 
concentration is termed the Ie~. This Ie~ differs for each 
concentration of agonist used because of the competitive 
nature of the interaction (Bourne & Roberts 1987). 
The ratio .of the concentration of an agonist necessary for 
a given degree of effect in the presence of a fixed concen-
tration of antagonist (e ' ) relative to the concentration 
required to give that same degree of effect in the absence 
of the antagonist (e) is called the dose ratio (DR) (Bourne 
& Roberts 1987). It is related to the dissociation constant 




The experimentally derived Ks shows reasonable agreement 
with ligand binding studies of radiolabelled competitive 
antagonists to receptors (Bourne & Roberts 1987). Thus the 
degree of inhibition observed depends on both the 
concentration of antagonist as well as agonist present. 
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2.3. IN VIVO DOSE-CONCENTRATION-EFFECT RELATIONSHIPS 
In the past, the assessment of the kinetics of drug effects 
(pharmacodynamics) in the whole animal has enjoyed less 
attention than has the delineation of the plasma concen-
tration-time relationships (pharmacokinetics). Recently 
much more attention has been focused on the concurrent 
measurement of the pharmacodynamics and pharmacokinetics of 
drugs and interpretation of their inter-relationships 
(Holford & Sheiner 1981,1982, Paalzow 1984, Van Rossum & 
Burgers 1984). The assumption that there is a relationship 
between the desired or unwanted effect of a drug and its 
concentration in plasma is the basis of therapeutic drug 
monitoring. Thus better characterization of these relation-
ships should improve therapeutics. 
2.3.1. Pharmacodynamic Models 
As already mentioned (2.1.1.2), much of the work carried 
out in the areas of both pharmacokinetics and pharmaco-
dynamics relies heavily upon the use of models. Clearly the 
preferred pharmacodynamic models would be those which also 
offer some insight into the underlying physiological 
processes (Holford & Sheiner 1982). 
A brief description of some simple pharmacodynamic models 
follows. It should be noted that these models all refer to 
the situation in which drug concentration at the effect 
site is either known or is in equilibrium with the sampled 
biological fluid. In a tissue bath it is assumed that the 
concentration in the tissue bath is in equilibrium with the 
effect site. In vivo, at steady state the tissue site of 
action may be in equilibrium with the blood or sampling 
site although this is not necessarily so. For some drugs 
the equilibration between tissue site and plasma is so 
rapid that concentration and effect can be directly related 
even in the non-steady state situation. 
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2.3.1.1. Fixed Effect Model 
This is the simplest pharmacodynamic model. It relates drug 
concentration to an effect which may be either present or 
absent ego seizures or to some degree of effect ego 50% 
reduction of anginal episodes. It has only one constant, 
the concentration at which the effect appears. This 
constant, however, varies among individuals. The 
probability of a particular effect occurring at a given 
concentration can be modelled but the parameters of this 
probability distribution would need to be defined. Although 
a sigmoid curve is obtained when probability is plotted 
against concentration the theoretical basis is in the 
statistical theory of cumulative distribution function and 
not in receptor theory (Holford & Sheiner 1982). 
This model has been successfully applied in determining 
plasma concentrations of alfentanil required to suppress 
various noxious stimuli (Ausems et al 1986). These 
concentrations were then used to programme a computer 
controlled infusion pump to provide more appropriate 
delivery of anaesthetic and hence better anaesthesia 
(Ausems et al 1988). 
Although there do not appear to be any published applica-
tions of this model to beta-blocker effects it could be 
readily applied to relate average steady state concen-
trations to anti - anginal effects, antiarrhythmic effects 
and migraine prophylaxis. 
2.3.1.2. Linear Model 
This is the simplest relationship between concentration and 
effect, where the intensity of effect (E) is proportional 




This model predicts no effect when drug is absent but lacks 
the ability to estimate maximum effects. The parameters can 
be easily estimated by linear regression. 
If effect has some value when drug is absent such as BP 
then the equation becomes: 
E - S. C + Eo 
where Eo is the effect without drug. Whether Eo is estimated 
as a parameter or not depends on the reliability of 
measurements of Eo relative to E (Holford & Sheiner 1982). 
This model is applicable as an empirical description of 
drug effects over the observed concentration range when it 
is not practicable to achieve maximum effects (Holford & 
Sheiner 1981) and the particular effect is studied in the 
range below 50% of Emu (Oosterhuis & Van Boxtel 1988). 
It has been successfully applied to the effects of cardiac 
glycosides (Kelman & Whiting 1980) and total and unbound 
disopyramide (Thibonnier et al 1984, Whiting et al 1980) on 
the QT interval of the cardiac cycle. 
Correlations between the effects of beta-blockers on heart 
rate and their mean steady state plasma concentrations are 
relatively weak (Duchin et al 1980, Von Bahr et al 1976). 
A linear relationship between propranolol concentration and 
the isoprenal i ne DR-1 was reasonably strong (Col tart & 
Shand 1970, Zacest & Koch-Weser 1972) (See 1.3.3.1.3). 
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2.3.1.3. Log-linear Model 
The relationship between concentration and effect has 
traditionally been represented by a log transformation of 
concentration on the abscissa . The equation is: 
E-S.logC + I 
where E, Sand C are the same as before and I is a constant 
with no physiological meaning. 
There are two reasons why this transformation has enjoyed 
popularity. The first is ease of graphical representation 
by compression of a wide concentration range. The second is 
the convenience that the relationship between log concen-
tration and effect is a linear approximation of the Emax 
model in the range of 20 to 80% of maximum effect. Prior to 
the availability of non-linear regression techniques, this 
enabled the use of linear regression to determine the slope 
of the line and tests of parallelism to compare effects 
after addition of antagonists (Holford & Sheiner 1981). 
There are theoretical and practical disadvantages to using 
this model (Hol ford & Sheiner 1981, Oosterhuis & Van Boxtel 
1988). The two major drawbacks are its inability to predict 
E when concentration is zero (Kelman & Whiting 1980) and 
its inability to predict a maximum effect (Holford & 
Sheiner 1981, 1982). Whilst this model holds wi thin the 
range of 20 to 80% of maximal effect the practical 
difficulty remains how to ascertain that one is working 
within this range if E is not known. Additionally, the max 
model is unable to accommodate a baseline effect and may 
lead to the abuse of a baseline effect as if it were known 
without error (Holford & Sheiner 1981). Graphical represen-
tation using a log transform of concentration may obscure 
the existence of a maximum effect and make recognition of 
the need for the sigmoid Emax model difficult (Holford & 
Sheiner 1981). 
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Much of the work quoted in Chapter 1 (1.3.3.) relating 
concentration of beta-blockers to effect makes use of the 
log-linear model. Although many authors claimed a 
significant correlation between log concentration and 
reduction in heart rate the correlation was relatively weak 
(Bengtsson et al 1975, Muller et al 1979, Quarterman et al 
1979, Van den Brink et al 1980, Wilson et al 1982). Only a 
few researchers recognized a maximum effect (Esler et al 
1977, Fitzgerald et al 1978, Hager et al 1981, Mason & 
Winer et al 1976, Nies & Shand 1975) and excluded 
concentrations above certain values (Serlin et al 1980) or 
below certain values (Leopold et al 1986). Lalonde et al 
( 1987) clearly showed that the use of this model for 
predicting inhibition of exercise tachycardia by 
propranolol, underestimated the observed effects at lower 
concentrations and overestimated observed effects at higher 
concentrations. 
2.3. 1 .4. Emax Model 
The existence of a maximum drug effect when drug concen-
trations are allowed to increase indefinitely is an 
important biological attribute and this model can therefore 
be justified on theoretical grounds (See 2.2 above). It is 
described mathematically by the so-called E model: max 
Emax. C E- ---=.=.:..-
ECso+C 
where E is the maximum effect ascribed to the drug and max 
ECso is the concentration producing 50% of the maximum 
effect . 
In common with the linear model, this model predicts no 
effect when concentration is zero. It can also accommodate 






If the effect is inhibition of a physiological phenomenon 
such as lowering of exercise heart rate by a beta-blocker 
the equation can be modified to: 
where ICso is the concentration of the antagonist producing 
50% inhibition of Em~ 
Holford & Sheiner (1982) maintain that the Em~ model should 
be considered the basic pharmacodynamic model wi th the 
linear model being used as an approximation only when no 
maximum effect can be predicted or observed effects are 
always less than 50% of maximum. 
They illustrate their point by showing how Singh et al 
(1980) erroneously concluded that there was only a weak 
correlation between timolol concentration and effect on 
exercise and resting heart rate after applying the log-
linear model. Using the same data and the E model, Holford max 
& Sheiner (1982) found a stronger relationship which 
predicted the lowest heart rates (E ) achievable at rest max 
and after exercise to be 56 and 68 beats per minute with 
concentrations of 10 and 12 ng/ml of timolol giving half-
maximal effects (ICso ) respectively. 
In Chapter 1 (1.3.3), much of the data quoted relating to 
beta-blocker concentration and effect might be more 
appropriately described by this model rather than the log-
linear model (see 2.3.1.2. above). Some of the early 
studies on beta-blockade clearly demonstrated that the E 
max 
model was applicable to the heart rate effects of these 
drugs when pooled patient data was used and that plateau 
effects were obtained with therapeutic doses (Chidsey et al 
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1976, McDevitt & Shand 1975). A few more recent studies 
have demonstrated the suitability of this model for 
predicting the effects of propranolol (Lalonde et al 1987) 
and metoprolol (Gengo et al 1985, Kendall et al 1991) on 
exercise tachycardia in individual subjects. 
The receptor binding studies of Wellstein et al (1985a, 
1985b) have also confirmed that this model is appropriate 
for atenolol and propranolol. These authors suggest that 
any deviations from the model may be indicative of 
additional compartments, active metabolites, partial 
agonist activity, counter-regulatory processes and adaptive 
mechanisms and should be verified. 
2.3.1.5. Sigmoid E Model . max 
This model has an additional parameter, n, which allows for 
differences in the shape of the relationship which now 
becomes the so-called Hill equation: 
~x·cn 
E- --:;.::::..:....--
Holford & Sheiner (1981) warn that it is probably unwise to 
use the sigmoid Emax model if the effect is not clearly 
defined by the observations or by a known physiological 
limit such as total muscle paralysis. Noise in the effect 
measurement is the most likely explanation 
deviations from unity in which case the simpler 






Where there is a rapid equilibration of drug between plasma 
and tissue this model can be directly applied. In patients 
with varying degrees of renal dysfunction, Kleinbloesem et 
al (1985) related haemodynamic effects of nifedipine to 
plasma concentrations using the sigmoid Emax model. They 
found that although slopes did not differ, E was·larger 
max 
and ECso smaller in patients with more severe renal failure. 
64 
This indicated increased sensitivity to the drug in severe 
renal failure patients, over and above the differences in 
nifedipine kinetics. The sigmoidal concentration effect 
relationship of nifedipine concentration to haemodynamic 
effects was unaltered by hypertension and liver cirrhosis 
(when corrected for altered protein binding) (Kleinbloesem 
etal1987). 
In heal thy volunteers it was found that the sigmoid Emax 
model was the most appropriate one in most of the subjects 
in describing the direct relationships between left 
ventricular systolic function and heart rate and serum 1-
propranolol concentration (Clifton et al 1990). This study 
demonstrated that propranolol was significantly more potent 
in reducing heart rate (IC~ of 10 ng/ml) than left 
ventricular systolic function (IC~ of 19 ng/ml) but the Emax 
for the latter was significantly greater than for the 
former (47% ver sus 30%). 
2.3.2. Methods of Assessing Pharmacokinetic-pharmacodynamic 
(PK-PD) Relationships in vivo 
In the intact animal the situation is often more 
complicated as the concentration at the effect site is 
usually unknown and cannot always be assumed to be in 
equilibrium wi t h the sampled site. 
The overall relationship between dose and effect can be 
represented diagrammatically (Fig 2.1.). The common link 
between the pharmacokinetic model (PK) (relating dose to 
concentration) and the pharmacodynamic model (PD) (relating 
concentration to effect) is the concentration (C) in the 
biophase. 
DOSE-----PK-----C-----PD-----EFFECT 
Fig.2.1. The role of pharmacokinetics (PK) and pharmaco-
dynamics (PD) i n the dose-effect relationship 
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Pharmacokinetic-dynamic analysis becomes difficult when 
pharmacological effects are delayed in relation to levels 
of drug in the central (or sampled) compartment. Such 
equilibration delays become obvious when effect is plotted 
against concentration in the central compartment; when the 
points are joined in chronological sequence, a counter-
clockwise hysteresis loop is generated. This counter-
clockwise hysteresis may be the result of: 
i) an equilibration delay between the sampled compartment 
and the effect compartment; 
ii) an active metabolite being formed; 
iii) the effect not being rapidly reversible; 
iv) acute development of sensitization. 
(Oosterhuis & van Boxtel 1988). 
2.3.2.1. Model Independent Methods 
The most direct means of defining the PK-PD relationship 
would be to measure the effect and simultaneously the 
concentration at the effect site. There is then no need to 
define either the pharmacokinetic or pharmacodynamic model. 
In most instances it is obviously impractical to sample at 
the effect site and even if it were possible, any error in 
concentration measurement is ignored by this method. 
Hull (1979) pointed out that meaningful correlations 
between plasma concentration and effect can also be made if 
effects are measured at several different steady state con-
centrations when free drug in plasma and biophase should be 
in equilibrium. Prior to the advent of computer controlled 
infusion pumps this method was also impractical. It would 
have entailed very long periods of infusion of the drug at 
different rates of input. 
A general approach for linking concentration and effect 
which is model independent has been proposed by Smolen 
(1976). Some aspects of a systems dynamics approach to the 
quantitative relationships between dynamics and kinetics of 
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drugs have been discussed by Van Rossum & Burgers (1984). 
The techniques of numerical deconvolution are potentially 
powerful tools for describing complex dose-concentration-
effect relationships (Holford & Sheiner 1982) but are not 
easily understood or applied. 
A method known as distributed lags analysis which is 
independent of compartmental modelling has been applied to 
the "high" caused by cocaine (Zahler et al 1982). This 
method can accommodate different effects when concentra-
tions are rising and falling but may not be universally 
applicable. This approach does not appear to have been 
utilised by any other investigators. 
2.3.2.2. Pharmacokinetic Compartment Modelling 
Compartmental analysis is the usual method for modelling 
the time course of drug concentration in sampled biological 
fluids. It allows prediction of concentration in compart-
ments not directly sampled and it enables prediction of 
concentration at any time. Thus effect and concentration 
need not be simultaneously measured. 
A number of attempts have been made to relate the time 
course of effect to predicted concentration in a pharmaco-
kinetic peripheral compartment. This has been fortuitously 
successful in a few cases such as the effect of clonidine 
on the cat nictitating membrane (Paalzow 1984). Galeazzi et 
al (1976) demonstrated that the effects of procainamide on 
prolongation of the QT interval appeared to be intermediate 
in time course between concentrations in the central and 
peripheral compartments but happened to coincide with 
procainamide saliva concentrations. In the main, however, 
this approach has been unsuccessful (Dahlstrom et al 1978 , 
Paalzow 1984). 
Kelman & Whiting (1980) have proposed a multicompartment 
method with partitioning of fractions of the effect among 
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the different pharmacokinetic compartments . This 'mixed 
compartment' approach whilst adequately describing the time 
course of the effects of disopyramide and two cardiac 
glycosides, is purely empirical. It is highly unlikely that 
a single eff'ect is mediated by drug concentrations at sites 
with different pharmacokinetic properties ie. at different 
effect sites (Holford & Sheiner 1982, Oosterhuis & Van 
Boxtel 1988). 
The requirement for modelling of effects on the basis of 
pharmacokinetic compartments to be successful is that the 
time course of effect-site concentration must parallel the 
distribution to tissue sites determining the multi-
exponential concentration-time course (Holford & Sheiner 
1982). The tissue sites must therefore have a relatively 
large drug capacity. Many sites of action may have slow 
drug penetration but a small capacity and therefore have no 
discernible influence on central compartment concentra-
tions. Additionally, this cannot be applied to drugs where 
equilibration delays are observed but which show one 
compartment kinetics (Oosterhuis & van Boxtel 1988). 
2.3.2.3. Effect Compartment Modelling 
The concept that the time course of the effect itself could 
be used to define the rate of drug movement into the effect 
site was first mooted by Segre (1968). It was first applied 
by Forrester et al (1974) to calculate the equilibration 
half-times of effect of various cardiac glycosides after IV 
bolus administration . However, they ignored the fact that 
concentrations were decreasing in the plasma. 
Hull et al (1978) in a study on pancuronium, proposed an 
additional effect site compartment with a negligibly small 
volume (1 ml), linked to the plasma compartment by a first 
order process represented by a single rate constant . They 
estimated this rate constant by iterative methods, solving 
for time points when both ris i ng and falling concentrations 
• 
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in the central compartment gave the identical intensity of 
effect. A conceptually similar method but involving complex 
mathematics and multiple effect compartments was applied to 
eliminate the lag between concentration and analgesic 
effect of morphine (Dahlstrom et al 1978). 
Using these ideas as a basis, Sheiner et al (1979) proposed 
a simpler method to estimate the rate constant of the 
effect site equilibration. This method used an effect 
compartment as an extension of the pharmacokinetic compart-
mental model (Schematically shown in Fig 2.2). The effect 
compartment was linked to the plasma compartment by a first 
order process but received a negligible amount of drug, 
therefore the input rate constant K'e was negligible. The 
rate· constant KeO was not directed back to the plasma 
compartment and thus characterised the time dependent 
equilibration between plasma concentration and effect. 





Fig 2.2. A pharmacokinetic-pharmacodynamic model showing 
the connection between the central compartment and the 
effect compartment. 
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The plasma concentration time course was used to estimate 
pharmacokinetic parameters. These parameters were then used 
to calculate concentrations in the hypothetical effect 
compartment which when combined with an effect · model 
yielded the equilibration constant together with the effect 
model parameters. Sheiner's model allows the determination 
of the rate constant of dissociation of the drug from the 
effect compartment (KeO )' Time independent sensitivity to 
the drug can be expressed as the steady state plasma 
concentration t hat results in 50% of maximal effect (ECso ) 
if a plateau effect is obtained (Tfelt-Hansen & Paalzow , 
1985) . 
This approach has been criticized as inadequate on the 
grounds that it is purely descriptive; is based on 
compartmental modelling which relegates the different 
components cont ributing to the delay in effect to a "black 
box"; and predictions from different routes of 
administration as well as from single dose to multiple 
dosing do not always hold (Colburn 1981, Colburn 1987). 
Sheiner's reply (Sheiner 1987) to this criticism is that 
effect compartment modelling: "is simply a means to 
"correct" non-steady state data to the equivalent of steady 
state data so that a dose-(concentration)-response curve 
can be discerned, unobscured by hysteresis". 
Whilst retaining a parametric pharmacokinetic model, Fuseau 
& Sheiner ( 1984) proposed a nonparametric form of the 
pharmacodynamic model which estimated KeO as the value that 
caused the hysteresis curve to collapse to a single curve. 
Unadkat et al (1986) have extended the nonparametric 
approach to include both the pharmacokinetic and 
pharmacodynamic models but retained a parametric link 
model. This method is appropriate when the pharmacokinetic 
model is uncertain. 
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Many and varied studies have successfully used effect 
compartment modelling to describe temporal discrepancies 
between concent ration and effect and to make clinically 
useful predictions. Some equilibration half-times for 
various drugs and effect measurements are given in Table 
2.1. overleaf. 
Knowledge of equilibration rate constants is of great 
assistance in ensuring the safe application of drugs. In 
anaesthetic practice for example, overdosage with drugs 
which are slow to equilibrate is far more likely to occur 
since dosing is influenced by clinical signs which are time 
lagged. 
The effect of beta-blockers on heart rate has been 
considered to follow the same time course as the plasma 
concentration and therefore effect compartment modelling 
has, for the most, not been attempted. Most studies have 
measured effects at the earliest 5-15 minutes after 
administration and may have missed a disequilibration 
phase. 
Corbo et al (1989) assessing the effects of propranolol on 
cardiac contractility in rabbits, have demonstrated a half-
time of equilibration of 15 minutes. In a study measuring 
the changes caused by metoprolol on flash fusion frequency 
it was found t hat these eNS effects were delayed relative 
to metoprolol concentrations, with a disequilibration rate 
constant of 1.43 h-1 (Gengo et al 1985a). 
Although the effects of beta-blockers on blood pressure are 
delayed relative to plasma concentration no one appears to 
have investigated this. Meaningful delineation of this 
relationship is probably hampered by variation in 
homeostatic feedback mechanisms but certainly needs some 
effort at investigation. 
I 
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2.3.3. Therapeutic Application of the Pharmacokinetic-
pharmacodynamic Relationship 
2.3.3.1. Duration of Effect 
The duration of a drug-induced effect cannot be directly 
equated to the drug I s elimination half-life across the 
whole concentration range. The decay of an effect is also 
influenced by dose since this determines in which portion 
of the concentration effect curve one is operating. 
The time course of drug effect can be divided into 3 phases 
(Holford & Sheiner 1981): 
i) When plasma concentration is above the concentration 
causing 80% of maximal effect the relationship between 
effect and concentration is shallow. Large changes in 
drug concentration cause small changes in effect (Em~ 
model) . 
ii) When plasma concentration is in the range of con-
centration giving 20 to 80% of maximal effect the 
effect will decline linearly with time whilst con-
centrations decline exponentially. During this phase 
effect and log concentration are linearly related 
(Log-linear model). 
iii) When effect is less than 20% of maximum then both 
concentration and effect decline exponentially and are 
directly proportional (Linear pharmacodynamic model). 
The nonlinear relationship between concentration and effect 
in i) is the reason for the duration of beta-blocker effect 
being much longer than the elimination half-life would lead 
one to expect. Propranolol has a half-life of 2 to 3 hours 
but an ICso of only 5-20 ng/ml for inhibition of exercise 
tachycardia (Lalonde et al 1987, Wellstein et al 1985b) and 
possibly also BP reduction (Esler et al 1977). Thus doses 
of 80 mg should maintain levels well above the ICso for a 
good part of the day. This was discussed by McDevitt & 
Shand in 1975. It is therefore surprising that until 
recently it was seldom recognised by clinical investigators 
that the dose of the beta-blocker determines the time that 
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concentrations remain above Emax and therefore also 
influences the duration of action. 
2.3.3.2. Dose Regimen Design 
In terms of the E model if concentrations are greater than max 
ECao for most of the day there will be little difference 
between an infusion and intermittent dosing. However, the 
influence of dosing regimen is greatest when the average 
concentration is in the region of the ECso and the dosing 
interval is much longer than the elimination half-life 
(Holford & Shei ner 1981). Knowledge of the pharmacokinetics 
as well as the E and ECso of a drug can then be used to max 
implement a rational dosing strategy. 
The relatively recent recognition of the applicability of 
the E model to the relationship between the concentration max 
and effect of beta-blockers has given great support to the 
development of slow release formulations. A great case for 
metoprolol CR and metoprolol 'Oros" has been made on the 
grounds that once daily administration of these formula-
tions not only gives effective 24 hour beta-blockade but 
gives rise to a better safety profile in terms of beta,-
selectivity (Kendall et al 1991). These formulations 
maintain a plateau level of 300-400 nmol/L corresponding to 
maximal beta-blockade without achieving needlessly high 
peaks which might well give rise to beta2-receptor blockade 
(Kendall et al 1991). Improved tolerability with these 
formulations of metoprolol in terms of lesser effects on 
airways, and reduced impairment of exercise tolerance has 
been demonstrated in relation to conventional atenolol 
(Dimenas et al 1990, Kendall et al 1991). 
The need for altered dosing schedules due to altered 
pharmacokinetics and/or pharmacodynamics in the elderly if 
they are the target population could easily be identified 
in phase II or III studies. The antihypertensive effect of 
amlodipine, a long acting calcium antagonist has been shown 
to be equivalent for young and elderly patients at a given 
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drug concentrat ion (Abernethy et al 1990). The increased 
antihypertensive effect seen in the elderly was associated 
with an increased amlodipine concentration due to reduced 
clearance for a given dose. 
Uccellini et al (1986) using simulations assessed the 
influence of intravenous infusion duration on the tissue 
drug concentration profile of drugs showing a classical two 
compartment pharmacokinetic disposition. They demonstrated 
that maximum tissue concentration is not greatly influenced 
by infusion duration but the time that tissue levels are 
maintained at a particular level (therapeutic or toxic) is 
dependent on both dose and duration of administration. Thus 
a proposal to s horten the infusion time of metronidazole in 
a bid to increase tumour levels (to increase radio-
sensi tization) (Rabin et al 1980) would probably not be 
successful. 
A dosing strategy may have to take into account an 
equilibration delay between concentration at the effector 
site and the plasma concentration . An understanding of the 
nature of the delay may allow safer or more effective use 
of drugs. Disregard of the equilibration delay between 
plasma and the eNS, as was the case initially with 
midazolam, may result in fatal overdosing of patients since 
time to peak tissue concentration (and effect) lags behind 
peak plasma concentrations (Buhrer et al 1990b) . Diazepam 
is a safer agent than midazolam because the former 
equilibrates into the eNS faster than the latter 
(equilibration half-time 1.6 versus 4.8 minutes) (Buhrer et 
al 1990b). The hysteresis can be overcome by administering 
the drug at a r ate slower than the equilibration rate; for 
example midazolam is safe if infused relatively slowly. The 
eNS effects of anaesthetic doses of benzodiazepines were 
determined by using fast Fourier transformation and 
aperiodic analysis of the EEG (Buhrer et al 1990a). 
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A pharmacokinetic-dynamic model incorporating an effect 
compartment has been successfully used with adaptive feed 
back control (measuring neuromuscular blockade) to 
determine atracurium administration (Olkkola & Schwilden 
1989) . 
2.3.3.3. Metabolite Activity 
Differences in the parameters of the pharmacodynamic model 
between oral and IV administration may indicate 
contributions from an active metabolite. 
A study comparing the pharmacodynamic effects of 
intravenous and oral propafenone in healthy extensive 
metabolizers using effect compartment modelling 
demonstrated t hat 5-hydroxy-propafenone contributes to the 
antiarrhythmic effects (Haefeli et al 1990). Using 
pharmacokinetic-dynamic effect modelling for a drug with a 
large first pass effect, with two different routes of 
administration (IV and oral) generating different amounts 
of metabolite, obviated the need to administer the active 
metabolite directly. 
2.3.3.4. Drug Combinations 
Knowledge of pharmacokinetic-pharmacodynamic relationships 
of a drug alone and in combination with other drugs may 
provide insight into mechanisms of drug interactions. This 
knowledge could be extracted from data collected in Phase 
IV (Marketing support) studies (Kroboth et al 1991). 
Lalonde et al (1990) studied the pharmacokinetics of oral 
labetalol and 4 of its stereoisomers as well as the beta-
blocking effects in the presence and absence of the 
oxidative enzyme inhibitor, cimetidine. They showed that 
although cimetidine increased total labetalol concen-
trations and Aue it did not influence the pharmacodynamic 
effect measured because it had little influence on (R,R)-
labetolol. 
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Kleinbloesem et al (1987) while studying the concentration-
effect relationship of nifedipine showed that beta-blockers 
interacted with nifedipine at a kinetic and dynamic level, 
the extent of t he interaction being dependent on dose and 
route of admini stration. 
After reviewing the literature it is clear that the 
characterization of dose-concentration-effect relationships 
is necessary and is in fact central to the application of 
rational (safe and effective) therapeutics. Studying these 
relationships and their variation across populations will 








3.1.1. Ethical Considerations 
The protocol was approved by the Uni versi ty of Durban-
Westville's Faculty of Health Science Ethics Committee. 
Approval was also obtained from The South African Medicines 
Control Council because atenolol was not registered for 
intravenous administration in South Africa at the time of 
the study. 
Informed, written consent was obtained from 
participants before the study was initiated. 
all 
Most 
participants were medical or pharmacy students. 
3.1.2. Inclusions 
Healthy volunteers (aged between 20 and 30 years) having 
normal blood pressure and belonging to the white (European) 
or black (African) population groups were recruited. 
All volunteers had a full physical examination and were 
only included if considered to be 
physical condition. Additionally, 
in good 
blood 
haematological studies and urinalysis were 
demonstrate no haematopoietic, hepatic 
abnormalities . 
3.1.3. Exclusions 





i) Indians and people of mixed ancestry (coloureds); 
ii) Any history of asthma or allergy; 
iii) Highly trained athletes; 
iv) An abnormal ECG; 
v) History of cardiac disease. 
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3.1.4. Demographic Details 
Using the student's t-test no significant differences 
between the two groups in terms of age, height, weight nor 
in pre-treatment values of systolic and diastolic blood 
pressure in t h e supine and erect position were found. 
Neither the wor kloads required to raise heart rate nor the 
pre-treatment resting and exercise heart rates were 
significantly different for the two groups (Table 3.1.). 
Table 3.1. Demographic details (mean and range) for the 
black and white volunteer groups. 
DEMOGRAPHIC BLACKS WHITES 
CHARACTERISTICS 
Mean Range Mean Range 
Age (years) 23. 1 20-27 21.3 20-30 
Weight (kg) 67.8 48-80 72.1 67-79 
Height (cm) 172 154-180 177 166-182 
Supine Systolic 111 98-130 111 103-118 
BP (mm Hg) 
Supine Diastolic 66.5 53-90 66.1 60-73 
BP (rom Hg) 
Erect Systolic 110 103-120 113 103-120 
BP (mm Hg) 
Erect Diastolic 76.0 65-90 70.6 60-98 
BP (rom Hg) 
Resting Heart 69.0 59-80 69.8 57-83 
Rate (bpm) 
Workload (W) 148 106-194 161 123-211 
Exercise Heart 141 130-154 138 128-160 
Rate (bpm) 
Demographic details of individual volunteers as well as 
means and standard deviations for the groups are presented 
in Appendix 1, Tables A1.1., A1.2., and A1.3. 
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3 • 2. EXPERIMENTAL PROCEDURE 
3.2.1. study Design 
The study was placebo controlled, single blind and 
crossover in design. 
The two phases of the study were separated by a washout 
period of at least one week but not more than six weeks. 
Details of the order in which volunteers received the two 
treatments (placebo or atenolol) are shown in Appendix 1, 
Table A1.4. 
3.2.2. Atenolol Administration 
Atenolol (5 mg/10 ml) for intravenous administration 
(Tenormin Ampoules) and matching placebo were obtained from 
ICI South Africa (Pharmaceuticals) Limited. Using a Sage 
syringe pump, a constant rate intravenous infusion was 
given into a vein in the left hand over 7-8 minutes. The 
line was then immediately flushed with saline and the exact 
duration of the infusion was noted. 
3.2.3. Plasma Sampling 
An IV catheter (Jelco 18 gauge) was positioned in a right 
forearm cubital vein and kept patent for the first 12 hours 
of sampling by means of a slow infusion of normal saline 
(Sabax). Samples were drawn into a syringe via a three-way 
stopcock. Care was taken to flush out the saline before 
sampling. All samples taken after 12 hours were obtained 
wi th (Venoject) needles and vacuum tubes. The blood was 
immediately placed in chilled heparinised tubes which were 
kept on ice until plasma was separated at 40 C. The samples 
were stored at -20 0 C until analyzed. 
While the subjects were seated on a bicycle ergometer, 
samples were drawn as close as possible to the following 
times before and after the infusion was completed: 15-30 
minutes before the infusion, 2, 5, 10, 15, 30, 45 minutes, 
1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 30, 36 hours after 
the infusion. 
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3.3. PLASMA ANALYSIS 
3.3.1. Atenolol Analysis 
A reverse phase HPLC method based on one developed by Yee 
et al (1979) and adapted by the University of the Orange 
Free State (H Hundt - Personal Communication) was used for 
the measurement of atenolol concentrations in plasma. 
3.3.1.1. Apparatus 
A modular HPLC system consisting of the following Spectra 
Physics units, autosampler (SP8780xR), pump (SP8810), 
integrator (SP4290), coupled to a Shimadzu fluorescence 
spectrophotometer (RF535) was utilized. Initially a 
Brownlee C18 stainless steel column (Anatech) was used. A 
Nova-pak C18 radial pak cartridge column (Millipore) was 
found to give as good separation while halving retention 
times. 
3.3.1.2. Reagents 
The following HPLC grade or analar grade reagents were 
used: cyclohexane (Protea), n-butanol (Merck), Sodium 
hydroxide (Holpro), Sulphuric acid (Saarchem), Acetonitrile 
(Kleber), Methanol (Mallinckrodt), Acetic acid (BDH) and 
Hexane sulphonic acid (BDH). 
Atenolol powder was obtained from ICI South Africa 
(Pharmaceuticals) Limited and the internal standard, 
nadolol, from Squibb Laboratories (Pty) Limited. 
3.3.1.3. Chromatographic conditions 
The excitation and emission wavelengths were set at 280 and 
298 nm respectively and both excitation and emission slit 
widths at 10 nm. 
The mobile phase was made up of 20% methanol, 20% aceto-
nitrile and 60% of a 0.01 M hexane sulphonic acid solution. 
The solution was adjusted to pH 3.4 with acetic acid. The 
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flow rate was maintained at 1 ml/min and the system 
operated at ambient temperature. 
3.3.1.4. Extraction procedure 
Nadolol and atenolol stock solutions were made up in 
methanol. Appropriate dilutions of atenolol were made by 
weight to produce working standards in plasma. 
A one ml plasma sample (standard or unknown) was placed in 
a centrifuge tube and 20 }J.I of nadolol (20}J.g/}J.I), the 
internal standard, was added. The plasma was subsequently 
alkalinised with 200 }J.I of 1 M sodium hydroxide. Atenolol 
and nadolol were then extracted into a 5 ml mixture of 
cyclohexane and .n-butanol (55/45 v/v) by vortex mixing for 
one minute. The two phases were separated by centrifuging 
for 10 minutes at 1250 g. 
The supernatant was transferred to another glass tube 
containing 40 }J.I of 0.1 N H2S04 and vortex mixed for 1 
minute. After further centrifugation as above, the organic 
layer was discarded and the H2S04 layer was transferred to 
injection vials. The autosampler was loaded and the system 
was allowed to operate overnight. 
A specimen chromatogram is shown in Figure 3.1. Average 
retention times for atenolol and nadolol were 7 and 14 
minutes for the Brownlee column and 4 and 5.5 minutes 
respectively for the Nova-pak column. The limit of 
sensitivity was 10 ng/ml. A set of standards (10-1500 
ng/ml) was processed with each batch of samples because 
there was some day to day variation in retention times. 
A typical calibration curve is linear over the range of 10-
1500 ng/ml with a regression coefficient of 0.9994 for the 
line, y = 2.38x - 7.43, where y is the peak height ratio of 
atenolol to internal standard and x is the concentration in 




from 10% at 20 ng/ml to 6% at 1500 ng/ml and inter-assay CV 
from 13% at 10 ng/ml to 6.2% at 1282 ng/ml. (See Appendix 
1, Table A1.5). 
A 
Figure 3.1. Specimen chromatograms using the Brownlee 
column a) blank plasma with internal standard (IS); 
b} volunteer sample containing atenolol (A) containing 676 
ng/ml and IS. 
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3.3.2. Plasma Renin Activity (PRA) 
A commercially available ki t, Gammacoa t [1251 ] plasma Renin 
Activity Radioimmunoassay Kit (Clinical Assays) obtained 
from Benmore Hospital Supplies was used. The PRA 
determination i nvolved an initial incubation of plasma to 
generate angiotensin I which was then quantitated by 
radioimmunoassay. The assay kit sensitivity is quoted as 
0.018 ng/tube. Percent recovery from spiked samples ranged 
from 99 to 117%. Intra-run precision ranged from CV% of 5.4 
to 9.6 with inter-run CV% from 4.4 to 7.6. 
Sodium and pot assium levels in urine were measured by 
standard flame-photometry techniques in the laboratory of 
the Department of Clinical and Experimental Pharmacology, 
University of Natal Medical School. 
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3.4. EFFECT MEASUREMENTS 
3.4.1. Blood Pressure Measurement 
Blood pressure (BP) was measured with an aneroid manometer 
(Arteriosonde 1011) operating on the Doppler system. The 
microphone was always carefully positioned over the 
brachial artery of the left arm. Systolic blood pressure 
was taken at the onset of Korotkoff sounds and diastolic 
pressure as that at which they became inaudible (phase V). 
All measurements were performed by the same observer. 
Supine blood pressure was measured after at least 3 minutes 
rest and erect blood pressure was taken 3 minutes after the 
volunteer stood up, prior to the exercise procedure. 
Supine and erect blood pressure measurements were carried 
out prior to administration of atenolol and placebo and at 
approximately 0.3, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 
24, 30 and 36 hours after the infusions. 
3.4.2. Exercise 
Exercise tachycardia was chosen as the most reliable 
quantitative measurement of beta,-receptor blockade 
(McDevitt 1977). This method was preferred to isoprenaline 
administration because it is physiological and safer for 
the volunteers (Johnsson & Regardh 1976). 
The volunteers were exercised for three minute periods on 
a Monark exerc i se bicycle at a constant load predetermined 
for a particular volunteer. The load had been chosen to 
increase the volunteers' heart rates to 140-150 
beats/minute. The individual workloads and pre-treatment 
exercise heart rates are given in Appendix 1, Table A1.3. 
The exercise testing was carried out at ambient temperature 
which varied from 18-25° C. Exercise testing was performed 
16 times over the 36 hours of the study subsequent to the 
BP measurements (See 3.4.1). 
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3.4.3. Heart Rate Measurement 
Heart rate measurements were taken from ECG recordings on 
an Elema-Schonander Mingograph 81 (chart speed 10 mm/sec). 
The ECG was connected via an oscilloscope (Solartron 
Schlumberger) to a Hewlett Packard telemetry system 
(Transmitter 78100A, Receiver 781 01A). Chest leads were 
used. Measurements were taken over 10 R-R intervals. 
Resting heart rate was measured at the end of 3 minutes of 
supine rest whereas exercise heart rate was measured during 
the last 10-15 seconds of each 3 minute exercise period. 
These measurements were carried out prior to the placebo 
and atenolol infusions and repeated at approximately 0.3, 
o . 5, 1, 1. 5, 2, 3, 4, 5, 6, 8, 1 0, 1 2, 24, 30 and 36 hours 
after the end of the infusions. 
For the pharmacokinetic-pharmacodynamic analysis the effect 
measurement was taken as the change in exercise heart rate 
after atenolol administration from that after placebo 
administration . It was obtained by subtracting the exercise 
heart rate at a particular time after atenolol treatment 
from the exercise heart rate at the equivalent time after 
placebo dosing . 
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3.5. DATA ANALYSIS 
3.5.1. Statisti cal Analysis of Pharmacodynamic Data 
3.5.1.1. Analysis of Variance 
Analysis of variance (ANOVA) using the SAS programme 
(SAS/STAT USER'S GUIDE, Release 6.03) was used to analyze 
the effect time data at each point of measurement. 
The following questions were asked: 
i) Did the d r ug affect heart rate, blood pressure or PRA 
at each time ? 
ii) Was there any evidence of a racial difference in the 
effect of the drug on HR, BP or PRA? 
The sources of variance were partitioned into between and 
within volunteers (split-plot design) and tests for 
differences were performed at each time point using the 
'within person' error. Additionally a test for 
Race*Treatment interaction using the 'within person' error 
was carried out. A value of p<0.05 was taken as significant 
at the 95% level. 
3.5.1.2. Area under the Curve Analysis 
Area under the Curve (AUC) was utilised as an alternative 
approach to the analysis of the effect-time data in an 
effort to obtain an overall assessment of the effect rather 
than looking at effect at specific times. This was thought 
to be necessary because the day to day intra-individual 
variation in blood pressure and heart rate dependent on 
extraneous factors appeared to affect the variation in 
measurements at discrete time points. Also any inter-
individual differences in the time course of atenolol 
effect would also be expected to increase the inter-
individual variation in effect at a particular time. 
AUC was calculated for each individual for each effect 
measured (resting and exercise heart rate, systolic and 
diastolic blood pressure and plasma renin activity) from 0 
to 12 hours after both placebo and atenolol administration. 
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The programme BIOPAK (Statistical Consultants, Inc., 
Lexington, Kentucky) was used to make the calculations. AUC 
was only calculated up to 12 hours because there were no 
measurements between 12 and 24 hours and measurements at 
24, 30 and 36 hours were subject to increased variation as 
volunteers were not restricted in their activities. Thus 
the sparse 24, 30 and 36 hour measurements which are 
subject to increased variation would contribute a sizeable 
area. 
The effect of atenolol in each individual was taken as the 
difference between the AUC after placebo and the AUC after 
atenolol for that particular effect . These differences for 
blacks and whites were compared using the unpaired 
Student's t-test with p<0.05 taken as a significant 
difference. 
3.5.2. Pharmacokinetic Data Analysis 
The pharmacokinetic parameters were estimated from the 
concentration time data. Parameters obtained in blacks and 
whites were compared using the Students t-test with p<0.05 
considered a significant difference. 
3.5.2.1. Model Independent Pharmacokinetic Analysis 
3.5.2.1.1. Clearance (CL) 





AUC- A UC( 0- tn) + AUC( tn- ex» 
AUC (O~tn) was calculated, using the trapezoidal rule 
(Gibaldi & Perrier 1982), from the start of the infusion to 
the last time (tn) at which a concentration (Cn) was 
measured. AUC (tn~oo) was calculated by dividing the last 
concentration measur ed (Cn) by the terminal elimination 
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rate constant ( A ). The terminal elimination rate constant z 
(A) was obtained by linear regression analysis of the z 
terminal log-linear decay phase (from 4 hours after the 
start of the infusion). 
3.5.2.1 .2. Half-life (tl) 
~ 
Mean residence time (MRT) is the statistical moment analogy 
to half-life and represents the time taken for 63.2% of the 
administered dose to be eliminated (Gibaldi & Perrier 
1982). It is related to half life as follows: 
and: 
t% - 0.693 . MRTIV 
T 
2 




AUMC - AUMC( 0- tn) + AUMC( tn- oo ) 
AUMC (O~tn) was obtained using the trapezoidal rule and the 
extrapolated AUMC as follows: 
AUMC(Cn-oo ) _ Cn. tn + Cn 
A z A 2 z 
(Rowland & Tozer 1989). 
Terminal elimination half-life was calculated as follows: 
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t1h _ 0.693 
Az 
Since atenolol is known to show multicompartment disposi-
tion characteristics the terminal elimination half-life is 
likely to be longer than that calculated from MRT above. 
3.5.2.1.3. volume of Distribution 
Apparent volume of Distribution at Steady State (V~) 
If a drug is given by a short term constant rate 
intravenous infusion then this parameter can be calculated 
as follows (Gibaldi & Perrier 1982): 
Dose INF • AUMC 
V ------=~------
SS AUC2 
Dose INF T 
AUC. 2 
It equates to the sum of the compartmental distribution 
volumes. 
Area Volume of Distribution (Vd ) 
This parameter is calculated as follows: 
Unlike Vss this parameter is dependent on terminal 
elimination rate and can thus vary without a true variation 
in distribution space. 
3.5.2.2. Model Dependent Pharmacokinetic Parameter 
Estimation 
Curve fitting of models to data can be used for estimating 
various model dependent pharmacokinetic parameters. These 
parameters can in turn be used for predictions. The 
suitability of the models can be assessed to some extent by 
comparison of certain of the parameters with those derived 
by model independent methods . 
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Pharmacokinetic-pharmacodynamic modelling requires a good 
description of the concentration-time data for the 
prediction of concentrations at times when effects (pharma-
codynamics) but not concentrations are measured. This is 
because it is seldom possible to measure concentrations and 
effects simultaneously. 
Population pharmacokinetic modelling using NONMEM in 
addi tion to giving better parameter estimates when the 
number of samples per patient are sparse, can assess the 
contribution of physiological (age, weight etc.) and 
pathophysiological factors (disease states) to inter-
subject variation in the pharmacokinetic parameters. 
3.5.2.2.1. Pharmacokinetic Models 
Since plasma-concentration- time data after intravenous 
atenolol administration has been reported to follow both a 
bi- and tri-exponential course (See 1.2.2.2.) both two and 
three compartment open models with zero-order input were 
fitted to the plasma concentration-time data for each 
volunteer (and for group data). 
The standard equation for t he two compartment open model is 
given below: 
For the two compartment model, the particular ELS 
regression and NONMEM subroutines chosen, generated 
parameters expressed in terms of clearance (CL), volume of 
the central compartment (V, ), intercompartmental clearance 
(Q' 2 ) and volume of the per ipheral compartment (V2). The 
relevant microconstants were then calculated from these 
parameters. 
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The standard three compartment model equation is given 
below: 
c-
The parameters estimated were clearance (CL), volume of the 
central compartment (Vc )' intercompartmental clearances (Q'2 
and Q'3) and volumes of the peripheral compartments (V2 and 
V
3
) from which the relevant microconstants were calculated. 
3.5.2.2.2. ELS Pharmacokinetic Parameter Estimation for 
Individual Volunteers 
The computer programme NONMEM (Double Precision NONMEM, 
Version III, level 1.0) was used for the estimation of all 
model dependent pharmacokinetic parameters. When data from 
a single person is analyzed with the NONMEM programme the 
analysis defaults to nonlinear extended least squares 
regression (ELS) (Beal & Sheiner 1979, Beal et al 1985). 
The NONMEM PREDPP package (ADVAN 5, TRANS 1) was used (Beal 
et al 1985). A multiplicative statistical error routine was 
implemented for all pharmacokinetic as well as 
pharmacodynamic data fitting. 
Concentration-time data for each individual was fitted to 
the 2 and 3 compartment models described above. For each 
individual, estimates of the various pharmacokinetic 
parameters were obtained together with standard errors of 
the estimates (SEE) and an estimate of the random intra-
individual var i ance in the concentration measurement (0€2). 
By taking the square root and multiplying by 100 this value 
was expressed as a coefficient of variation. This estimate 
equates to error in the measurement, in the above case 
mainly assay error. 
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In this two stage analysis, the arithmetic mean of the 
individual estimates was taken as the group parameter 
estimate. Variation was calculated as follows: 
CV (%) = SD*100/mean 
This method is analogous to the Standard Two Stage (STS) 
method described by Sheiner & Beal (1981, 1983) although in 
the present study variances were not estimated. Although 
seldom calculated, the population variances in the STS 
method have an upwards bias dependent on the number of 
samples per pat ient (Sheiner & Beal 1983). 
3.5.2.2.3. Population Pharmacokinetic Parameter Estimation 
using NONMEM for Group Data 
The computer programme NONMEM (Double Precision NONMEM, 
Version III, level 1.0) was used for the estimation of 
group (population) pharmacokinetic parameters. 
The use of NONMEM as an alternative method of data analysis 
was implemented for the following reasons: 
i) NONMEM has been shown to be markedly superior to the 
STS method for the estimation of inter-individual 
random effect parameters (Sheiner & Beal 1980, 1981) 
particularly when the number of samples per individual 
differs as was the case with the present data. 
ii) NONMEM is ideal for assessing the influence of fixed 
effects such as age, weight or possibly race in this 
case, on pharmacokinetic parameters (Driscoll et al 
1989, Mungall et al 1985). 
Two and 3 compartment models as described above were used 
for estimation of population pharmacokinetic parameters. 
Thereafter, the contribution of weight and race in 




The same subroutines in NONMEM were utilised as were used 
in the ELS estimation (ADVAN5, TRANS 1 from PREDPP). 
Subroutine Trans 1, expresses parameter values in terms of 
volume of the central compartment (Vc )' clearance (CL), 
volumes of the second or third compartments (V2 and V3 ) and 
intercompartmental clearances (Q'2 and Q'3)' depending on the 
model. 
Inter-individual variation in clearance and volume as well 
as residual intra-individual variability were modelled with 
proportional (heteroscedastic) error models. 
NONMEM utilization gave estimates of: 
1 . population means of pharmacokinetic parameters; 
2. variance of the inter-individual random effects of 
parameter estimates (~2); 
3. variance of the residual intra-individual error (oe2 ); 
4. correlation matrix of the estimates; 
5. value of the minimum objective function (MOF), which 
is equal to minus twice the log-likelihood of the 
data. 
3.5.2.2.4. Pharmacokinetic Model Choice 
The most suitable pharmacokinetic model for each individual 
was chosen using the following criteria: 
i) Minimum Objective Function (MOF)i the smaller the MOF 
value the better the fit of the data. 
ii) Akaike's Information Criterion (AIC) 
AIC - MOF + 2p 
where p is the number of parameters by which 
models being compared differ. The lowest AIC 
considered the best model. 
the 
was 
iii) Chi squared test comparing the difference in minimum 
objective function (DOBF) relative to a tabled value 
wi th 1 or 2 degrees of freedom (the di fference in 
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number of parameters between the models being 
compared) . 
iv) Additionally, correlations between parameters were 
assessed and plots of weighted residuals were 
examined. 
The same criteria as above (i-iv) were used with NONMEM 
fitting of the 2 and 3 compartment models and subsequently 
to asses the influence of weight and race in building up 
models where one model was a restriction of the other. 
However, when evaluating two models neither of which is a 
restriction of the other, the likelihood ratio was used. 
A difference of at least 10 was considered a significant 
improvement (Ludden Personal Communication). 
3.5.3. Pharmacokinetic-Pharmacodynamic Analysis 
Only the influence of atenolol on exercise tachycardia was 
used as an effect (E) in this procedure. The inter- and 
intra-individual variation in resting heart rate, blood 
pressure and plasma renin activity made these effect 
measurements in individuals unsuitable for kinetic-dynamic 
analysis. These measurements appeared to be influenced, to 
a much greater extent than exercise tachycardia, by factors 
other than atenolol administration (See Chapter 1, Resting 
HR 1.1.2.1.2. and BP 1.1.2.2). Unfortunately the method of 
BP measurement was probably not accurate enough to allow 
meaningful 
modelling. 
evaluation in terms 
3.5.3.1. Pharmacodynamic Models 
of pharmacodynamic 
The following pharmacodynamic models were tested, firstly 
with effect data from each individual and secondly with all 
data combined. 
i) Linear model with estimation of slope (S) only: 
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E - S.C 
ii) Log-linear model with estimation of S and the constant 
( I) : 
E - S.logC+I 
iii) The inhibitory E model with estimation of the max 
iv) 
maximum inhibitory effect attributable to the drug 
(E ) and the concentration causing 50% inhibition of 
max 
the maximum effect (IC~): 
The sigmoid E model with parameters as above but max 
including the parameter (n) describing the slope: 
~x·Cn 
E-
A few individuals appeared to have less of an effect at the 
first measurement than at subsequent points. An attempt was 
therefore made wi th the group data only, to assess the 
possibility of a delay in the onset of the reduction in 
exercise tachycardia. Accordingly, the following model was 
tested: 
v) Emax model wi th an effect compartment: 
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Where . C is the concentration in the effect compartment 
e 
and K the partition coefficient between the effect and 
p 
central compartments (Holford & Sheiner 1982). 
3.5.3.2. Parameter Estimation 
3.5.3.2.1. Individual Kinetic-Dynamic Parameter Estimation 
using ELS regression 
Constraining the pharmacokinetic parameters (including 
variance) to those estimated from the best pharmacokinetic 
model in an individual, ELS regression was used to generate 
dynamic parameters relating effect to concentration with 
each of the effect models i-iv) for each subject in turn. 
3.5.3.2.2. NONMEM Parameter Estimation for Group Data 
The complete concentration-time-effect data set in all 14 
volunteers was analyzed using the effect models i-i v) 
described above, in the NONMEM programme. An attempt was 
made to discern a possible lag time between atenolol 
concentration and inhibition of exercise tachycardia by 
fitting model v). 
In addition, the possible influence of race on ICso and E max 
were assessed. 
3.5.3.3 . Pharmacodynamic Model Choice 
The most suitable effect model (for each volunteer and for 
group data) was determined by using the same tests outlined 
in 3.5.2.2.4. above, for choosing pharmacokinetic models. 
Examination of the correlation matrices and plots of 
weighted residuals were particularly important in 
distinguishing between models in individuals. 
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CHAPTER 4 
PHARMACODYNAMICS IN BLACK AND 
WHITE VOLUNTEERS 
EXPERIMENTAL RESULTS AND DISCUSSION 
Results and discussion presented in this chapter relate to 
effect measurements only. 
4.1. RESULTS 
4.1.1. Effects on Heart Rate 
4.1.1.1. Resting Heart Rate 
The mean rest i ng heart rate (RHR) measurements for all 
volunteers taken at intervals over 36 hours after placebo 
and atenolol administration are shown in Fig 4.1. RHR was 
significantly reduced after atenolol compared to placebo at 
most times measured from 0.5 to 36 hours after infusion 
(Table 4.1.). At 8, 24 and 36 hours post infusion the RHR 
although lower after atenolol treatment was on the 
borderline of statistical significance at the 5% level 
(p=O.0522, p=O.0606 and p=O.0505 respectively). 
Although at 1 and 1.5 hours, RHR was significantly higher 
in blacks than in whites after both placebo and atenolol 
treatment (Fig 4.2) there was no significant racial 
difference in the RHR response to atenolol at any time of 
measurement (Fig 4.3.)(Table 4.1.). The mean maximum 
reduction in RHR due to atenolol was comparable in blacks 
and whites and followed a similar time course (Fig 4.3.) 
(Table 4.2.). 
Factors other than treatment (atenolol or placebo) appeared 
to influence RHR at particular times. In whites and to a 
greater extent in blacks, RHR increased relative to 
baseline measurements during the first two hours after 
placebo administration, possibly due to frequent cycling (5 
times in the first hour) (Fig 4.2.). A very similar 
response pattern was maintained in blacks after atenolol 
although at a somewhat reduced heart rate level (Fig 4.2.). 
Table 4.1. Mean resting heart rate (sem) after placebo and atenolol administration to all volunteers 
(n=16) and probability values for differences due to treatment, treatment interaction with race and 
race. 
---
I MEAN HEART RATE (sem) Probability Values 
TIME (beats/minute) (* p<0.05 taken as significant) I 
(hours) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 68.0 (2.3) 70.5 (2.8) 0.2400 0.1800 0.8971 
0.5 78.4 (2.3) 67.5 (5.1) 0.0230* 0.1191 0.0706 
1 .0 78.4 (2.3) 70.5 (2.9) 0.0440* -0.7070 0.0175* 
1 .5 72.0 (2.2) 66.7 (1.6) 0.0240* 0.8379 0.0171* 
2.0 76.6 (2.0) 66.6 (2.0) 0.0002* 0.9264 0.3161 
3.0 
I 
74.8 (2.0) 63.0 (2.1) 0.0001* 0.9295 0.1746 
4.0 69.7 (2.4) 60.7 (2.0) 0.0011* 0.4746 0.1561 
5.0 67.8 (2.3) 59.8 (1.8) 0.0014* 0.3274 0.6733 
6.0 70.3 (2.3) 63.6 (1.9) 0.0301* 0.5705 0.4943 i 
8.0 67.7 (1.6) 62.9 (2.2) 0.0522 1.0000 0.8521 
10.0 64.7 (2.1) 58.1 ( 1 .6) 0.0282* 0.2725 0.6354 
12.0 66.9 (2.5) 61.4 (1.8) 0.0269* 0.2867 0.3593 
24.0 66.7 (2.7) 62.3 (2.8) 0.0606 0.5936 0.7909 
30.0 70.4 (2.1) 63.5 (1.2) 0.0089* 0.2451 0.3791 




Fig 4.1. Mean resting heart (RHR) after 
placebo and atenolol in all volunteers. 
Resting heart rate (beats/minute) 
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Fig 4.2. Mean RHR in blacks and whites 
after placebo and atenolol. 
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Fig 4.3. Reduction in RHR in blacks and 
whites after atenolol administration 
(Placebo-atenolo!). 
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In whites, however, the increase in RHR above baseline 
seen with placebo in the first 1.5 hours was suppressed by 
atenolol. There was thus a short lived racial difference in 
RHR response in the first hour or two of the study with 
higher RHR observed in blacks after both placebo and 
atenolol (Table 4.1.). The lowest RHR in all volunteers 
occurred at 4-5 hours post treatment with another trough at 
10 hours, irrespective of whether placebo or atenolol was 
given. These times coincided with periods when most 
volunteers were dozing. The serving of lunch between 5 and 
6 hours after treatment (placebo and atenolol) appeared to 
correspond with a slight upswing in RHR in both groups of 
volunteers (Fig 4.2.). 
In an attempt to analyze effects over a time period rather 
than at particular time points, resting heart rate area-
under-the-curve (AUe) from 0 to 12 hours was calculated for 
each volunteer for both treatments. The overall individual 
response to atenolol was taken as the difference between 
Aue for placebo and Aue for atenolol. When these 
differences for blacks and whites were compared, no 
statistically significant difference was found (Fig. 4.4.). 
The following results are given in Appendix 2: 
Table A2.l. Resting heart rate in black and white individuals after placebo administration . 
Table A2.2. Resting heart rate in black and white individuals after atenolol administration. 
Table A2.3. Mean resting heart (beats/minute) after placebo and atenolol administration in the 
black and white groups (n=8 in each group). 
Table A2.4 . Area under the curve (AUC) for resting heart rate from 0 to 12 hours (beats/mi nute.hr) 
for placebo and atenolol and the d i fference between placebo and atenolol. 
Table A2.29. Individual maximum changes in heart rate (E ) and time to maximum (T ) after 
max max 
atenolol. 
Fig A2.l-A2.2. Resting heart rates in black individuals. 
Fig A2.3-A2.4. Resting heart rates in white individuals. 
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Table 4.2. Maximum effects (EmaX> taken as the difference 
between heart rates after placebo and atenolol and the time 
O f maximum effects (T ) in all volunteers and in blacks and max 
whites separately. 
Resting Heart Rate Exercise Heart Rate 
Emax Tmax Emax Tmax 
(bpm) (hrs) (bpm) (hrs) 
ALL 
Mean 17.8 3. 1 36.3 0.3 
Median 18.0 3.0 37.5 0.3 
CV% 35.0 43.7 17.6 42.4 
Range 5-29 1.5-6.0 26-48 0.2-0.5 
BLACKS 
Mean 15.6 2.9 36.9 0.4 
Median 15.5 3.0 38.5 0.4 
Range 5-26 1.5-4.0 26-44 0.2-0.5 
WHITES 
Mean 19.9 3.2 35.6 0.3 
Median 20.0 3.0 34.5 0.2 
Range 11-29 1.5-6.0 27-48 0.2-0.5 
4.1.1.2. Exerc i se Heart Rate 
When compared to placebo, atenolol significantly reduced 
exercise heart rate (EHR) at all times measured from 0.2 up 
until 24 hours post infusion (Fig 4.5.)(Table 4.3.). The 
effect was max i mal during the first half hour (Table 4.2.) 
and wore off wi th time until no significant difference was 
observed at 30 hours after the start of the infusion. 
Although baseline measurements (prior to treatment) were 
not different in blacks and whites, the experimental 
procedure appeared to increase the heart rate of blacks 
wi th repeated exercising to a peak of 10 -12 beats per 
minute above baseline between 1 and 2 hours following 
placebo treatment (Fig 4.6.). In whi tes the EHR after 
placebo was more or less stable for the duration of the 
study. At a l l times between 0.2 and 24 hours post-
trea tmen t ( a tenolol and placebo) the blacks had a mean 
exercise heart rate 5-10 beats higher than that of whites. 
This apparent racial difference in response to the exercise 
Table 4.3. Mean exercise heart rate (sem) after placebo and atenolol administration to all 
volunteers (n=16) and probability values for differences due to treatment, treatment interaction 
with race and race. (# Values missing therefore statistical significance uncertain) 
---
MEAN EXERCISE HEART RATE (sem) Probability Values 
TIME (beats/minute) (* p<0.05 taken as significant) 
(hours) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 137.9 (2.8) 140.8 (2.5) 0.2345 0 . 7110 0.3948 
0.2# 139.9 (2.0) 107. 1 ( 1 .9) 0.0001* 0.8492 0.0191* 
0.4# 143.5 (3.1) 112.0 (2.9) 0.0001* 0.2283 0.6016 
0.5 144.2 (2.8) 110.9 (1.9) 0.0001* 0.8957 0.0802 
0.8# 142.2 (3.5) 11 2 . 1 ( 2 . 3 ) 0.0001* 0.4016 0.0095* 
1 .0 145. 1 ( 2 .8) 112.4 (2.0) 0.0001* 0.5231 0.0233* 
1 .5 145.2 (3.3) 114.3 (2.0) 
I 
0.0001* 0.4022 0.0039* 
I 
2.0 147.5 (3.0) 116. 1 ( 2 . 1 ) 0.0001* 0.9300 0.0243* 
3.0 145.7 (2.4) 116.9 (2.2) 0.0001* 0.6301 0.0222* 
4.0 145.7 (2.5) 116.8 (2.2) 0.0001* 0.7757 0.0248* 
5.0 142.8 (2.5) 118.7 (2.0) 0.0001* 0.7736 0.0488* 
6.0 144.9 (2.6) 122.2 (2.4) 0.0001* 0.6736 0.0911 
8.0 141.9 (2.0) 123.1 ( 2 . 3 ) 0.0001* 0.3096 0.0795 
10.0 141.8 (1.9) 125.2 (2.5) 0.0001* 0.4640 0.1754 
12.0 144. 1 ( 2 . 3 ) 129. 1 ( 2 . 0 ) 0.0001* 0.3469 0.0208* 
24.0 141.8 (2.4) 133.0 (2.3) 0.0005* 0.2179 0.0560 
30.0 142.3 (2.4) 140.4 (2.4) 0.4900 0.7367 O. 1669 





Fig 4.5. Mean exercise heart rate after 
placebo and atenolol in all volunteers. 
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Fig 4.7. Reduction in EHR in blacks and 
whites by atenolol relative to placebo. 
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protocol achieved statistical significance from 0.5 to 5 
hours post infusion (Table 4.3.). There was, however, no 
ethnic difference in the maximum magnitude of the reduction 
in EHR in response to atenolol taken as the difference 
between the EHR seen after placebo and that after atenolol 
administration nor in the time course of the effect (Fig 
4.7.) (Table 4 . 2.). 
When utilising the difference in EHR AUC (0 to 12 hours) 
after placebo and atenolol as a measure of the overall 
effect of atenolol, no significant difference between 
blacks and whites was observed (Fig 4.8.). 
The following results are given in Appendix 2: 
Table A2.S. Exercise heart rate in black and white individuals after placebo administration. 
Table A2.6. Exercise heart rate in black and white individuals after atenolol administration. 
Table A2.7. Mean exercise heart rate (beats/minute) after placebo and atenolol administration in 
the black and white groups (n=8 in each group). 
Table A2.8. Area under the curve (AUC) for exercise heart rate from 0 to 12 hours (beats/minute.hr) 
for placebo and atenolol and the difference between placebo and atenolol. 
Table A2.29. Individual maximum changes in heart rate (E ) (bpm) and the t i me to maximum (T ) max max 
after atenolo1. 
Fig A2.S-A2.6. Exercise heart rates in black individuals. 
Fig A2.7-A2.8. Exercise heart rates in white individuals. 
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4.1.2. Blood Pressure Responses 
4.1.2.1. Erect Blood Pressure 
4.1.2.1.1. Erect Systolic Blood Pressure 
Mean erect systolic blood pressure (ESBP) for all 
volunteers (n~16) was reduced by atenolol relative to 
placebo from 0.5 hours to 12 hours although the reduction 
was significant only from 1.5 to 8 hours post infusion (Fig 
4.9.)(Table 4.4.). 
There were no significant racial differences in overall 
ESBP responses at any time points measured (Fig 4.10.) 
although marked intra- and inter-individual variation was 
seen (See individual graphs in Appendix 2). When comparing 
the mean magnitude of effect of atenolol on ESBP in blacks 
and whites, the whites showed a greater mean response at 
all times up to 30 hours after administration although this 
was not statistically significant at any time point (Fig 
4.11.) (Table 4.4.). Maximal effects were seen at about 3-4 
hours in whites and at 5 hours in blacks (Table 4.5.) with 
mean effects d i sappearing on average more quickly in blacks 
(10-12 hours) than in whites (12 to 24 hours). 
Using differences between placebo and atenolol Aue (0 to 12 
hours) for ESBP as an indication of the response to 
atenolol there was no statistical difference between blacks 
and whites (Figure 4.12). One black (MN) and one white (NF) 
appeared to have an increased BP after atenolol relative to 
placebo values thus a negative overall response in terms of 
Aue differences between placebo and atenolol. Four whites 
had a greater response (difference in AUe) than the highest 
amongst the blacks. 
The power to detect a difference between the two groups was 
very low because of the great inter-subject variation. To 
show a 20% difference in Aue change (unpaired, two-tailed 
with a~0.05 and B~0 . 02) taking the whites as the reference 
group would require 59 volunteers per group. 
Table 4.4. Mean erect systolic blood pressure (sem) after placebo and atenolol administration to 
all volunteers (n=16) and probability values for differences due to treatment, treatment interaction 
with race and race. 
-
TIME MEAN ERECT SYSTOLIC BP (sem) Probability Values 
(hours) (mm Hg) (* p<O.05 taken as significant) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 112.8 (2.8) 111.3 (2.1) 0.5521 0.6908 0.9564 
0.5 111.4 (1.9) 107.8 (2.1) 0.0732 0.3657 0.9736 
1 .0 108. 1 ( 2 . 0 ) 104.9 ( 1 .8) O. 1863 0.5659 0.7250 
1 .5 111. 1 ( 2 . 1 ) 104.3 (2.3) 0.0049* 0.1603 0.8339 
2.0 111.8 (1.8) 102.5 (2.3) 0.0026* 0.2550 0.3854 
3.0 112.8 (1.9) 104. 1 (2.4) 0.0023* 0.1414 0.8653 
4.0 109.9 (2.5) 103. 1 (2.5) 0.0036* 0.0794 0.6032 
5.0 109.9 (2.2) 103.9 (2.3) 0.0190* 0.5089 0.9289 
I 
6.0# 112.7 (2.1) 107.8 (2.4) 0.0610 0.9903 0.9961 
8.0 113.6 (1.8) 107.4 (2.1) 0.0199* 0.5059 0.8473 
10.0 114.2 (2.2) 107.9 ( 2 . 5 ) 0.1352 0.7838 0.6463 
12.0# 116. 1 (1 . 6 ) 116.5 ( 2 .6) 1 .0000 0.1490 0.4088 
24.0 11 0.1 (1 . 6 ) 110.5 (2.1) 0.8253 0.6825 0.8739 
30.0 112.6 (2.1) 112. 7 (2. 5 ) 0.9551 0.3747 0.9292 






Fig 4.9. Mean erect systolic BP in all 
volunteers after placebo and atenolol. 
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Fig 4.10. Mean Erect systolic BP after 
placebo and atenolol in whites & blacks. 
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Fig 4.11. Change in mean erect systolic 
BP in blacks and whites after atenolol. 
Reduction in systolic BP (mm Hg) 
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The following results are given in Appendix 2: 
Table A2.9. Erect systolic blood pressure for black and white individuals after placebo 
administration. 
Table A2.10. Erect systolic blood pressure in black and white individuals after atenolol 
administration. 
Table A2.11. Mean erect systolic blood pressure (mm Hg) after placebo and atenolol administration 
in the black and white groups (n=8 in each group). 
Table A2.12. Area under the curve (AUC) for erect systolic blood pressure from 0 to 12 hours (mm 
Hg.hr) after placebo and atenolol and the difference between placebo and atenolol. 
Table A2.30. Individual maximum changes in BP (Emax) (mm Hg) and the time to maximum (Tmax ) (hours) 
after ateno 10 l. 
Fig A2.9-A2.10. Erect blood pressures in black individuals. 
Fig A2. ll-A2. 12. Erect blood pressures in white individuals. 
Table 4'.5. Maximum change in BP (Emax) (mm Hg) and time to 
maximum effects (Tmax) (hours) after atenolol for erect and 
supine systolic and diastolic blood pressure in all 
volunteers and in blacks (B) and whites (W) considered 
separately. 
ERECT BP SUPINE BP 
SYSTOLIC DIASTOLIC SYSTOLIC DIASTOLIC 
Emax Tmax Emax T max Emax Tmax Emax T max 
ALL 
Mean 16 4.5 12.9 8.7 12.7 5.5 11 . 5 8.3 
Median 16 4 15 8 10 6 10 6 
Min 0 1 .5 0 3 5 0.9 0 0.9 
Max 30 10 25 24 23 12 20 24 
BLACKS 
Mean 14 5.4 14.4 8.5 10.0 5.7 11 .5 9 
Median 15 5 15 8 10 5.5 10 8 
Min 0 2 5 4 5 1 .4 0 3 
Max 20 8 25 12 15 12 20 24 
WHITES 
Mean 18 3.6 11 .5 8.9 15.4 5.2 11 .5 7.6 
Median 20 3 12.5 8 15 5 12.5 4.5 
Min 0 1 .5 0 3 5 0.9 4 0.9 
Max 30 10 20 24 23 10 20 24 
B vs W 
p< .316 .373 .389 .903 .033 .716 # .786 
No statistically significant differences between blacks and 
whites. 
# Sample means identical. 
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4.1.2.1.2. Erect Diastolic Blood Pressure 
When all volunt eers were considered together atenolol was 
found to reduce mean erect diastolic blood pressure (EDBP) 
relative to placebo from 3 to 24 hours after 
administration (Table 4.6.)(Fig 4.13.). This reduction was 
only statistically significant at 8 hours after treatment 
when effects were maximal (Table 4.6.). Race did not 
significantly influence either EDBP (Fig 4. 14.) or the 
effect of treatment on it at any time of measurement (Fig 
4.15.)(Table 4.6.). Marked intra-individual variation in 
maximal effect (0-25 mm Hg) and time of maximum effect (3-
24 hours) on EDBP was observed in both blacks and whites 
(Table 4.5). One white (JFO) showed no discernible 
reduction below placebo levels at any time after atenolol 
whilst two blacks showed minimal reductions (MN, ZN). 
The difference between placebo and atenolol in AUC for EDBP 
(0 to 12 hours ) was not significantly different between the 
black and white groups (Fig 4.16.). 
The following results are given in Appendix 2: 
Table A2.l3. Erect diast olic blood pressure values in black and white individuals after placebo 
administration. 
Table A2.l4. Erect diastolic blood pressure values in black and white individuals after atenolol 
administration. 
Tab l e A2. 15. Mean erect diastolic blood pressure (mm Hg) after placebo and atenolol administ ration 
in the black and white groups (n=8 in each group). 
Table A2.l6. Area under the curve (AUC) for erect diastolic blood pressure from 0 to 12 hou rs (mm 
Hg.hr) for placebo and atenolol and the difference between placebo and atenolol. 
Tab l e A2.30. Individual maximum changes in BP (E ) (mm Hg) and time to max i mum (T (hours) 
max max) 
after atenolol. 
Fig A2.9-A2.10. Erect blood pressures in black individuals. 
Fig A2. ll-A2. 12. Erect blood pressures in white individua l s. 
Table 4.6. Mean erect diastolic blood pressure (sem) after placebo and atenolol administration to 
all volunteers (n=16) and probability values for differences due to treatment, treatment interaction 
with race and race. 
MEAN ERECT DIASTOLIC BP (sem) Probability Values 
TIME (mm Hg) (* p<0.05 taken as significant) 
(hours) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 70.5 (2.0) 74.0 (2.2) 0.0857 0.4918 o . 1198 
0.5 71.9 (2.2) 71.8 (1.9) 0.9552 0.2290 0.6266 
1 .0 71.7 (1.5) 69.6 (2.5) 0.3929 0.9373 0.6243 
1 .5 69.3 (2.0) 70.0 (2.4) 0.7094 0.8035 0.6045 
2.0 68.4 (2.2) 69.0 (2.3) 0.8059 0.5256 0.8261 
3.0 71.0 (1.8) 67.8 (2.1) O. 1779 0.3920 0.7162 
4.0 71.8 (1.5) 69.8 (2.4) 0.4017 0.8735 0.7240 
5.0 69.9 (1.9) 67.9 (2.3) 0.3285 o . 1180 0.3633 
6.0# 68.8 (1.6) 67.2 (1.9) 0.4288 0.8117 0.2617 
8.0 73.4 (2.0) 67.6 (1.9) 0.0030* 0.6972 0.0527 
10.0 74.8 (1.4) 71.8 (2.6) 0.2513 0.7693 0.1690 
12.0# 73.8 (2.4) 69.4 (2.3) 0.1464 0.1592 0.5304 
24.0 71.8 (1.3) 69.6 (1.9) 0.2241 0.2241 0.0830 
30.0 67.5 (1.8) 70.3 (2.1) 0.1974 0.8562 0.4016 
36.0 70.8 (2.2) 72.7 (2.0) 0.4224 0.2851 0.8261 





Fig 4.13. Mean erect diastolic BP after 
placebo and atenolol in all volunteers. · 
Erect diastolic BP (mm Hg) 
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Fig 4.14. Mean erect diastolic BP after 
placebo and atenolol in blacks & whites. 
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Fig 4.15. Reduction in erect diastolic 
BP in blacks and whites after atenolol. 
Reduction in diastolic BP (mm Hg) 
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Fig 4.16. Change (Placebo-Atenolol) in 
AUC (0-12 hrs) for Erect Diastolic BP. 
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4.1.2.2. Supine Blood Pressure 
4.1.2.2.1. Supi ne Systolic Blood Pressure 
Although it had little effect in the first hour after 
administration , atenolol significantly ~educed supine 
systolic blood pressure (SSBP) compared with placebo at all 
time points measured between 1.4 and 10 hours post dosing 
except for the 5 hour measurement (Fig 4.17.)(Table 4.7.) 
when all volunteers were considered together. The mean 
maximal reduction of 10 and 15 mm Hg in blacks and whites 
respectively was seen at 5-6 hours (Table 4.5.) with a 
return to placebo values by 24 hours in most individuals. 
Mean supine systolic BP values after placebo and atenolol 
for blacks and whites considered separately are given in 
Fig 4.18. As with erect systolic BP the mean response to 
atenolol was less in blacks than in whites at most times 
measured but was statistically significantly different at 
only 4 and 10 hours after administration (Figure 
4.19.)(Table 4.7.). Although there was marked inter-
individual variation in the time course of this response 
all volunteers showed a reduction below placebo values at 
some point after atenolol administration. 
Considering AUC (0-12 hours) differences (placebo minus 
atenolol) in individuals there was a significantly greater 
response in whites compared with blacks (Figure 4.20). 
Again NF proved to be an outlier wi thin the white group 
showing a negative response to atenolol treatment ie. a 
relative increase in BP. 
The following results are given in Appendix 2: 
Table A2.l7. Supine systolic blood pressure in black and white individuals after placebo 
administration. 
Table A2.1B. Supine systolic blood pressure in black and white individuals after atenolol 
administration. 
Table A2.l9. Mean supine systolic blood pressure (mm Hg) after placebo and atenolol administration 
in the black and white groups (n=B in each group). 
Table A2.20. Area under the curve (AUC) for supine systolic blood pressure fr~n 0 to 12 hours (mm 
Hg.hr) after placebo and atenolol and the difference between placebo and atenolol. 
Table A2.30 . Individual maximum changes in BP (E ) (mm Hg) and time to maximum (T ) (hours) 
max max 
after ateno 10 1). 
Fig A2. 13-A2. 14. Supine blood pressures in black individuals. 
FIg A2. lS-A2. 16. Supine blood prossures in white individual s . 
Table 4.7. Mean supine systolic blood pressure (sem) after placebo and atenolol administration to 
all volunteers (n=16) and probability values for differences due to treatment, treatment interaction 
with race and race. 
- -
I MEAN SUPINE SYSTOLIC BP (sem) Probability Values 
TIME (mm Hg) (* p<O.05 taken as significant) 
(hours) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 108.4 (2.9) 112.5 (2.1) 0.1609 0.6718 0.8835 
0.4 109.8 (2.0) 112.7 (2.2) 0.1747 0.0666 0.6139 
0.9 109.4 (2.0) 106.9 (1.8) 0.3125 0.8951 0.8010 
1 .4 108.8 (2.1) 104.7 (2.2) 0.0428* 0.5967 0.9268 
2.0 110.3 (1.5) 103. 1 ( 2 . 1 ) 0.0015* 0.1396 0.8212 
3.0 108.9 (2.1) 103.9 (2.2) 0.0218* 0.3403 0.6939 
4.0 107 . 1 (1 . 9 ) 101 . 1 (1 .8) 0.0003* 0.0191* 0.6219 
I 
5.0 105.8 (2.1) 105.4 (2.2) 0.8712 0.2896 0.8956 I I 
6.0 109.3 (2.6) 105.6 (2.4) 0.0061* 0.3343 0.7881 
8.0 108.4 (1.9) 104.6 (2.1) 0.0238* 0.4914 0.5425 
10.0 112.0 (2.4) 106.1 ( 2 .3) 0.0028* 0.0060* 0.7756 
12.0 112.9 (1.8) 110.3 (2.5) 0.1875 0.3125 0.7716 
24.0 106.5 (1.3) 106.8 (2.0) 0.8851 0.6146 0.4285 
30.0 110.3 (2.3) 107.6 (2.1) 0.0932 0.1915 0.8141 





Fig 4.17. Mean supine systolic BP 
after placebo and atenolol in all 
volunteers. 
Supine systolic BP (mm Hg) 
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Fig 4.18. Mean supine systolic BP in 
blacks and whites after placebo and 
atenolol. 
Supine systolic BP (mm Hg) 
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Fig 4.19. Reduction in supine systolic 
BP in blacks & whites after atenolol. 
Reduction in systolic BP (mm Hg) 
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Fig 4.20. Change (Placebo-Atenolo!) in 
AUC (0-12 hrs) for Supine Systolic BP. 
Change in AUC (mm Hg.hour) 
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p<0.0102 
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4.1.2.2.2. Supine Diastolic Blood Pressure 
Atenolol reduced mean supine diastolic blood pressure in 
most individuals from 6 to 30 hours after administration 
although this was only statistically significant at 6, 8 
and 24 hours (Fig 4.21.)(Table 4.8.). The mean results for 
the separate race groups are given in Fig 4.22. Although 
the diastolic blood pressure showed great interindividual 
variation in both groups the mean maximum reduction seen 
wi th atenolol in blacks and whites was similar ( 12 rom 
Hg) (Table 4.5 . ). One black (MN) showed no reduction in 
supine diastolic BP at any point after atenolol 
administration. 
The only apparent racial difference in response to atenolol 
treatment was at 12 hours after administration when whites 
showed a significantly greater effect. The relevance of 
these results is brought into question by the finding that 
baseline values of SDBP were also significantly influenced 
by an interaction between treatment and race (time 0 hours) 
before either atenolol or placebo infusions had begun (Fig 
4.23) . 
Blacks and whites were found to be similar when SDBP AUC 
(0-12 hour) differences for placebo and atenolol were 
compared (Fig 4.24). One black (MN) showed an overall 
increase in SDBP after atenolol whilst 3 blacks and 2 
whites showed minimal changes over the 12 hours. 
The following results are given in Appendi x 2: 
Table A2.21. Supine diastolic blood pressur e in black and wh i te individuals after placebo 
administration. 
Table A2.22. Supine diastolic blood pressure in black and white individuals after atenolol 
administration. 
Table A2.23. Mean supine diastolic blood pressure (mm Hg) after placebo and atenolol administration 
i n the black and white groups (n=8 in each group). 
Table A2.24. Area under the curve (AUC) for supine diastolic blood pressure fr~n 0 to 12 hours (mm 
Hg.hr) after placebo and atenolol and the di fference between placebo and atenolol. 
Table A2 . 30. Individual maximum changes in BP (E ) (mm Hg) and time to maximum (T ) after 
max max 
atenolo l . 
Fig A2. l3-A2. 14. Supine blood pressures in blac k i ndividuals . 
Fig A2.1S-A2. 16 . Supine blood pressures in white individuals. 
Table 4.8. Mean supine diastolic blood pressure (sem) after placebo and atenolol administration to 
all volunteers (n=16) and probability values for differences due to treatment, treatment interaction 
with race and race. 
MEAN SUPINE DIASTOLIC BP (sem) Probability Values 
TIME (nun H9) (* p<0.05 taken as significant) 
(hours) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 65.1 ( 2 . 1 ) 65.1 (1 .8) 1 .0000 0.0310* 0.8847 
0.4 59.7 (1.2) 60.0 (2.0) 0.8119 0.8119 0.9249 
0.9 61.4 (1.9) 60.8 (2.3) 0.8199 0.8199 0.6604 
1 .4 60.4 (1.9) 61 . 1 ( 2 . 0 ) 0.7187 0.9520 0.9722 
2.0 59.4 (1.5) 61.6 (2.1) 0.2076 0.2921 0.7059 
3.0 60.8 (1.6) 58.7 (1.7) 0.3140 0.2626 0.9230 : 
4.0 60.2 (1.6) 58.9 (1.6) 0.5747 0.9101 0.8067 
5.0 60.5 (1.7) 60.9 (2.3) 0.7627 0.1260 0.8323 
6.0 60.6 (1.5) 56.6 (2.1) 0.0047* 0.7575 0.2144 
8.0 61.6 (1.6) 58.3 (1.6) 0.0408* 0.3869 0.1343 
10.0 65.3 (1.5) 62.5 (1.8) 0.2562 0.5289 0.3999 
12.0 63.8 (1.5) 62.0 (1.4) 0.3162 0.0492* 0.6234 
24.0 61.6 (1.4) 57.9 (1.4) 0.0431* 0.3010 0.6385 
30.0 59.7 (1.3) 58.2 (1.9) 0.3918 0.3918 0.1015 




Fig 4.21. Mean supine diastolic BP after 
placebo and atenolol in all volunteers. 
Supine diastolic BP (mm Hg) 
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Fig 4.22. Mean supine diastolic BP after 
placebo and atenolol in blacks & whites. 
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Fig 4.23. Reduction in supine diastolic 
BP after atenolol in blacks & whites. 
Reduction in diastolic BP (mm Hg) 
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Fig 4.24. Change (Placebo-Atenolol) in 
AUC (0-12 hrs) for Supine Diastolic BP. 
Change in AUC (mm Hg.hour) 
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4.1.3. Plasma Renin Activity 
plasma renin activity (PRA) was measured in only 10 of the 
volunteers (5 blacks and 5 whites). These results 
demonstrated great intra-subject variation after both 
placebo and atenolol administration which was clearly 
influenced by factors other than treatment (See individual 
graphs in Appendix 2). These factors include posture, 
exercise and sodium levels (Lijnen et al 1978). The 
protocol involved not only posture changes and exercise at 
variable times prior to plasma sampling but also the 
infusion of normal saline. In addition, the sodium content 
of the volunteers' diet was not controlled. Because PRA as 
an effect was clearly unsuitable for concentration-effect 
modelling further analyses were deemed not to be cost 
effective. 
The PRA results following treatment will be discussed 
briefly but should be viewed with great circumspection 
because of the lack of control of factors mentioned above 
which are known to alter PRA. 
When the 10 volunteers were considered as a group the 
average PRA prior to dosing (0 hours) was identical on 
placebo and atenolol days as were the values at 30 hours 
post dose (Fig 4.25)(Table 4.9.). At all other times, 
except 3 hours post dosing, the average values were always 
lower after atenolol than after placebo (Fig 4.25). 
However, the difference was only significant at 0.2, 0.3 
and 6.0 hours because of inter- and intra-individual 
variation (Table 4.9.). At all times of measurement after 
placebo administration, except at 6 hours and 30 hours post 
dose, blacks had a lower average PRA activity than whites 
(Fig 4.26). At 0.2, 0.5 and 5 hours race significantly 
influenced overall PRA (Table 4.9.). When the average 
change in PRA after atenolol administration was assessed in 
the two race groups, the whites on the whole had a greater 
change than the blacks particularly in the first two hours 
Table 4.9. Mean plasma renin activity (sem) after placebo and atenolol administration to 10 
volunteers and probability values for differences due to treatment, treatment interaction with race 
and race. 
MEAN PLASMA RENIN ACTIVITY (sem) Probability Values 
TIME (ng/ml/hr) (* p<O.05 taken as significant) 
(hours) 
Placebo Atenolol Treatment Treatment*Race Race 
0.0 3.49 (0.72) 3.33 (0.78) 0.8572 0.1476 0.2538 
O. 1 3.22 (0.72) 3.06 (0.62) 0.8508 0.1423 0.0810 
0.2 4.07 (0.91) 2.26 (0.50) 0.0359* 0.1678 0.0336* 
0.3# 4.85 (0.93) 2.60 (0.57) 0.0449* 0.2187 0.3981 
0.5# 4.17 (0.97) 2.72 (0.49) 0.3066 0.4495 0.0424* 
0.8 3.94 (0.96) 2.26 (0.47) 0.0593 0.0344* 0.2072 
1 .0 3.35 (0.63) 2.20 (0.46) 0.1729 0.4361 0.2029 
1 .5 3.83 (0.93) 2.68 (0.66) 0.3689 0.1641 0.1748 
2.0 3.62 (0.87) 2.45 (0.47) O. 1892 0.4350 0.1357 
3.0 2.57 (0.48) 3.06 (0.80) 0.5934 0.8692 0.0670 
4.0 2.50 (0.53) 1.66 (0.41) 0.2890 0.5513 0.2967 
5.0 2.54 (0.55) 2.15 (0.52) 0.5554 0.4978 0.0484* 
6.0 3.52 (0.68) 1.38 (0.21) 0.0273* 0.8645 0.8499 
8.0 2.10 (0.51) 1.33 (0.22) 0.1926 0.2032 0.0951 
10.0# 2.61 (0.61) 1.94 (0.43) 0.5360 0.4985 0.0821 
12.0 1.97 (0.54) 1.73 (0.58) 0.7876 0.2792 0.3521 
24.0# 1.83 (0.32) 1.70 (0.27) 0.4655 0.5494 0.0564 
30.0# 2.29 (0.54) 2.31 (0.36) 0.7031 0.5586 0.6204 





Fig 4.25. Mean PRA after placebo and 
atenolol in all volunteers. 
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Fig 4.26. Mean PRA in blacks and whites 
after placebo and atenolol. 
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Fig 4.27. Reduction in mean PRA after 
atenolol in blacks and whites. 
Reduction in PRA (ng Ang.lml/hr) 
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Fig 4.28. Change (Placebo-Atenolol) In 
AUC (0-12 hrs) for PRA. 
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(Fig 4.27) but only at a single point, 0.8 hours, was race 
a significant factor in treatment response (Table 4.9.). 
There was no statistically significant difference between 
blacks and whites in baseline PRA (mean of baseline both 
before placebo and atenolol) (p<0.2535) although the mean 
in the blacks (2.7 ng Ang./ml/hr) was lower than that in 
whites (4.11 ng Ang./ml/hr). Taking the difference in AUC 
(0-12 hours) after placebo and atenolol as a measure of 
overall PRA response to atenolol there was no significant 
difference between blacks and whites (Fig 4.28.). 
Because baseline PRA was measured prior to any exercising 
and within a few minutes of the initiation of the normal 
saline infusion it was considered a reasonable measure of 
basal PRA in the individual. Since the overall supine 
systolic BP response to atenolol (as measured by difference 
in AUC) was found to be significantly less in blacks than 
whites it seemed reasonable to test whether it might be 
related to baseline PRA. Although only 10 data points were 
available there did appear to be some relationship in these 
10 individuals (r2=0.578, p<0.0107) (Fig 4.29.). There was 
no significant correlation between baseline PRA and either 
erect systolic BP, erect diastolic BP or supine diastolic 
BP responses over 12 hours (difference in AUC) (Table 
4. 10. ) . 
A correlation between overall atenolol response (AUC 0-12 
hour differences) for PRA and SSBP also showed a 
relationship (r2=0.552, p<0.0138) (Fig 4.30.) in the 10 
individuals. There was however, no correlation between AUC 
differences in PRA and AUC differences in ESBP, EDBP or 
SDBP (Table 4.11.). 
The 24 hour urinary sodium and potassium elimination was 
measured in al l volunteers after both placebo and atenolol. 
The mean results are given in Table 4.12. 
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Fig 4.29. Correlation between baseline 
PRA and change (Placebo-Atenolo!) in 
AUC (0-12 hrs) for supine systolic BP. 
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Fig 4.30. Correlation between changes in 
AUC (0-12 hrs)(Placebo-Atenolo!) for PRA 
and Supine Systolic BP. 
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Table 4.10. Correlation between baseline PRA and AUC (0-12 hours) 
differences between placebo and atenolol administration for erect 
and supine systolic and diastolic BP. 
Correlation of PRA Equation r2 p< 
vs Change in AUC 
for: 
Erect Systolic BP Y = 34.19X - 36.91 0.2736 0.1208 
Erect Diastolic BP Y = 18.96X - 23.02 0.1648 0.2444 
Supine Systolic BP Y = 22.53X - 32.18 0.5782 0.0107* 
Supine Diastolic BP Y = 16.50X - 29.57 0.2056 0.1881 
* Significant correlation 
Table 4.11. Correlation between Change in PRA AUC (0-12 hours) 
after placebo and atenolol administration versus change in AUC 
(0-12 hours) after placebo and atenolol administration for erect 
and supine systolic and diastolic BP. 
Correlation of PRA Equation r2 p< 
Change in AUC vs 
Change in AUC for: 
Erect Systolic BP Y = 3 . 29X + 45.6 0.2109 0.1818 
Erect Diastolic BP Y = 1 .31 X + 28.0 0.0659 0.4741 
Supine Systolic BP Y = 2.41X + 19. 7 0.5522 0.0138* 
Supine Diastolic BP Y = -20.7X + 24 . 5 0.0027 0.8865 
* Significant correlation 
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Table 4.12. Twenty four hour urinary sodium and potassium 
elimination in blacks (B) and whites (w) and both groups 
together (All) after placebo (PI) and atenolol (At). 




n 6 6 
Mean 300 368 
SD 64 50 
CV (%) 21 14 
WHITES 
n 7 7 
Mean 259 329 
SD 125 92 
cv (%) 48 28 
B vs W 
p< 0.4799 0.3841 
ALL 
n 13 12 
Mean 278 348 
SD 100 73 
cv (%) 36 21 
Blacks 
At vs PI 
p< 0.0698 
Whites 
At vs PI 
p< 0.2832 
All 
At vs PI 
p< 0.0593 
n = number of samples 




















There was no difference in 24 hour sodium elimination 
between blacks and whites after either placebo or atenolol 
or when both treatments were considered together. Although 
more sodium was eliminated after atenolol than after 
placebo in both groups this did not reach statistical 
significance. There was no treatment effect on potassium 
elimination in ei ther blacks or whi tes or all subjects 
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considered together. Blacks on average eliminated less 
potassium per 24 hours after both placebo and atenolol 
treatments (53 mEg for both periods) than whites (73 and 84 
mEg after placebo and atenolol respectively) although this 
did not reach statistical significance (p<0.2235 and 0.0666 
respecti vely) . 
A correlation of the log of 24 hour sodium elimination with 
FRA measured at the end of the urine collection ie. twenty 
four hours after treatment (without regard to race or 
treatment) yielded the expected inverse relationship (r2 = 
0.4251, P < 0.0115) (Figure 4.31.). 
The following results are given in Appendix 2: 
Table A2.2S. Plasma renin activity in black and white individuals after placebo administration. 
Table A2.26. Plasma renin activity in black and white individuals after atenolol administration. 
Table A2.27. Mean plasma renin activity (ng Ang/ml/hr) after placebo and atenolol administration 
in the black and white groups (n=S in each group). 
Table A2.28. Area under the curve (AUC) for PRA from 0-12 hours after placebo and atenolol and the 
difference between placebo and atenolol. 
Table A2.31. Twenty four hour urinary elimination of sodium and potaSSium in black and white 
subjects after placebo and atenolol administration. 
Fig A2.l7. PRA in blacks after placebo and atenolol administration. 
Fig A2.18. PRA in whites after placebo and atenolol administration. 
Fig 4.31. Correlation between 24 hour 
urinary sodium elimination and PRA. 
PRA (ng Ang./mllhrl 
5.---~----------------------------------______ ~ 
2 
r • 0.4251 p<0.0115 Blacks -PI 
+ Whites -PI 
* Blacks -At 
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4.2. DISCUSSION 
4.2.1. Effects on Heart Rate 
As expected the influence of atenolol on mean resting heart 
rate was lower and less consistent than that on exercise 
heart rate. This is because there is a lower level of 
sympathetic activity at supine rest (Robinson et al 1966). 
The peak effect on EHR (25% reduction) occurred almost 
immediately (5-25 minutes after the end of the infusion) 
while maximal reduction in RHR ( 15%) was seen only on 
average at 3 hours (range 1.5 to 6.0) post dose (Fig 4.32). 
The mean maximum fall of about 18 beats/minute in RHR was 
similar to that seen in other studies (14 to 20 
beats/minute) in volunteers receiving comparable oral doses 
of atenolol ie. 100 mg (Fitzgerald et al 1978, Fuller & 
Vallance 1982, Maling et al 1979). 
After IV atenolol maximum reductions in RHR have been 
reported to occur from 1-3 hours after the dose (Fitzgerald 
et al 1978). The peak reduction in RHR after oral atenolol 
is reported to be delayed by 1-2 hours relative to plasma 
concentrations. A similar delay in the time course of 
reduction of RHR has been observed with other beta-
blockers. Myers & Thiessen (1980) showed that although 
orally administered metoprolol concentrations peaked at 1.5 
hours, maximal reduction in RHR occurred at 3 hours. These 
researchers suggest that this can be explained by a delay 
in reaching the relevant receptors. This seems unlikely if 
the beta-receptors responsible for exercise heart rate 
increases are maximally blocked almost immediately . The 
effect on RHR may be an indirect response to other changes 
in the cardiovascular system in response to atenolol 
treatment. 
Both blacks and whi tes showed an increase in RHR above 
baseline after placebo administration. This was possibly 
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the result of insufficient time being allowed for RHR to 
recover after exercise stimulation . Although no significant 
racial difference in response to atenolol was found the 
atenolol appeared to antagonise this rise above baseline 
more in the whites than the blacks. The rise above baseline 
RHR therefore appeared to have a greater sympathetic 
component in whites than in blacks. 
The finding that there was no significant influence of race 
on the degree of reduction of resting heart rate by 
atenolol in young volunteers confirms the findings of 
Venter et al (1984b) with propranolol. 
The almost immediate onset (0.3 hours after start of 
infusion) of the effect of atenolol on EHR in this study 
was similar to other studies with IV atenolol where maximal 
effects were measured at the first observation time after 
administration (Brown et al 1976, Shanks et al 1977) . 
n-16 
Fig 4.32. Mean % Reduction in Exercise 
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Although the average maximum reduction in this study (24%) 
(Fig 4.32.) was lower than the 30-32% observed by Shanks et 
al (1977) and Brown et al (1976) using the same dose, the 
initial heart rate in this study was also lower. It has 
been demonstrated that heart rate reduction by beta-
blockade is greater at higher exercise levels (Leenen et al 
1980) . 
In blacks, EHR after placebo administration showed an 
increase over baseline during the first 2 hours and 
remained 5 to 10 beats higher than baseline for the 
duration of the experiment. Whites on average showed 
relatively little change from baseline in EHR during the 
study period (Fig 4.33.). The diurnal variation and placebo 
effects on heart rate and blood pressure obviously require 
placebo control in drug efficacy studies. However, the 
apparent ethnic difference in 'placebo response' on EHR was 
unexpected. Had a placebo phase not been included in the 
experimental design it would have appeared that the EHR 
response to atenolol in blacks was less than that in whites 
(Fig 4.34). In fact the response to atenolol taken as the 
difference between HR after placebo and after atenolol is 
equivalent in blacks and whites with very similar maximal 
effects and time course. This was in contrast to a report 
(Venter & Joubert 1982) that penbutolol reduced exercise 
tachycardia less in blacks than in whites and that there 
was a shift to the right in the dose response curve for 
propranolol i n blacks compared with whites (Venter & 
Joubert 1984a ) . In the latter study ethnic differences 
disappeared at higher exercise levels and higher doses. 
It is interesting to speculate as to the reason for the 
significantly higher EHR, irrespective of placebo or 
atenolol treatment, observed in blacks compared with whites 
during the first 5 hours of the experiment. It appeared 
unlikely that the blacks were less fi t than the whi tes 
because nei ther resting heart rates, nor workloads nor 
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Fig 4.33. Mean EHR in blacks and whites 
after placebo administration. 
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baseline exercise heart rates differed significantly 
between the two groups. On the other hand our results were 
not entirely incompatible with a difference in fitness 
since it has been shown that reduced heart rates in trained 
individuals are the result of increased vagal tone and not 
decreased sympathetic reactivity (Leenen et al 1980). 
Lewis et a l (1991) have reviewed cardiovascular 
characteristics which are reported to differ between blacks 
and whites. They cite a number of reports indicating an 
increased blood pressure response to physical and 
psychosocial stressors in black compared with white 
children as well as a faster heart rate in black newborns 
compared with whites. The present study demonstrated a 
similar phenomenon of increased reacti vi ty of exercise 
heart rate (and to a lesser degree resting heart rate) to 
the stress of the study protocol in young blacks compared 
wi th whites. This ethnic difference did not appear to 
involve the sympathetic system as the differential was 
maintained after supra-maximal doses of atenolol. Venter et 
al (1984b) demonstrated a higher intrinsic heart rate and 
a greater vagal component to restirig heart rate in young 
black volunteers compared with whites although they found 
no difference in the sympathetic component. These 
differences tended to disappear at higher levels of 
exercise (Venter & Joubert 1984a, Venter et al 1986). With 
mild exercise increase in heart rate is mainly due to vagal 
wi thdrawal whi I eat maximal exerc i s e ( 1 80 - 2 0 0 bpm) the 
sympathetic system is the major component (McDevitt 1977, 
Robinson et al 1966, Venter et al 1986). Erect bicycle 
ergometry involves sustained handgrip which may increase 
heart rate via vagal wi thdrawal even in the presence of 
propranolol, and independently of exercise (McDevitt 1977). 
The present study utilised sub-maximal exercise in the form 
of repeated erect bicycle ergometry. Ethnic differences in 
intrinsic heart rate and particularly vagal wi thdrawal 
might therefore have influenced absolute exercise heart 
rates without influencing the response to atenolol. 
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4.2.2. Blood Pressure Responses 
This study confirmed that single IV doses of beta-blockers 
lower BP in normotensive volunteers (Fig 4.35. & 4.36.). 
Atenolol reduced erect and supine BP with maximal 
reductions of 16/13 mm Hg and 13/12 mm Hg respectively 
occurring between 4 and 8 hours after dosing. The onset and 
offset of atenolol's effect on diastolic BP lagged behind 
the effects on systolic BP. 
The finding that onset of blood pressure reduction was 
delayed relat i ve to the reduction in heart rate was in 
agreement with other studies of various beta-blockers given 
orally or IV which report delays of 1-6 hours (Collste et 
al 1980, Fagan et al 1982a, Man in' t Veld & Schalekamp 
1983, Myers & Thiessen 1980). Early studies which claimed 
no effects of IV beta-blockers used very low doses in some 
cases and for the most part did not follow effects for long 
enough (See Chapter 1, 1 . 1.2.2.1.1 . ). 
Similarly results in this study were comparable with other 
studies in normotensive and hypertensive subjects in terms 
of maximal BP reduction and time course with the most 
consistent reduction being in supine systolic BP. (See 
Chapter 1,1.1.2.2.1.). Fitzgerald et al (1978) showed an 
almost identical time course of BP reduction with 10 mg IV 
and 200 mg of oral atenolol, the effect on heart rate and 
systolic BP occurring earlier (1 to 3 hours) than effects 
on diastolic BP (from 3 hours onwards). In a study of a 
single oral 100 mg dose of atenolol in normotensive 
volunteers, maximal reduction of about 15 mm Hg in systolic 
BP was seen at 7 hours while diastolic BP was maximally 
reduced (10 mm Hg) between 5 and 8 hours (Maling et al 
1979) . Similarly single 100 mg doses of atenolol in 
hypertensive patients reduced BP 17/11 mm Hg at 6 and 10 
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In the present study there was minimal evidence of ethnic 
differences in blood pressure response after a single IV 
dose of atenolol to healthy normotensive young men except 
for the effect on supine systolic BP. Although erect 
systolic BP response (difference in AUC) tended to be less 
in blacks it did not reach statistical significance. 
However any inter-subject variation in effect and time 
course would make it difficult to detect subtle differences 
between blacks and whites with only 8 subjects in each 
group. In fact in the present study the effect of atenolol 
on BP (particularly diastolic BP) showed great inter-
subject variation in terms of both magnitude and time 
course. One black (MN) and one white (NF) showed increases 
in BP after atenolol. Others have also reported inter-
individual differences in the time course and magnitude of 
blood pressure reduction by single doses of beta-blockers 
with effects on diastolic BP being most variable (Collste 
et al 1980). 
The greater reduction in supine systolic BP in whites may 
appear surprising in view of there being no ethnic 
difference in atenolol' s effect on either EHR or RHR. 
However, as the blood pressure and exercise heart rate 
responses differ in time course one should probably not 
expect a parallel between these two responses . 
Whether this racial difference in the effect of atenolol on 
resting systolic BPin normotensives is in any way relevant 
to or predictive of the reduced response of black 
hypertensives to beta-blockers is a matter of conjecture. 
The first point to consider is whether single dose studies 
are predictive of long term hypotensive responses. The 
second point is whether extrapolation from normotensive to 
hypertensive subjects is valid. 
Some studies in hypertensive patients claim similar 
responses in BP after single doses and continued therapy 
(Leonetti et al 1980, Leenen et al 1982, Myers & Thiessen 
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1980) while others claim no relationship (Collste et al 
1980). 
A study of short-term and long-term haemodynamic and blood 
pressure responses to single and multiple dose beta-
blockade comparing a beta-blocker with ISA and one without 
in matched hypertensive blacks and whites may cast some 
light on these issues. Continuous ambulatory BP monitoring 
techniques could facilitate these comparisons. 
To state categorically that black hypertensives do not 
respond while white hypertensive patients do respond to 
monotherapy with beta-blockers is incorrect. It is probably 
more accurate to say that more whites respond adequately 
than . blacks to this form of therapy. There are blacks who 
show a good response while there are some whites who show 
a poor response. The inter-individual variability in the 
magnitude of the response in the ~wo ethnic/race groups 
would provide useful information for predicting the 
probability of an adequate response. 
A dose ranging study using NONMEM analysis of BP reduction 
in reasonably matched black and white hypertensives, 
·similar to a recently published study comparing two beta-
blockers, atenolol and betaxolol (Sambol & Sheiner 1990), 
might give some insight into the intra- and inter-subject 
variation in response. In the above mentioned study a 
graded dose response to atenolol (25, 50 and 100 mg) was 
demonstrated for supine diastolic blood pressure measured 
24 hours after dosing . The maximal reduction in supine 
diastolic BP was 13 mm Hg (95% confidence interval 10 to 15 
mm Hg) with an interindividual variability (coefficient of 
variation) of 31% (95% confidence intervals of 0% to 47%). 
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4.2.3. Effects on Plasma Renin Activity 
Baseline PRA values were wi thin the limits reported for 
normotensive subjects between 20 and 30 years of age on an 
ad libitum sodi um diet (Lijnen et al 1978). Measurements of 
PRA after both placebo and atenolol administration were 
inconsistent and showed great intra- and inter-subject 
variation. 
PRA is known to show diurnal variations as well as changes 
in response to sodium levels, posture, stress and exercise. 
Although the placebo period of measurement controlled for 
diurnal variation the other factors were not standardized 
in the present study. There was no control of dietary 
sodium in the subjects and normal safine was infused during 
the first 12 hours. Relatively high sodium intake would be 
expected to suppress basal PRA while the change in position 
from recumbency to being seated on the bicycle as well as 
the previous exercise sessions would have had the opposite 
effect. The stress involved when blood sampling proved 
difficult might also have contributed to the intra-
individual variation . 
Beta,-selective blockers such as atenolol and metoprolol 
(Amery et al 1977b, Lijnen et al 1978, Lijnen et al 1979) 
as well as nonselective blockers such as propranolol (Traub 
et al 1980) without ISA have been reported to lower basal 
PRA while those with ISA do not (Buhler et al 1975b, Traub 
et al 1980). In the present study although there was a 
general trend for atenolol to lower PRA relative to placebo 
the only statistically significant reduction was observed 
within the first hour. The small number of subjects and 
inter- and intra-individual variation probably accounted 
for the lack of significance. 
Blacks on average tended to have lower PRA after both 
placebo and a t enolol when compared with whites. However, 
the differences were not significant probably because of 
the small numbers. The relative differences are similar to 
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those found between normotensive black and white Americans 
(Hildreth & Saunders 1991). As expected the PRA measured 24 
hours after treatment was correlated inversely with the 
amount of sodium eliminated in the previous 24 hours 
(Lijnen et al 1978). There was insufficient data to test 
whether the correlation was different between races and 
between treatments. 
Although not significant in the present study the reduced 
potassium elimination by blacks compared with whites (in 
normotensive and hypertensive people) is widely recognized 
(Kuminyika & Adams-Campbell 1991, M'Buyamba-Kabangu 1986, 
Touyz et al 1987). Atenolol did not appear to influence 
potassium elimination as found by other investigators 
(Colantonio et al 1991). The non-significant increase in 
sodium natriuresis after atenolol administration noted in 
the present study, might be ascribed to atenolol. Similar 
small increases in sodium elimination after short-term 
atenolol administration in hypertensive patients have been 
reported (Colantonio et al 1991). 
There appeared to be a significant correlation between: 
i) reduction in systolic BP by atenolol (AUC differences) 
and baseline PRAi and 
ii) reduction in systolic BP and reduction in PRA by 
atenolol (AUC differences). 
Thus it would appear that baseline PRA may predict the 
response of systolic BP to atenolol ie. the higher the PRA 
the greater t he overall reduction in systolic BP in 
response to single doses of atenolol. In addition the 12 
hour reduction in systolic BP and the reduction in PRA 
produced by atenolol, paralleled one another. There were 
too few subjects in each group to investigate whether or 
not the correlation differed between blacks and whites. 
A number of studies in hypertensive patients have shown a 
relationship between blood pressure reduction by beta-
blockers and basal PRA values (Volpe et al 1983, Von Bahr 
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et al 1976, Weber et al 1980) while others have shown no 
relationship (Salvetti et al 1977). Hollifield et al 
(1976), using propranolol, showed a positive correlation 
between fall in BP and fall in PRA in a group including 
high, medium and low renin patients. Others however, have 
shown little (Leonetti et al 1975) or no relationship 
(Pedersen et al 1981) between BP changes and PRA changes 
with continuous propranolol therapy in hypertensive 
patients. 
The relative importance of the renin-angiotensin-aldo-
sterone system (RAAS) in the various subsets of patients 
with hypertension has been extensively debated over the 
past 20 years or more (Buhler et al 1972, Buhler et al 
1975, Fagard 1978). Much emphasis has been placed by 
certain investigators on renin profiling in order to select 
appropriate antihypertensive medication (mainly diuretics 
versus beta-blockers but more recently also ACE-inhibitors 
and calcium antagonists). However, others maintain that 
renin-profiling is not helpful in determining the extent of 
BP reduction to be expected with diuretics or beta-
blockers. Some of the discrepancies are undoubtedly due to 
methodological problems in the assay methods, lack of 
standardization of sampling conditions (Amery et al 1977b) 
and poor study design. PRA is often regarded as a 
discontinuous variable ego division of patients into groups 
above or below certain values. The conclusions in some 
studies are even frankly erroneous. For example, Holland & 
Fairchild (1982), in a study assessing the antihypertensive 
efficacy of hydrochlorothiazide (HCTZ) and metoprolol in 
black hypertensives with normal and low renin, concluded 
that the response to HCTZ was equivalent in low and normal 
renin groups. To obtain an adequate (equivalent) response 
however, required on average 90 mg HCTZ in those patients 
with normal renin while the low renin group required only 
71 mg. Renin status was thus predictive of response to 
HCTZ. 
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The present study tends to support the idea of a 
relationship between PRA and BP lowering effects in normal 
individuals although the number of subjects was too small 
to assess whether the relationships were different in the 
two race groups. 
Carefully controlled studies utilizing NONMEM analysis of 
antihypertensive drug treatment effects might be able to 
relate response variability to factors such as PRA and 
other components of the RAAS across a continuum of values. 
This might assist in elucidating mechanisms of action of 
drugs as well as physiological mechanisms controlling BP. 
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4.3. CONCLUSION 
The effects of atenolol in reducing heart rate and blood 
pressure which were observed in this study were in broad 
agreement with those found by most other investigators. 
The apparent racial difference in exercise heart rate with 
repeated bicycle ergometry clearly demonstrated the 
necessi ty for crossover placebo control in any study of 
drug effects on haemodynamics, particularly at sub-maximal 
exercise. 
In young normotensive volunteers the reduction in exercise 
tachycardia in response to beta-blockade showed no ethnic 
differences. Since inhibition of exercise tachycardia is 
considered a good measure of beta, -blockade, the ethnic 
difference in blood pressure response which has been 
reported in hypertensive patients is probably not a 
function of any genetic difference in beta,-receptors. 
Obviously caution is necessary in extrapolating results to 
hypertensive patients where the disease state may affect 
receptor activity. 
The predictive significance of the reduced response in 
supine systolic blood pressure in young normotensive blacks 
compared with whites is uncertain. Further single dose and 
long term studies of BP responses to beta-blockers (with 
and without ISA) in matched hypertensive blacks and whites 
using continuous ambulatory BP monitoring may assist in 
elucidation of ethnic differences. NONMEM analysis of 
effects may assist in elucidating factors responsible for 
variation within and between ethnic groups. 
PRA appears to be predictive of systolic BP reduction by 
single dose beta-blockade in normotensive volunteers. 
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CHAPTER 5 
PHARMACOKINETICS IN BLACK AND WHITE VOLUNTEERS 
EXPERIMENTAL RESULTS AND DISCUSSION 
5.1. RESULTS 
Plasma concentration time data from only 14 of the 16 
volunteers was used in the pharmacokinetic analysis because 
the plasma samples for two volunteers (HA and AK) were 
damaged during storage. 
5.1.1. Model Independent Analysis 
Clearance (CL), half-life (t!) (terminal and 0.693.MRT), 
area volume of distribution (Vd ) 
distribution at steady state (V~) 
volunteers (7 black and 7 white) 
methods as discussed in 
and apparent volume of 
were calculated for 14 
by model independent 
3 ( 3 . 5 . 2 . 1 . ) . The Chapter 
individual results are presented in Table 5.1. 
For all volunteers, the mean CL, t~ (terminal), t~ 
(0.693.MRT), Vd and V~ values were 17.4±3.2 L/hr, 6.4±2.0 
hrs, 5.2±1.6 hrs, 155.6±41.1 and 126.1±28.8 L respectively. 
The greatest variation (32%) was seen in t~ (terminal) with 
the least variation in CL (18%). The weight normalised mean 
value of CL was O. 26±0. 05 L/hr /kg, while Vd and V~ were 
2.31±0.77 and 1.87±0.53 L/kg respectively (Table 5.2.). 
Weight normalization marginally increased the variation in 
CL (19%) and increased it more markedly in Vd (33%) and Vss 
( 28% ) . 
Using the Student's t-test, no statistically significant 
differences between blacks and whites were found for any of 
the above parameters whether they were normalised for 
weight (Table 5.2.) or not (Fig. 5.1-5.4.). 
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Table 5.1. Parameters (t~ (terminal), CL, t~ (0.693.MRT), 
Vd and Vss ) for black (B) and white (W) volunteers calculated 
by model independent methods. 
Subject t! (hr) CL It! (hr) Vd V 
terminal (L/hr) 0.693.MRT (L) (i1 
MN (B) 7.1 18.0 5.2 185 136 
CM (B) 5.8 15.3 5. 1 129 112 
VL (B) 3.5 20.5 3.1 105 90 
AP (B) 9.5 15.0 7.4 206 161 
ZN (B) 8.9 15.7 6.8 202 153 
DS (B) 5.7 13.5 4.7 112 92 
NM (B) 8.7 16.4 7.1 205 168 
Mean 7.0 16.3 5.6 163 130 
SD 2.17 2.29 1 .54 46. 1 32.5 
cv (%) 31 14 28 28 25 
NV (W) 7.7 17 . 0 5.9 189 145 
BB (W) 4.3 15.5 3.9 96 88 
ACA(W} 8.3 13. 1 7.4 156 139 
NF (W) 4.5 24.0 3.6 155 130 
JFI(W) 6.7 19.9 5.4 194 154 
JFO(W} 5.4 17.8 4.0 138 103 
ACL(W} 3.4 22.1 3.0 107 94 
Mean 5.8 18.5 4.7 148 122 
SD 1 .85 3.79 1 .55 37.4 26.4 
CV (% ) 32 20 33 25 22 
ALL 
Mean 6.4 17.4 5.2 155.6 126. 1 
Median 6.3 16.7 5.2 155.5 133.0 
SD 2.04 3.2 1 .56 41 . 1 28.8 
sem 0.55 0.86 0.42 11 . 0 7.70 
CV ( % ) 32 18 30 26 23 
't~ (terminal) > t~ (0.693.MRT) because atenolol shows 
multicompartment disposition. 
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Fig 5.1. Model independent 
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Fig 5.3. Model independent 
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Table 5.2. Weight normalised values of CL, Vd and Vss by 
model independent methods for individual black and white 
volunteers. 
Subject CL Vd V 
(Race) (L/hr/kg) (L/kg) (Llkg) 
MN (B) 0.26 2.6 1 .94 
CM (B) 0.24 2.0 1 .77 
VL (B) 0.29 1 .5 1 .30 
AP (B) 0.23 3.3 2.55 
ZN (B) 0.32 4.2 3.20 
DS (B) 0.20 1 .6 1 .36 
NM (B) 0.21 2.6 2.10 
Mean 0.25 2.5 2.03 
SD 0.04 0.97 0.67 
CV (% ) 16 39 33 
NV (W) 0.23 2.6 1 .99 
BB (W) 0.22 1 .4 1 .23 
ACA (W) 0.19 2.2 1 .99 
NF (W) 0.34 2.2 1 .86 
JFI (W) 0.26 2.5 2.00 
JFO (W) 0.27 2.1 1 .54 
ACL ( W) 0.32 1 .5 1 .34 
Mean 0.26 2.1 1 .56 
SD 0.05 0.46 0.45 
cv (%) 19 22 29 
ALL 
Mean 0.26 2.31 1 .87 
Median 0.25 2.20 1 .90 
SD 0.05 0.77 0.53 
SEM 0.01 0.21 0.14 
cv (%) 19 33 28 
B vs W 
p< 0.6697 0.2665 0.2740 
Mean values for terminal elimination rate constant (lz) I 
area under the curve (AUCo_) and mean residence time (MRT rv ) 
in blacks and whites are given in Table 5.3. There were no 
significant racial differences in any of these intermediate 
parameters. 
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Table 5.3. Mean values of l.z' AUCo-+~ and MRT IV for blacks (B) 









Mean 0.109 3110 8. 12 
SD 0.040 407 2.24 
cv (%) 37 13 28 
WHITES 
Mean 0.133 2810 6.86 
SD 0.020 594 2.20 
cv (%) 15 21 32 
B vs W 
p< 0.3324 0.2900 0.3100 
The following can be found in Appendix 3: 
Table A3.1. Atenolol plasma concentration (ng/ml) versus time (hours after start of infusion) data 
for black volunteers. 
Table A3.2. Atenolol plasma concentration (ng/ml) versus time (hours after start of infusion) data 
for white volunteers. 
Table A3.3. Intermediate model independent pharmacokinetic parameters. 
Figure A3.1-3.14. Individual plasma concentration-time plots a) with concentration on a linear 
scale and b) concentration on a log scale. 
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5.1.2. Model Dependent Analysis 
5.1.2.1. Extended Least Squares (ELS) Parameter Estimation 
The concentration-time data for each of the 14 volunteers 
was individually fitted to both a two and a three compart-
ment model by ELS regression. The estimated parameters for 
each individual for the respective models are given in 
Tables 5.4 and 5.6. 
The utilization of a two compartment model for curve 
fi tting of the plasma concentration-time data produced 
average clearance and volume estimates which were similar 
to those obtained by model independent methods. For all 
subjects, an average volume of 36.3±6.7 L was obtained for 
the central compartment (Ve ) with 89.8±26.0 L for the 
average peripheral volume (V2 ). Adding these two average 
volumes together gave a total of 126.1 L which was 
identical to the average Vss obtained using model 
independent analysis above. The average CL of 17.2±3.6 L/hr 
was also very similar to that obtained by model independent 
means viz. 17.4±3.2 L/hr. 
No statistically significant differences were found when 
these parameters were compared between blacks and whites 
(Table 5.4.) (Fig 5.5. and 5.6.). The weight normalised 
parameters (Ve , CL and V2 ) from the two compartment fit 
given in Table 5.5 also showed no significant differences 
between the two ethnic groups. Mean CL was marginally 
smaller in blacks than whites (0.25 versus 0.26 L/hr/kg) 
although the variation was greater in whites than in blacks 
(25 versus 14%). Mean Ve on the other hand was marginally 
smaller in blacks than whites (0.53 and 0.54 L/kg 
respectively) showing 26% variation in blacks and 17% 
variation in whi tes. Mean V2 was smaller in whi tes than 
blacks (1.25 versus 1.38 L/kg) but coefficients of 
variation were similar (30 and 32 % respectively). 
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Table 5.4. Pharmacokinetic parameters (Ve , CL, V) and 
microconstants (k,o' k'2 and k~,) for individual black tB) and 
white (W) volunteers obtalned by two compartment ELS 
analysis. 
I Subject I Vc CL V2 klQ, k12 k21 
(L ) (L/hr) (L) (hr- ) (hr-1) (hr-1) 
MN (B) 35.6 17.5 99.2 0.49 1 .37 0.49 
CM (B) 33.8 15.6 80.7 0.46 1 .64 0.68 
VL (B) 23.8 20.2 65.4 0.85 3.19 1 .16 
AP (B) 44.5 14.8 117.0 0.33 0.91 0.34 
ZN (B) 33.9 14.0 92. 1 0.41 0.65 0.24 
OS (B) 28.3 14. 1 52.3 0.50 1 .47 0.80 
NM (B) 40.5 16. 1 121 .0 0.40 1 .65 0.55 
Mean 34.3 16.0 89.7 0.49 1 .55 0.61 
SO 7.0 2.2 25.5 0.17 0.81 0.31 
CV (% ) 20 14 28 35 52 51 
NV (W) 34.5 16.4 123.0 0.47 1 .64 0.46 
BB (W) 33.3 15.2 50.2 0.45 2.18 1. 45 
ACA(W) 42.6 11 . 3 115.0 0.27 1 .24 0.46 
NF (W) 43.1 24.4 84.8 0.57 2. 16 1 .10 
JFI(W) 42.6 19.8 117.0 0.46 1 .52 0.55 
JFO(W) 43.4 18.4 72.0 0.42 0.92 0.55 
ACL(W) 27.7 22.4 67.2 0.81 3.72 1 .53 
Mean 38.2 18.3 89.9 0.49 1 .91 0.87 
SO 6.3 4.4 28.6 o . 1 7 0.92 0.48 
CV ( %) 16 24 32 35 48 55 
Mean 36.3 17.2 89.8 0.49 1 .73 0.74 
Median 35.0 16.3 88.4 0.46 1 .58 0.55 
SO 6.7 3.6 26.0 0.16 0.85 o . 41 
CV (% ) 18 21 29 33 49 55 
~ p< .3022 .2575 .9884 .9875 .4826 .2445 
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Fig 5.5. Central compartment 
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Fig 5.6. ELS 2 compartment 
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Table 5.5. Weight normalised values for Ve , CL and Vz 





Vc CL V2 
(L/kg) (L/hr/kg) (L/kg) 
BLACKS 
MN 0.51 0.25 1 .42 
CM 0.54 0.25 1. 28 
VL 0.34 0.29 0.93 
AP 0.71 0.23 1. 86 
ZN 0.71 0.29 1 .92 
OS 0.42 0.21 0.77 
NM 0.51 0.20 1 .51 
Mean 0.53 0.25 1 .38 
SO 0.138 0.036 0.433 
CV (% ) 26 14 32 
WHITES 
NV 0.47 0.22 1 .68 
BB 0.47 0.21 0.71 
ACA 0.61 o . 1 6 1 .64 
NF 0.62 0.35 1 .21 
JFI 0.55 0.26 1 .52 
JFO 0.65 0.27 1 .07 
ACL 0.45 0.30 1 .10 
Mean 0.54 0.26 1 .25 
SO 0.094 0.066 0.372 
CV (%) 17 25 30 
ALL 
Mean 0.54 0.25 1 .33 
SO 0.109 0.049 0.384 
CV (%) 20 20 29 
B vs W 
p< 0.9469 0.7288 0.5581 
Curve fitting of a 3 compartment kinetic model presented 
problems in certain individuals. This was probably the 
result of insufficient samples having been collected from 
12 hours onwards, together with an increase in assay error 
in the samples close to the limit of sensitivity of the 
assay (10 ng/ml). 
Table 5.6. Pharmacokinetic Parameters (Ve ' CL, V2) and microconstants (k,o' k'2' k 2" k'3' k 3,) for 
individual blacks and whites estimated by three compartment model ELS analysis. 
I Subject I Ve CL V2 kl9, k12 k21 kl~ 
(L) (L/hr) (L) (hr- ) (hr-1 ) (hr-1 ) (hr- ) 
MN (B) 25.3 22.5 64.4 0.89 3.70 1 .45 0.0016 
CM (B) 33.3 15.8 78.3 0.47 1 .71 0.73 0.0013 
VL (B) 'Minimization routine terminated due to rounding errors. 
AP (B) 39.6 19. 1 74.9 0.48 1 .23 0.65 
ZN (B) 21 .4 1 8 . 4 55.0 0.86 3.44 1 .34 
DS (B)' 21 .7 0.262 34.2 0.01 2.97 1 .88 
NM (B) 29.6 20.1 86.0 0.70 2.88 0.99 
NV (W) 23.8 21 .0 79.0 0.88 4.37 1 .32 
BB (W) 32.7 15.5 48. 1 0.47 2.36 1 .60 
ACA(W) 37.0 13. 7 64.0 0.37 1 .94 1 .12 
NF (W) 42.6 24.6 83.4 0.58 2.23 1 .14 
JFI(W) 36.8 22.3 88.3 o . 61 2.36 0.98 
JFO(W) 38.5 19.7 56. 1 0.51 1 .70 1 .17 
ACL(W) 26.6 22.7 63.1 0.85 4.02 1 . 70 
3 Mean 32.3 19.6 70.1 0.64 2.66 1 .18 
Median 33.0 19.9 69.7 0.69 2.36 1 . 1 5 
SD 6.9 3.3 13.3 0.19 1 .01 0.32 
CV(%) 21 17 19 30 38 27 
, All attempts at curve fitting unsuccessful, rounding errors dominating. 
2 Unrealistic parameter estimates. 









































It was impossible to fit the 3 compartment model to the 
data from volunteer VL due to the minimization routine 
terminating with rounding errors. A 3 compartment model is 
probably a model misspecification in this individual 
(Boeckmann et al 1990). For volunteer DS on the other hand, 
3 compartment curve fitting attempts, although successful 
in terms of MOF, resulted in unrealistically low CL values, 
no matter what the initial parameter estimates (Table 5.6). 
Average values of Ve , CL and V2 obtained from 3 compartment 
model curve fitting, together with calculated 3 compartment 
microconstants, for the remaining 12 individuals are 
presented in Table 5.6. To make a comparison between the 
average parameters from this model and the model 
independent and two compartment model dependent analysis is 
probably not meaningful because of the exclusion of 2 
subjects from the 3 compartment analysis. Similarly, no 
comparison between blacks and whites in terms of 3 





in undertaking three 
obtain the best fit 
compartment 
individual 
pharmacokinetic parameters for use in effect modelling to 
be discussed in Chapter 6. To achieve this, 2 and 3 
compartment models were compared in each individual using 
a number of criteria including MOF, AIC, chi-squared test 
(Table 5.7.) (See Chapter 3, 3.5.2.2.4.). There was little 
difference between the 2 and 3 compartment model in 4 
volunteers (CM, BB, NF, ACL) and therefore the simplest 
model (2 compartment) was chosen (Table 5.7. ) . In 8 
volunteers (MN, AP, ZN, NM, NV, ACA, JFI, JFO) the 3 
compartment model was clearly better (Table 5.7. ) . The 
parameters generated from the 2 compartment fit were 
utilised for individual effect modelling in subjects VL and 
DS because 3 compartment curve fi tting was considered 
unsuccessful. 
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Table 5.7. Tes t s for choice between a 2 compartment model 
(2BCM) and a 3 compartment model (3BCM) including Minimum 
Objective Function (MOF) , Akaike's Information Criterion 
(AIC) and Chi square probability of difference in Objective 
Function (DOBF ) together with the intra-subject 
variation (ae ). 
Subject Model MOF AIC Chi Square a e 
Probability (CV%) 
(OOBF) 
MN 2BCM 147 147 21 
3BCM# 124* 128* p<0.005 1 1 
CM 2BCM# 119 119* 7 
3BCM 118 122 p<0.6 7 
VL 2BCM# 101 9 
3BCM Curve fit unsuccessful' -
AP 2BCM 124 124 9 
3BCM# 112* 116* p<0.005 10 
ZN 2BCM 155 155 24 
3BCM# 141 * 145* p<0.005 16 
DS 2BCM# 133* - 13 
3BCM 1122 - - 6 
NM 2BCM 129 129 15 
3BCM# 98* 104* p<0.0005 6 
NV 2BCM 147 147 22 
3BCM# 123* 127* p<0 . 0005 1 1 
BB 2BCM# 110 110* 5 
3BCM 106* 110 p<0.1 5 
ACA 2BCM 135 135 14 
3BCM# 116* 120* p<0.0005 8 
NF 2BCM# 111 111* 9 
3BCM 110 114 p<0.6 9 
JFI 2BCM 120 120 13 
3BCM# 99* 103* p<0.0005 7 
JFO 2BCM 121 121 17 
3BCM# 115* 119* p<0.05 13 
ACL 2BCM# 84 84* 6 
3BCM 82* 86 p<0.3 6 
# Final Model Choice 
* Intermediate Choice of Model 
, All attempts at curve fitting a 3 compartment model 
unsuccessful due to rounding errors. 
2 Although the 3 compartment model appeared better ( MOF & 
AIC), CL was unrealistic. 
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5.1.2.2. NONMEM Parameter Estimation 
All concentration time data for the 14 volunteers was 
subjected concurrently to NONMEM analysis. Firstly, the two 
and three compartment models were compared in order to 
select the most appropriate pharmacokinetic model. 
Subsequently the influence of weight on the variability of 
Ve and CL and lastly the effect of race on CL were 
investigated in a stepwise fashion as described below. 
Step 1. Both an open two compartment model and an open 3 
compartment model, expressed in terms of parameters, Ve , 
CL, peripheral volumes (V2 and V3 ) and intercompartmental 
clearances (Q'2 and Q13)' were fitted to the data. Both 
pharmacokinetic models assumed that all volunteers had the 
same values for the respective parameters irrespective of 
weight or race and that differences were due to random 
inter- and intra-subject variation. Iterative estimates of 
the parameters with residual inter-individual variance (~2) 
and residual intra-subject error variance 
presented in Table 5.8. 
are 
Table 5.8. NONMEM parameter estimates with inter-individual 
parameter variances (~2) as well as residual intra-subject 
variance (a2€) and MOF values for 2 and 3 compartment 
pharmacokinetic models. 
2 Compartment 3 Compartment 
Parameter Inter- Parameter Inter-
individual individual 
variance (~2) variance 
(lo)2) 
Vr- 36.5 L 0.0112 28.0 L 0.0567 
CL 15.4 L/hr 0.0497 13.6 L/hr 0.0728 
V? 101 L O. 1140 53.9 L 0.0479 
Q,? 58 L/hr 0.0204 92.8 L/hr 1 .3T's 
V1 - - 69.7 L 0.2560 
Q13 - - 11 .5 L/hr 0.0723 
if" 0.0329 0.00934 
MOF 1967.3 1781.8 
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The 3 compartment model was clearly superior to the 2 
compartment model using the criteria of MOF (1781.8 versus 
1967.3), and the Chi-squared test with 2 degrees of freedom 
(DOBF = 175.5, p<0.0005). 
The residual inter-subject variance of Q'2 in the 3 
compartment estimation yielded a negligibly small value 
(1 .3T's) and was therefore removed. Because this removal 
caused no alteration in the MOF or any of the parameter 
estimates the exclusion of this term was applied throughout 
further analyses. 
step 2. Using the three compartment model (with ~~'2 
removed) as the reduced model (Model 1, Table 5.9) linear 
functions incorporating weight (WT) as follows were tested: 
i) Vc only, (Vc = P1 *WT+P2) (Model 2, Table 5.9); 
ii) CL only, (CL = P1*WT+P2) (Model 3, Table 5.9); 
iii) WT in Vc and CL simultaneously (Model 4, 
Table 5.9). 
When comparing Model 2 with Model 1, a difference in 
Minimum Objective Function (DOBF) of 3.2 indicated only a 
marginal improvement (0.05<p<0.10). Model 3 compared with 
Model 1 yielded a DOBF of 4.2 (p<0.05) suggesting that 
weight could account for some variability in CL (p<0.05). 
Inter-individual variation in CL, however, increased from 
27 to 138%. Incorporating weight into both CL and Vc 
simul taneously (Model 4, Table 5.9) was unsuccessful in 
that the minimizati~n routine could not converge (requiring 
in excess of 4000 iterations). Model 3 thus appeared the 
best of the weight adjusted models tested. Estimates of 
parameters, inter-individual variation, as well as MOF and 
intra-individual variation are given in Table 5.9. 
step 3. The next step in model building was to assess 
whether race together with weight might contribute to the 
inter-individual variability in CL. 
Table 5.9. Parameter estimations for Models 1 to 4 assessing the influence of weight on Vc and 
CL separately and together and Model 5 with race and weight in CL. 
Parameter Model 1* Model 2 
Vr (L) 28.0 0.383*WT+1.86 
. CL (L/hr) 13.6 13.7 
V') (L) 53.9 55.3 
Q ,,) (L/hr) 92.8 91 .4 
V3 (L) 69.7 70.4 
Q n (L/hr) 11 .5 1 1 . 5 
(Jvc 23.8% 273.5% 
(J r.1 27.0% 26.7% 
(J \L2 21 .9% 23.7% 
(J V3 50.6% 51 .1% 
(J013 26.9% 28.1% 
°E 9.7% 9.8% 
MOF 1781.8 1778.6 
* 2 d (J Q12 remove . 
# Unsuccessful in converging. 
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Accordingly, the following linear model (Model 5, Table 
5.9.) was tested: 
CL = (P1*WT+P2)*(P3) 
where P3 is some estimated value in blacks and 1 in whites. 
A DOBF of 4.5 relative to the reduced model of only weight 
in CL (Model 3 ) showed that differentiating CL by race made 
a small but significant contribution to the definition of 
the model (1 degree of freedom, p<0.0250). From model 5 it 
appeared that in the present study the black volunteers had 
a weight adjusted CL 1 . 27 times faster than the whites. 
Because Model 5 appeared to give the best description of 
the concentration-time data by virtue of having the lowest 
MOF it was used in subsequent pharmacokinetic-dynamic 
modelling in Chapter 6 . 
However, the finding that blacks had a faster weight 
adjusted CL than whites was in contradiction to results 
from both two stage assessments viz. model independent and 
2 compartment ELS regression. The possibility that the 
above finding might be an artefact arising from the NONMEM 
model building procedure was therefore considered in the 
following step. 
step 4. Scrutiny of Model 5 output of the NONMEM 
minimization routine, revealed that parameters 1 and 2 (P1 
and P2) were highly inversely correlated (-0.948). Some 
inverse correlation was even evident between P1 and P2 in 
Model 2 (-0 . 800). This signified that the two parameters 
were poorly distinguished. Therefore a simpler model (Model 
6) of weight related to CL was investigated: 
CL = P1*WT. 
Results are presented in Table 5 . 10, indicating little 
advantage of Model 6 over Model 1. Using the maximum log-
likelihood ratio, Model 6 was 6 . 4 times more likely than 
Model 1 which was not considered a significant improvement . 
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In a similar manner the influence of race on CL was 
considered (Model 7, Table 5.10.): 
CL =P1 * p2 
where P2 is an estimated value for blacks and 1 for whites. 
From the results in Table 5.10. it is evident that the 
factor of 1.06 for blacks relative to 1 in whites is 
inconsequential . The two models gave almost identical MOF 
values. 
Thus in the final analysis, neither weight nor race 
substantially influenced the inter-individual variability 
of the clearance of atenolol as assessed by NONMEM 
analysis. 
Table 5.10. Parameter estimations of simpler models 
assessing the influence of weight and race on CL. 
I Parameter I Model 1 Model 6 Model 7 
v,. (L) 28.0 28.0 27.9 
CL (L/hr) 13.6 0.207*WT 13.1*1.06(B) 
V') (L) 53.9 54.2 53.8 
Ql,) (L/hr) 92.8 92.7 92.8 
V, (L) 69.7 68. 1 69.7 
Q n (L/hr) 11 .5 11 . 0 11 .6 
(ijvr- 23.8% 23.5% 23.8% 
(ijr.1 27.0% 25.9% 27.6% 
(ijl!? 21 .9% 20.5% 22.1% 
(ijv, 50.6% 57.8% 48.4% 
(ijOl, 26.9% 27.6% 25.7% 
0" 9.7% 9.7% 9.6% 
MOF 1781 .8 1778.1 1781.5 
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5 . 1.2.3. NONMEM versus Two stage Analysis 
Since NONMEM assumes a logarithmic error model, estimates 
generated from NONMEM proper should be compared to 
geometric means (Sheiner & Beal 1981) obtained from 
individual ELS estimations or moment analysis and not 
arithmetic means as given in the results tables. Correction 
for geometric means however, only marginally reduced values 
from those in t he results tables. 
Two compartment NONMEM estimates on the whole concurred 
with two stage estimates obtained by both ELS regression 
and model independent analysis of individual data although 
CL was lower at 15.4 L/hr . 
The 3 compartment NONMEM CL estimate of 13.6 L/hr was lower 
than the geometric mean found with both 3 compartment ELS 
regression (19.3 L/hr) or moment analysis (17.2 L/hr) in 
indi viduals. It is probably not valid to compare the 
NONMEM values (obtained from data for 14 volunteers) with 
the mean of the 3 compartment ELS regression because of the 
exclusion of two volunteers in the ELS analysis. Moment 
analysis however, included all the same volunteer data as 
NONMEM . The h igher 
compared with the 
CL obtained from moment analysis 
3 compartment NONMEM estimate, is 
possibly the result of poor characterization of the 
terminal slope in most of the individuals because of few 
samples and levels close to the limit of detection. NONMEM 
by pooling the data from all individuals would be expected 
to give a mor e reliable (unbiased) definition of this 
terminal elimination phase using all available data. 
The average Vss of 126 L obtained from both two stage 
methods ie . moment analysis and ELS regression was 
intermediate between that of 94.5 L from two compartment 




5.2.1. Model Independent Pharmacokinetics 
The model independent pharmacokinetic parameters (CL, V~ 
and t-!) of atenolol in healthy young blacks and whites 
showed no significant racial differences. This is not 
surprising because the elimination of atenolol is almost 
exclusi vely via the renal route and all volunteers were 
healthy young males with normal serum creatinine values. 
Atenolol clearance is correlated with renal function (Kirch 
et al 1981, Wan et al 1979) with a strong correlation 
between GFR and plasma clearance (ke1 = 0.024 + 0.00056 GFR, 
r = 0.82)(Kirch et al 1981) . Thus impaired renal function 
and age (probably a result of deteriorating renal function) 
are known to influence the clearance and half-life of 
atenolol (Barber et al 1981, Rigby et al 1985). Phenotype 
would therefore be unlikely to affect the disposition 
kinetics as is the case with the beta-blockers metoprolol, 
bufarolol, timolol and bopindolol, which undergo extensive 
oxidation (Lennard et al 1986). The disposition of atenolol 
has been shown to be unrelated to debrisoquine phenotype 
(Lennard et al 1986, Lewis et al 1985). 
The mean terminal elimination ti of 6.4 hrs is in 
reasonable agreement with other ~V atenolol studies in 
healthy volunteers where values range from 5.33 hrs (Wan et 
al 1979) to 6 and 7 hrs (Brown et al 1976, Mason et al 
1979, McAinsh et al 1980a). Terminal elimination half-lives 
after oral dosing in subjects with normal renal function 
are reported to range from 4.8 hrs to 9.2 hours (Kunka et 
al 1989, McAinsh et al 1980b, Rigby et al 1985, Riva et al 
1980) depending to some extent on the dose administered and 
the age of the subjects . An average half - life of 11.1 hours 
has been reported in a group of hypertensive patients over 
60 years of age (Dimenas et al 1990). Some studies in 
hypertensive subjects appear to indicate a somewhat longer 
half-life at steady state (11.5 hours) than after a single 
dose (7.2 hours) (Dixon et al 1990). 
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The average atenolol MRT1V of 450 minutes found in the 
present study is in the same range as the 517 minutes 
calculated from the data of Mason et al (1979) (Hinderling 
et al 1984). 
The mean clearance of 17.4 L/hr found in this study was 
somewhat higher than has been previously reported in 
healthy young adults. Reported clearances have ranged from 
6 L/hr (Brown et al 1976, Reeves et al 1978b) through 9 
L/hr (Kirch et al 1981) to 11-12 L/hr (Mason et al 1979, 
Rubin et al 1982). The mean weight normalised Vss of 1.9 
L/kg was also 58% higher than the 1.2 L/kg found by Kirch 
et al (1981). The large CL and Vss were the consequence of 
a relatively small AUCo_oo which was 30-40% lower than in 
another study where the same dose was used (Mason et al 
1979) . 
The variation between studies, of published values of 
pharmacokinetic parameters of beta-blockers, using 
apparently specific assay methods, has been highlighted by 
Hinderling et al (1984). Comparing two studies in each 
case, these authors showed a 38% difference in Vss of 
propranolol, a 141% difference in renal clearance of 
timolol and an 86% difference in non-renal clearance of 
oxprenolol. The reasons for the discrepancies are not 
readily apparent. 
Various possibilities in accounting for the differences 
between the present findings and published studies have 
been considered. 
Although the specificity of the assay methods were not in 
question, none of the above mentioned studies used the same 
method of atenolol measurement as was used in the present 
study. Also, most unfortunately, the plasma samples were 
stored for 30 months prior to analysis and some degree of 
degradation could have occurred. Although an early report 
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claimed atenolol was unstable when stored at -20o e (Yee et 
al 1979) a more recent report has shown atenolol to be 
stable under these storage conditions (Lewis et al 1985). 
All samples were, however, stored for the same length of 
time, under identical conditions. Therefore the comparison 
between blacks and whites would not be invalidated by the 
possibility of some degree of deterioration. 
One white volunteer (NV) had a respiratory tract infection 
on the day of atenolol administration. Inflammation 
(respira tory tract infections) has been shown to reduce 
plasma levels and Aue of atenolol by about 40% while 
increasing renal clearance (Kirch et al 1983). This might 
explain a relatively rapid clearance of 17 L/hr found in 
this one individual but not in the others. 
Another point of difference between the present study and 
the atenolol kinetic studies mentioned above was that none 
of them included exercise in their procedure. 
There is relatively little information available on the 
effects of exercise on the pharmacokinetics of drugs in 
general and on the beta-blockers in particular, despite the 
fact that many studies have assessed the effect of beta-
blockers on exercise haemodynamics. Exercise causes 
profound haemodynamic changes including increased cardiac 
output and redistribution of blood flow away from the 
splanchnic area and the kidneys towards the skeletal muscle 
and skin (Van Baak 1990). 
Increased distribution of drugs to skeletal muscle and skin 
and adipose tissue with exercise might increase the volume 
of distribution of some drugs. Van Baak (1990) cites 
conflicting evidence on distribution of beta-blockers 
during exercise. Rapid increases in plasma concentrations 
of oxprenolol, propranolol and acebutolol have been found 
when sampling was done during exercising while no change in 
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distribution was seen in different studies of propranolol 
and atenolol. 
Frank et al (1990) in a study of the effect of exercise on 
the kinetics of IV propranolol in 14 healthy volunteers, 
showed a large difference in the degree and direction of 
changes in individuals with exercise. Although the 
differences were not significant, exercise, on average, 
decreased total propranolol plasma clearance and increased 
average volume of distribution, relative to the sedentary 
study phase (Frank et al 1990). A reduction in clearance of 
high extraction ratio drugs like propranolol would be 
expected when blood is diverted away from the liver as 
occurs with exercise. 
Exercise would not be expected to markedly alter atenolol 
clearance because the drug is eliminated via the kidneys. 
In a study using orally administered atenolol, a reduction 
of 8% in renal clearance was demonstrated, possibly the 
result of reduced renal blood flow (Mason et al 1980). The 
above mentioned study differed from the present one in that 
the volunteers were exercised (Bruce protocol) at 4, 8 and 
24 hours post dosing when distribution would have been 
expected to be complete. In the present study exercising 
was most frequent during the initial distribution phase (8 
periods of 3 minutes of exercise between 0-2 hours post 
dose). The exercise might therefore have increased the 
initial distribution volume (demonstrated to be large in 
the model dependent analysis discussed below). This would 
in turn contribute to a larger V 
55. 
5.2.2. Model Dependent Pharmacokinetics 
5.2.2.1. ELS Estimations 
The average pa rameters obtained from two compartment ELS 
fitting of ind i vidual volunteer data sets was in agreement 
with the parameters obtained from model independent 
methods. This was not surprising when it is considered that 
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the atenolol concentrations from 4 hours onwards were used 
in calculating the terminal slope and would have biased 
results in the direction of two compartment modelling. Thus 
the model independent values conf~rmed that the two 
compartment model provided an adequate description of the 
concentration time data. 
As with model i ndependent kinetics, the two compartment ELS 
modelling produced no evidence of any ethnic differences in 
atenolol disposition. 
As expected, the three compartment model appeared to give 
a better fit in those volunteers where more concentrations 
from 24 to 36 hours were available. However, the relatively 
poor definition of this terminal phase in most individuals 
(24-36 hours) due to lack of samples or levels close to or 
below the assay sensitivity casts some doubt on the 
relevance of the ELS generated 3 compartment 
pharmacokinetic parameters in individual subjects. 
For comparative purposes, the published study by Mason et 
al (1979) in which an IV atenolol infusion was administered 
to 12 healthy volunteers is probably the most informative. 
These investigators used NONLIN to curve fit both two and 
three compartment models, finding the three compartment 
model more suitable in eleven of the 12 volunteers. Their 
findings differ from ours in that they measured much higher 
levels in the first hour after the infusion, accounting for 
the much smaller initial distribution compartment of 13 L 
(range 3 to 26 L) compared with 32 L (range 21 to 40 L) 
found in the present study. Despite their subjects not 
being exercised and their sampling time only extending to 
24 hours, the reported parameters and microconstants showed 
much greater inter-individual variation than was noted in 
the present st~dy . The possibili ty that the exercising 
immediately prior to administration and during the early 
distribution phase might have influenced the present 
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results cannot be discounted. This has been discussed in 
5.2.1. above. 
As much as the present study differs from that of Mason et 
al (1979), other studies involving similar IV doses of 
atenolol differ in the opposite direction. Brown et al 
(1976) after administration of 50 mg of atenolol (IV) to 4 
volunteers, obtained a Vc of 17.5 L, a Vd of only 51 Land 
a clearance of only 5 L/hr. The last two parameters are 
half of those found in the study discussed above (Mason et 
al 1979) but in agreement with a study by Wan et al (1979). 
5.2.2.2. NONMEM Estimations 
Concurrent analysis of concentration-time data from all 14 
volunteers by means of NONMEM, clearly showed that the 3 
compartment pharmacokinetic model was more appropriate than 
the 2 compartment model for the group as a whole. Most 
other investigators who have administered an IV dose of 50 
mg or more, have also found a 3 compartment model 
appropriate for describing atenolol concentration-time data 
(Brown et al 1976, Mason et al 1979, Wan et al 1979). 
The 3 compartment NONMEM estimate of 28 L (0.4 L/kg) for 
the central volume of distribution although lower than the 
32 L obtained from the 2 stage ELS regression estimates 
remained much l arger than most previously published values. 
Only one study, in children, reported a comparable V of 
c 
0.33±0.06 after 0.1 mg/kg of IV atenolol (Buck et al 1989). 
Mason et al (1979) using NONLIN 3 compartment curve fitting 
in 12 volunteers, reported wide ranging values from 3.27 to 
22.3 L (mean 12.8±5.72). Exercise as a possible reason for 
differences from published values in the initial 
distribution space have been discussed in the previous 
sections (5.2.1. and 5.2.2.). 
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In support of the reliability of the NONMEM generated CL 
value of 13.6 L/hr (See 5.1.2.3.) is its similarity to the 
11-12 L/hr reported for young healthy volunteers after IV 
administration in two different studies (Mason et al 1979, 
Rubin et al 1982)~ Apparent oral CL in young people (23-33 
years) with normal renal function is reportedly about 22 
L/hr (Rigby et al 1985). Assuming 50% bioavailability in 
the above study, would give an estimated CL corrected for 
F, of approximately 11 L/hr, again reasonably consistent 
with the NONMEM estimation in the present study. 
The significance of the results of modelling for factors 
contributing to inter-individual variability in Vc and CL in 
the present study is debatable. Modelling for a weight 
adjustment in CL while improving the MOF significantly at 
the 5% level, increased the inter-individual CV for CL from 
27 to 138%. A subsequent adjustment for race and weight in 
CL further improved the MOF but reduced interindi vidual 
variabili ty back to 26.6%. Surprisingly, this analysis 
yielded a factor indicating that blacks had a weight 
adjusted CL 1.27 times that of whites. This was contrary to 
results from both moment analysis and ELS regression where 
blacks on average appeared to have a slightly slower 
clearance. This discrepancy might be the result of 
different statistical assumptions in the different methods 
but is most probably an artifact generated in the NONMEM 
model building. The latter appears to be the case because 
further NONMEM modelling of weight and race used separately 
as scaling factors did not improve the estimates or fit 
(Table 5.10.). 
The influence of renal function (probably the most 
important factor) on the CL of atenolol could not be 
evaluated because neither serum creatinine values nor 
creatinine clearance values were available. If a real 
difference in CL between the blacks and whi tes in the 
present study existed, it would be most unlikely the result 
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of a true ethnic difference which could be extrapolated to 
other groups of blacks and whites. It would almost 
certainly be the result of differences in renal function 
within the group studied. Defining population variability 
of CL of atenolol should always take renal function into 
account. The lack of creatinine clearance values in the 
present study was a serious oversight. 
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5.3. CONCLUSION 
Moment analysis produced estimates of half-life and MRT1V 
which were comparable to literature values. CL, Vd and V~ 
were however, larger than literature values, possibly the 
result of the exercising protocol. There were no 
significant differences between blacks and whites in any of 
the parameters obtained from model independent methods. 
ELS regression analysis using a two compartment 
pharmacokinetic model exhibited no evidence of kinetic 
differences between the blacks and whites in the present 
study. The mean parameters obtained from two compartment 
modelling with ELS regression and NONMEM were consistent 
with mean values from moment analysis. 
Although 3 compartment ELS modelling in individuals was not 
particularly successful, NONMEM analysis appeared to yield 
reliable parameter estimates. The estimate of CL (13 L/hr) 
was lower than the other methods used, being only 
marginally larger than two published reports of 11-12 L/hr 
(Mason et al 1979, Rubin et al 1982). Attempts to ascribe 
inter-individual variation in Vc and CL to weight or race 
contributed nothing of scientific interest. 
CHAPTER 6 
PHARMACOKINETIC-DYNAMIC MODELLING 




EXPERIMENTAL RESULTS AND DISCUSSION 
6.1. RESULTS 
The atenolol induced decrease in exercise heart rate (EHR) 
was the only effect measurement considered sui table for 
pharmacokinetic-dynamic modelling. The BP, resting heart 
rate and PRA measurements were thought to have too much 
baseline noise to give meaningful results in relating 
atenolol concentration to effect. 
6.1.1. ELS Analysis of Data for Individuals 
The pharmacokinetic parameters were constrained to the 
values obtained from the best fit derived previously for 
each individual (See Chapter 5, 5.1.2.1.). Thereafter, ELS 
regression was used to relate concentration to the change 
in EHR. The linear, log-linear, E~ and Sigmoid Em~ models 
were tested with the data from each individual. A direct 
relationship between concentration and effect was assumed 
because change in exercise tachycardia appeared maximal at 
ei ther the first or second measurement after the 
termination of the atenolol infusion. 
Curve fitting of the pharmacodynamic data in individuals 
proved somewhat problematic. This was the result of a 
fundamental flaw in the study design. Namely, that many 
measurements were carried out during the first 6 hours but 
few measurements of either concentration or effect were 
done at the cri tical time between 12 and 30 hours when 
effect changes were maximal. 
The DOBF, AlC and chi-squared tests, although suitable for 
differentiating between the E and sigmoid E ,models were 
max max 
not appropriate for making a selection between the linear, 
log linear and Emax models because the models are not nested. 
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Although the maximum log-likelihood ratio could be used, 
the following were also considered in making a choice: 
i) Successful termination without rounding errors 
dominating; 
ii) Exclusion of the model, if any of the parameter 
estimates neared boundaries which were obviously 
unreasonable ego Em~> 70 bpm; Ieso >1000 ng/ml; 
or slope, 0.1>n>S.0; 
iii) Exclusion of the model if a correlation between any 2 
of the parameters describing the model was greater 
than ±0.9 (to ensure parameter differentiation); 
iv) inspection of the scatter plots of weighted residuals 
against predicted values, for the absence of a 
pattern; 
v) relatively low standard errors of the estimates (SEE); 
vi) low random intra-individual variation (oe) (measurement 
error or model misspecification) expressed as a 
coefficient of variation . 
For all individuals, the MOF values for each of the models 
where the minimization routine terminated without rounding 
errors dominating, is given in Table 6.1. overleaf. The 
best model overall is indicated by an asterisk (*), with 
footnotes indicating why some models were rejected. 
Details, including parameter estimates, are available in 
Appendix 4 (Tables A4 . 1-4.4.). 
In all subjects, the linear model was the least suitable by 
virtue of having by far the largest MOF value as well as 
the largest variation in random intra-individual error, the 
latter indicating model misspecification. The plot of 
weighted residuals versus predicted values showed a pattern 
(similar to that in Fig.6.4. for NONMEM group data 
analysis) again indicating model misspecification. 
When comparing the log-linear to the E model, in only two max 
volunteers was the former superior to the latter as judged 
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by a maximum log likelihood ratio of greater than 10 (>1000 
and 27 times more likely for VL and NF respectively). In 
one subject (CM) the log-likelihood ratio of 9 in favour of 
the log-linear over the Emax model indicated a marginal 
advantage in favour of the former. In 8 of the 14 subjects, 
curve fitting to the log-linear model resulted in the ELS 
minimization routine terminating with rounding errors 
dominating. These results were therefore considered 
unreliable (Boeckmann et al 1990). 
Table 6.1. Individual MOF values for the various effect 
models tested in blacks (B) and whites (W). 
Linear Log- Emax Sigmoid 
Model linear Model Emax 
Model Model 
MN (B) 195.4 # 176.4* 175.8,,2 
CM (B) 254.5 181 .2 185.6* 177.1,,2 
VL (B) # 156.2* 198.9 189.5,,2 
AP (B) 225.2 185.92 186.3* 185.82 
ZN (B) 222.7 # 208.62 195.8* 
DS (B) 269.2 # 228.1* 224.8,,2 
NM (B) 226.8 178.02 179.2* 179.02 
NV (W) 230.6 # 193.2* 193.02 
BB (W) 295.0 # 178.8* 172.1 2 
ACA (W) 221 .3 # 201.9* 201 .22 
NF (W) 293.6 187.9* 194.5 182.0,,2 
JFI (W) 3 184.2 # 1 77 . 72 137.3,,2 
JFO (W) 311 .2 # 251.2* 251 .2 
ACL (W) 269.4 155.1 2 163.7* 157.0' 
* Most suitable model overall. 
# Minimization routine terminated due to rounding errors 
dominating. 
, Estimate of parameter near boundary and therefore 
rrobably uninterpretable. 
Parameters correlated, therefore poorly distinguished. 
3 No suitable model. 
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In the remaining individuals (AP, NM and ACL) a correlation 
between the slope and intercept parameters led to rejection 
of the model. (See Appendix 4, Table A4.2. and 4.3. for 
full details.) 
Plots of the average EHR against time (Chapter 4, Fig.4.5 
and 4.6.) indicated an initial relatively small decline in 
effect in the first hour, followed by a plateau phase 
lasting about 3-5 hours after atenolol administration. 
Thereafter a more rapid decline occurred. This corresponds 
to the typical plateau effect seen with beta-blockade on 
reduction of exercise tachycardia (See Chapter 1 , 
1 .3.3. 1 .2. ). Thus either an Emax or a sigmoid Emax model 
appeared reasonable possibilities. 
When the sigmoid E model was max fitted to the data, 
significant correlation between 2 or more of the parameters 
was observed in 11 of the 14 volunteers. This demonstrated 
that the data was insufficient to obtain reasonably well 
defined estimates of all parameters describing this model. 
In one of the 3 remaining volunteers (ZN) a DOBF of 12.8 in 
favour of the sigmoid Emax model when compared to the Ema,x 
model, indicated a significantly better fit (one degree of 
freedom, p<0.0005). In another (VL) the IC~estimate was on 
a boundary of 1000 ng/ml leading to rejection of the 
sigmoid Emax model. In the last individual (JFO) the MOF was 
identical for both sigmoid and Emax models, the choice thus 
being the simpler Emax model. In subject JFI none of the 
models tested appeared to adequately describe the data. 
In summary: the sigmoid E model proved best in one max 
subject; in two subjects the log-linear model appeared most 
appropriate; the data from one subject proved impossible to 
fit to any of the models; and the E model was chosen for max 
the remainder. 
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Estimates of E and max (with standard errors of 
estimates, SEE) for all individuals together with intra-
individual variability in measurement are given in Table 
6.2. An asterisk marks those subjects where the Emax and 
sigmoid E models were considered unsuitable. These values max . 
were not included in subsequent comparisons or calculations 
of means. 
When the Emax and ICso values (excluding VL, NF and JFI) were 
compared between blacks and whites, no significant 
differences were found (Fig 6.1. and 6.2.). The Emax and ICso 
mean values with standard deviation for the 11 subjects 
were 32.9±S.73 bpm and 49.S±3B.9 ng/ml. The mean Em~ values 
in blacks and whites were very similar (33. 7±3. 43 and 
32.0±B.OB bpm respectively) while the mean ICso in the 
blacks (n=6) was 62.S±40.6 compared with 34.0±34.2 ng/ml in 
the whites (n=S) although the difference was not 
significant. 
In subjects where a two compartment pharmacokinetic model 
was applied, low ICso values (Fig. 6.3.) with particularly 
large errors of the estimates were found (Appendix 4, Table 
A4.3 and A4.4.). The value of the ICso became dependent on 
the pharmacokinetic model chosen. The limitation in 
defining the ICso estimates below 10 ng/ml lay in the 
inability to accurately measure low atenolol concentrations 
compounded by the paucity of samples. Failure to define a 
slow elimination phase thus distorted the pharmacodynamic 
results. 
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Table 6.2. Individual parameter estimates with SEE in 
brackets, and random measurement error (0) for the E or € max 
sigmoid E models. max 
I I 
Emax ICso n °e 
(bpm) (ng/ml) CV% 
MN (B) 37.4 124.0 - 33 
( 3 . 6 ) (38.2) 
CM (B) 34.7 18.9 - 23 
( 2 . 0 ) ( 5 . 1 ) 
VL (B)* 24.8 2.2 - 17 
(3.4) ( 4 . 5 ) 
AP (B) 28.4 27.4 - 36 
( 3 . 1 ) ( 5 .7) 
ZN (B) 34.9 95.4 1 .86 30 
( 7 .8) ( 9 .3) 
DS (B) 30.8 47.4 - 54 
( 3 . 6 ) (17.8) 
NM (B) 36.2 61 .6 - 19 
( 2 . 7 ) ( 8 . 9 ) 
NV (w) 35.5 45.6 - 30 
( 2 . 5 ) (13.1) 
BB (w) 34.3 5.4 - 19 
( 2 . 5 ) ( 3 .0) 
ACA (W) 35.5 86.0 - 39 
( 2 . 2 ) (23.6) 
NF (W)* 36.7 4.7 - 29 
( 3 . 5 ) ( 2 . 8 ) 
JFI (W)* 42.7 252 - 51 
( 8 . 3 ) ( 1 21 ) 
JFO (W) 36.9 30.8 - 26 
( 1 .8) ( 3 . 0 ) 
ACL (W) 17.6 2.3 - 55 
( 3 .0) ( 2 . 5 ) 
*Both E~x and sigmoid Em~ unsuitable in describing data. 
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Fig 6.3. ICSO values in relation 
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6.1.2. NONMEM Analysis of Group Data 
The data set of atenblol induced changes in exercise 
tachycardia for all 14 volunteers was subjected to NONMEM 
analysis. With the pharmacokinetic parameters constrained 
to the values obtained with Model 5 in Chapter 5 
(5.1.2.1.), cur ve fitting of the effect data to the linear, 
log-linear, E and sigmoid E models was effected. The 
m~ m~ 
assumption at this point was that race would not influence 
inter-individual variation in parameter estimates. The 
parameter estimates with standard errors of the estimates 
(SEE), inter-individual parameter variation (hl) and intra-
individual random variation (0£) for each of the four models 
are presented in Table 6.3 . overleaf. 
The linear mod el not only had the largest MOF and intra-
individual variation of all 4 models, but the plot of 
weighted res i duals versus predicted values clearly 
indicated model misspecification (Figure 6.4.). As a result 
this model was rejected . 
The log-linear model was considered inappropriate because 
although the minimization routine appeared to terminate 
successfully, an error message resulted (R matrix 
algori thmically non-posi ti ve semidefini te but nonsingular) . 
The reliability of final estimates were therefore in doubt. 
The model is possibly misspecified (Boeckmann et al 1990). 
This is supported by a diamond pattern (Figure 6.5.) 
displayed by the plot of weighted residuals against 
predicted values. When comparing the log-linear model to 
the Emax model, a DOBF of 111.8 in favour of the E~ model 
demonstrated t hat it described the data considerably better 
than the log-linear model (Table 6.3.) . 
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Table 6.3. NONMEM generated. effect model parameters with 
standard errors of the estimate (SEE), MOF and inter-
indi vidual parameter variation (fA) together with random 




PARAMETER fo) MOF °e 
(SEE) (CV %) (CV %) 
LINEAR* 5=0.0814 102 3415.1 157 
(0.0192) 




Emax Emax=37 . 0 (1. 3) (bpm) 
12 2855.9 19 
IC5f=36.5 121 
( 7 . 2 (ng / ml ) 






* Plot of weighted residuals versus predictions indicated 
that this model was inappropriate. 
** Although minimization routine terminated successfully, 
error message: R matrix algorithmically non-positive 
semidefinite but nonsingular. 
# Including inter-individual variation on slope did not 
alter MOF (28 43.1) but increased ° (22%) and an inverse 
correlation between Emax and ICse (-0 ~ 918) became evident. 
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Figure 6. 4 • A plot of 
predicted values (PRED) 
pharmacodynamic model. 
weighted residuals (WRES) versus 
from NONMEM analysis using a linear 
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Figure 6.5. A plot of weighted residuals (WRES) versus 
predicted values ( PRED) from NONMEM analysis using a log-
linear pharmacodynamic model. 
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Figure 6.6. A plot of 
predicted values (PRED) 
pharmacodynamic model . 
WRES ,,~ PRED '0:'). 
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weighted residuals (WRES) versus 
from NONMEM analysis using an E~x 
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Figure 6.7. A plot of weighted residuals (WRES) versus 
predicted values (PRED) from NONMEM analysis using a 
sigmoid E~ model . 
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The sigmoid E model when compared to the E_~_ model max ,,~ 
produced a DOBF of 12.9 in favour of the former, indicating 
a significant improvement in data fitting (one degree of 
freedom, p<O.OOOS) (Table 6.3.) . The inter-individual 
variability in parameter estimates was very similar 
although with the sigmoid E~ 
variability was marginally better 
for the E~ model (Table 6.3). 
model intra-individual 
at 16% compared with 19% 
Plots of the weighted 
residuals versus predicted values for these two models are 
given in Figures 6.6. and 6 . 7. Although both plots showed 
a random distribution of points with little to choose 
between the two, they were both better than the plots from 
the linear and log-linear models which demonstrated 
distinct patterns. 
NONMEM analysis thus demonstrated that the sigmoid E~ model 
best represented the data as a whole. The E~, leso and 
slope (n) estimates were 43.8±2.7 bpm, 32.1±9.6 ng/ml and 
O.738±O.074 respectively. 
An attempt to f it the sigmoid E~ model including inter-
individual variance on the slope parameter did not alter 
the MOF but increased intra-individual variation and caused 
Emax and lCso estimates to become inversely correlated. 
Al though there was little evidence of disequilibration 
between inhibition of exercise tachycardia and atenolol 
plasma concentration, an effort was made, by means of 
NONMEM, to fit the whole data set to the sigmoid E~ model 
with an effect compartment. Unfortunately, the minimization 
procedure was unsuccessful for reasons which are not clear 
at present. 
The final step was to assess whether race influenced the E max 
and lCso values for inhibition of exercise tachycardia with 





E = P1*P2 max 
IC50 = P1*P2 
with P2 in each case being some estimated value in 
blacks and 1 in whites. 
The results are presented in Table 6.4. 
Table 6.4. Parameters (SEE) obtained by NONMEM analysis of 
the sigmoid Emax model and then separately incorporating a 
factor for the influence of race on Emax and IC~. 
I I 
Sigmoid E = ICso= max 
Emax P1*P2{B) P1*P2{B) 
Emax 43.8 42.6*1.05(B) 43.7 
(bpm) (2.74) (3.11) (2.64) 
IC 32. 1 32.3 35.4*0.848(B) 
(ngfml) (9.55) (9.67) (13.0) 
n 0.738 0.741 0.742 
(0.075) (0.073) (0.069) 
MOF 2843.0 2841.0 2841.4 
a~ (CV%) 16 16 16 
Including a factor for race, had little influence on the 
fit of the data, with only small changes seen in either MOF 
values or parameter estimates (Table 6.4.) Relative to the 
plain sigmoid Emax model, both models with race resulted in 
increased inter-individual variation of the parameter 
estimates, Em~ ( from 8 to 13%) and IC~ (from 120 to 180%). 
Inclusion of race increased the standard error of the IC
50 
estimate from 30 to 37%. The Em~ value in blacks was higher 
(1.05 times) and the IC50 lower (0.848 times) than that of 
the whites in the present study. These differences were not 




6.2.2. ELS Estimation in Individuals 
As a result of the inappropriate timing of blood samples 
and heart rate measurements the characterization in 
individuals, of the relationship between change in EHR and 
atenolol concentration was not satisfactory. Firstly, model 
selection was difficult in some volunteers and secondly, 
the group mean of parameters particularly IC~ is probably 
questionable. Group variability was also likely to be 
biased upwards because of contributions from not only 
inter-individual biological sources but also from parameter 
estimation (Sheiner & Beal 1980a). 
The identification of a suitable pharmacodynamic model was 
a greater problem in those individuals where atenolol 
concentrations displayed two compartment pharmacokinetic 
disposition. This was thought to have resulted from the 
limitation imposed by sensitivity of the atenolol assay and 
lack of samples after 12 hours. 
Nevertheless, in the majority of subjects (11 of 14) a 
maximum effect was reasonably well defined. The average of 
32.9±S.7 bpm (in 11 subjects) was comparable to the mean E max 
of 36.3 bpm obtained from visual inspection of the data in 
16 volunteers (Chapter 4, 4.1.1.2.). As already discussed 
(Chapter 4, 4.2.1.) this was lower than that demonstrated 
by some other investigators with the same dose of atenolol 
(Shanks et al 1977, Brown et al 1976) but was possibly the 
result of either a lower level of exercise (Leenen et al 
1980) or lower atenolol concentrations than those found by 
Brown et al (1976). 
The estimation of a reliable IC~ value for the group using 
a two stage analysis with only 2 to 3 data points per 
subject was much more difficult. After excluding 3 
volunteers because of the unsuitability of the E model 
max 
the reliability of results became even more suspect. The 
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major reason for employing NONMEM was to try to improve the 
reliability of this estimate. This will be discussed below. 
Similar difficulties have been encountered by others when 
attempting to define the concentration response curve for 
the influence of (-)-propranolol on exercise tachycardia in 
individuals (Clifton et al 1990). These authors found that 
curve fitting by iterative least-squares regression, showed 
the E or sigmoid E models to adequately describe the 
m~ m~ 
decrease in heart rate in only 8 of 11 subjects, the linear 
model in 2 subjects while none of the models appeared 
suitable in another subject. 
In the present study, using two stage analysis, the maximal 
effect was no different between blacks and whites and ICso 
showed no significant ethnic differences but large inter-
individual vari ation. This corroborates the findings in 
Chapter 4, 4.1.1.2. when no racial differences in change in 
EHR after atenolol were found in the study groups. 
6.2.2. NONMEM Estimations 
Because of the shortcomings in the design of the study, 
difficul ties were experienced firstly, in selecting an 
appropriate model and secondly in obtaining reliable 
parameter estimations particularly ICso ' in individual 
subjects. It is in precisely this situation (few samples 
available from an individual) when the strength of NONMEM 
as an alternative approach in analyzing the data is 
manifested (Sheiner & Beal 1980a, Grasela et al 1986). 
NONMEM's estimates from pharmacokinetic data analysis have 
been demonstrated to be at least as good as the standard 
two stage method (STS) for mean parameters and for residual 
variabili ty but better for inter-individual variability 
(Sheiner & Beal 1981). With experimental data from 
relatively few individuals the latter estimates are 
however, not acceptable as population values as they are 
unlikely to be representative of the population as a whole. 
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The selection of the E and sigmoid E models as more max max 
appropriate than the linear or log-linear models posed no 
difficulty. When comparing the Emax and sigmoid Emax model the 
latter gave a significantly better description of the data 
based on MOF. However, the physiological relevance of the 
value of the slope parameter viz. 0.738±0.074 being less 
than one in the present study is debatable. 
The slope reflects the mechanism of action of a drug as 
well as its binding to the receptor (Ross & Gilman 1985). 
Values usually range between 1 and 3 unless there is an all 
or nothing response (Rowland & Tozer 1989). The relatively 
shallow slope might be the consequence of timing of 
measurements rather than a true difference from unity in 
the slope parameter. The effect might have returned to 
baseline before a measurement was actually made. It has 
also been suggested that the in vivo effect on suppression 
of heart rate may only be discernable when it is 10 to 20% 
different from baseline. This is due to variation in 
baseline EHR in response to internal and external stimuli 
(Rowland & Tozer 1989). This would also tend to make the 
slope appear less steep as well as difficult to 
characterise. Therefore it did not seem worthwhile to 
attach any great significance to the actual value of the 
slope parameter. A value of 1.3±0.5 has been reported for 
the slope of the sigmoid Emax model as applied to the effect 
of (-)-propranolol on exercise tachycardia (Clifton et al 
1990). 
The Em~ estimate from NONMEM analysis using the sigmoid E max 
of 43.8±2.7 bpm appears to be on the high side relative to 
visual assessment where a mean value of 36.3 was obtained 
( Chapter 4, Table 4.2) as well as the STS method above 
(32.5 bpm) and even compared to the NONMEM fit using the E max 
model (37.0±1 .83). With hindsight it might have been better 
to fix the Emax value instead of estimating it when fitting 
the sigmoid E model. max 
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The NONMEM sigmoid E~ model estimate of IC~ of 32.1±9.6 
ng/ml is much lower than the ICso values of 180 and 300 
ng/ml quoted by Wellstein et al (1985b). These values were 
obtained by re-evaluating the data of Shanks et al(1977) 
and McAinsh e t al (1977) respectively, using fairly 
complicated cal culations involving the time course of 
clinical effects after oral dosing. 
The ICso value would be expected to vary according to the 
amount of agonist present at the receptors. With exercise 
tachycardia the endogenous agonist concentration is 
obviously unknown but would be expected to be related to 
the degree of exercise. utilising NONMEM, it should be 
possible to relate the E~ value to baseline tachycardia as 
an indirect measure of agonist concentration although this 
was not done in the present study. 
Race (black versus white) did not appear to significantly 
influence the value of either the Emax or ICso of atenolol 
with respect to inhibition of exercise tachycardia. This 
confirms the observations made in Chapter 4.(4.1.2) where 
neither the treatment effect on EHR at discrete time points 
nor the EHR change in AUC with atenolol demonstrated any 
racial differences. 
This apparent lack of any black-white difference in 
inhibition of exercise tachycardia while a reduced overall 
effect on supine systolic BP in blacks was noted, should be 
viewed in relation to a series of recent studies 
investigating ethnic differences in response to beta-
blockade between Chinese and Caucasians. 
In response to the perception that substantially lower 
doses of propranolol are prescribed in China compared to 
those used in Europe and the USA, a series of experiments 
in normotensive young men have been conducted. Zhou et al 
(1989) demonstrated a two fold greater sensitivity to the 
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negative chronotropic effects of propranolol and a ten fold 
greater sensitivity to the BP lowering effects of 
propranolol in the supine position, in Chinese compared to 
American white men. No difference in lymphocyte · beta-
receptor density or affinity was found between the two 
groups. However, the Chinese subjects although having lower 
blood levels of propranolol, had a 45 percent higher free 
fraction of propranolol which may have contributed to the 
increased effect although it did not fully explain it. This 
ethnic difference in plasma protein binding of propranolol 
( and some other drugs) was found to be due to reduced 
levels of o,-aci d glycoprotein in Chinese subjects (Zhou et 
al 1990). 
Because most beta-blockers including propranolol are 
administer ed as racemates, another possible explanation for 
the grt •. t er effect at lower total propranolol 
concentra t i ons in Chinese was that there might be a 
difference in stereoselective disposition of propranolol 
between Chinese and Caucasians (Zhou & Wood 1990a). This 
was found not to be the case because, although plasma 
concentrations of both (-)- and (+)-propranolol were lower 
in the Chinese than the white subjects the proportion of 
the two isomers did not differ. 
Since differences in propranolol disposition do not explain 
the marked ethnic difference in the hypotensive response, 
a pharmacodynamic explanation for the altered sensitivity 
in Chinese subjects is currently being sought. A recent 
abstract (Zhou & Wood 1990b) has reported a significantly 
greater reduction in plasma renin activity (after exercise) 
in Chinese compared to Caucasian subjects in response to 
propranolol. The mean blood pressure reduction in this 
study correlated with the reduction in plasma renin 
activity (r=0.6760, p<0.001.) 
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Zhou et al (1989) found that the ethnic difference in 
response to propranolol, between Chinese and Caucasians was 
10 fold on supine BP, fourfold on erect BP but only twofold 
on inhibition of exercise tachycardia. This suggests an 
amplification of the ethnic difference at a level of BP 
control either removed from or not involving the 
chronotropic beta-receptors. Altered effects are probably 
related to components of the renin-angiotensin-aldosterone 
system as this latest study suggests (Zhou & Wood 1990b). 
Clifton et al (1990) have reported significantly greater 
potency of propranolol in reducing exercise heart rate 
compared with its effects on left ventricualr systolic 
function. Concentration-response curves for the various 
effects of beta-blockers in an individual are clearly 
different and could be expected to vary independently 
across populations (Zhou et al 1989) and possibly with 
different disease states. 
From the results in the present study, it would seem that 
in normotensive subjects, black-white differences in beta-
blocker responses are not as drama tic as whi te-Chinese 
differences. The black-white differences may however, be 
accentuated in hypertensive subjects. Hypertensive subjects 
differ from normotensive subjects in having increased 
peripheral vascular resistance. A very interesting recent 
publication has demonstrated that the apparent abnormality 
in a-receptor mediated arterial vasodilatation (inability 
to respond to volume expansion) in patients with 
hypertension can be . corrected by low sodium intake (Naslund 
et al 1990). Although this study involves the vasodilatory 
beta2-receptor the role of sodium in receptor regulation 
points to the involvement of the renin-angiotensin yet 
again. 
Thus careful assessment of the concentration-response 
relationship of beta-blockers using supine BP (where ethnic 
differences appear greatest) in reasonably matched 
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hypertensive black and white subjects should prove 
worthwhile. Provided baseline noise is minimised, it should 
be feasible to model for the delay in BP responses using 
effect compartment modelling as has been done for the 
slowly developing effect of ergotamine on peripheral 
arteries (Tfelt-Hansen & Paalzow 1985). This would be 
particularly useful if response or lack of it could be 
related to physiological variables (eg. PRA, sodium 
handling) across a spectrum of values. This could assist in 
identifying physiological variables predictive of response 




Due to methodological problems in the sampling design of 
the study, curve fitting of inhibition 
response to atenolol was particularly 
individuals. The simultaneous use of 
volunteers in the programme NONMEM, 
satisfactory in obtaining IC~ values. 
of EHR data in 
problematic in 
data from all 
proved more 
Pharmacokinetic-dynamic modelling corroborated the findings 
in Chapter 4, that race did not significantly influence the 
reduction in exercise tachycardia induced by atenolol in 
normotensive young men. 
Assessment of the BP response differences between 
hypertensive blacks and whites in a rigorous experimental 
protocol in order to define the dose-concentration-response 
relationship with effect compartment modelling should yield 
interesting results. In addition response variation could 
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APPENDIX 1 
Appendix to Chapter 3 
A2 
Table Al.l. Details of age, weight, height and pretreatment 
supine and erect blood pressure and resting heart rate 
(RHR) of black volunteers. 
Age Weight Height Supine Erect RHR* 
(yrs) (kg) (cm) BP* BP* (bpm) 
(mm Hg) (mm Hg) 
MN 25 70 180 130/90 120/90 61 
CM 27 63 170 122/65 118/85 80 
VL 21 70 173 120/68 110/75 59 
AP 21 63 175 103/68 103/80 62 
ZN 24 48 154 100/53 103/65 77 
DS 23 68 173 98/63 103/65 64 
NM 24 80 175 110/65 115/75 73 
AK 20 80 175 105/60 105/73 76 
Mean 23.1 67.8 172 111/60 110/76 69 
SD 2.4 10.3 7.8 12/9 7/9 8.4 
SEM 0.8 3.7 2.7 4/3 3/3 3.0 
CV% 10.4 15.2 4.5 10/15 6/12 12.2 
Table A1 .2. Details of age, weight, height and pretreatment 
erect and supine blood pressure and resting heart rate 
(RHR) for white volunteers. 
Age Weight Height Supine Erect RHR* 
(yrs) (kg) (cm) BP* BP* (bpm) 
(mm Hg) (mm Hg) 
NV 22 73 177 105/60 118/68 78 
HA 23 79 173 110/63 110/68 75 
BB 21 71 178 115/73 120/78 61 
ACA 21 70 180 118/73 115/78 57 
NF 23 70 166 116/71 116/77 83 
JFI 20 77 180 118/63 120/63 79 
JFO 20 67 182 103/63 103/73 63 
ACL 20 70 181 103/63 103/60 62 
Mean 21 .3 72. 1 177.0 111/66 113/71 69.8 
SD 1 .3 4.0 5.3 6/5 7/7 10.0 
SEM 0.5 1 .4 1 .9 2/2 3/3 3.5 
CV% 6.1 5.5 2.8 5/8 6/10 14.3 
'I< Mean of 2 basellne readln s g 
A3 
Table Al .3. Workloads and pretreatment exercise heart rates 
(EHR) for blacks and whites. 
BLACKS Workload EHR* WHITES Workload EHR* 
(W) (bpm) (W) (bpm) 
MN 141 137 NV 211 138 
CM 123 154 HA 176 145 
VL 194 130 BB 176 133 
AP 123 133 ACA 176 128 
ZN 106 147 NF 141 160 
DS 176 142 JFI 159 129 
NM 159 139 JFO 123 137 
AK 159 149 ACL 123 130 
Mean 148 141 Mean 161 138 
SD 29.8 8.2 SD 30.4 10.7 
SEM 10.5 2.9 SEM 10.7 3.8 
CV% 20. 1 5.8 CV% 18.9 7.8 
Mean of two basellne readln s 9 
Table Al.4. Order in which volunteers received placebo {P} 
and atenolol treatment (A). 
BLACKS Phase 1 Phase 2 WHITES Phase 1 Phase 2 
MN P A NV P A 
CM A P HA A P 
VL P A BB P A 
AP A P ACA A P 
ZN P A NF P A 
DS A P JFI A P 
NM P A JFO P A 
AK A P ACL A P 
A4 
Table A1.5. Inter-assay coefficients of variation (%) for 
seeded control samples analysed over a 3 day period. 
I Concentration I 10 39 161 321 1282 
Day 1 11 .2 43 . 9 161 334 1315 
12. 1 39.1 161 318 1257 
Day 2 10.7 43 . 9 176 338 1402 
12.3 43 . 8 166 - 1305 
Day 3 9.2 40.7 159 - 1195 




10.8 41 .2 162.8 330 1282 
SD 1 .36 3.2 7.7 10.6 80 
CV% 12 . 6 7.8 4.6 3.1 6.2 
AS 
APPENDIX 2 
Appendix to Chapter 4 
Table A2.1. Resting heart rate values in black and white individuals after placebo administration. 
TIME 
(hours) 
MN CM VL 
0.0 64 83 55 
0.3 N/A 78 N/A 
0 . 5 82 82 79 
1 .0 65 75 84 
1 .5 82 65 75 
2.0 80 73 69 
3.0 75 73 76 
I 
4.0 57 69 59 
5 . 0 65 64 53 
6.0 57 80 55 
8 . 0 72 71 56 
10.0 60 68 59 
12.0 60 75 57 
24 . 6 60 67 56 
30.0 60 77 72 
36.0 56 77 70 
RESTING HEART RATE AFTER PLACEBO (beats/minute) 
BLACKS WHITES 
AP ZN PB NM AK NV HA BB ACA NF 
63 69 60 70 66 83 73 66 56 82 
77 90 N/A N/A N/A 84 N/A 68 N/A N/A 
76 78 83 74 90 87 72 68 68 99 
72 87 94 78 88 83 64 67 57 77 
76 73 77 76 83 80 60 69 58 70 
76 73 80 77 98 86 77 73 65 79 
72 75 77 87 84 87 75 76 65 69 
68 74 86 67 93 80 69 60 63 67 
73 66 59 75 86 78 61 57 71 64 
69 65 65 75 81 81 64 72 60 65 
68 69 65 62 81 73 64 67 57 67 
55 56 63 73 66 88 62 57 68 57 
54 65 67 61 72 72 64 63 63 58 
71 66 59 66 99 79 62 64 50 72 
72 67 60 62 73 78 83 74 61 85 








































Table A2.2. Resting heart rate in black and white individuals after atenolol administration. 
---
RESTING HEART RATE AFTER ATENOLOL (beats/minute) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 57 81 58 60 84 66 81 86 75 72 55 65 84 80 65 59 
0.3 74 79 78 N/A N/A N/A 80 99 68 N/A 64 64 72 N/A 66 63 
0.5 70 68 79 68 74 78 76 99 72 76 N/A 62 63 76 53 58 
1 .0 60 65 82 68 81 82 75 99 64 69 77 57 65 63 57 64 
1 .5 69 60 70 66 73 72 68 83 67 62 66 58 62 64 69 58 
2 . 0 60 58 66 68 72 74 66 84 74 57 66 59 56 67 64 75 
! 3 . 0 49 60 74 54 69 63 71 83 65 57 62 56 58 56 67 64 
4 . 0 48 52 68 65 63 67 74 77 58 57 58 57 54 58 54 61 
5.0 48 52 64 64 60 62 73 70 69 56 56 55 58 58 49 63 I 
I 
6.0 57 53 63 58 63 76 66 70 64 56 63 58 65 75 54 76 . 
8 . 0 52 74 63 69 63 63 51 71 72 54 55 52 65 77 54 72 
10.0 63 54 76 54 54 57 53 61 55 55 54 54 56 68 53 63 
12.0 48 55 69 54 57 68 63 73 66 58 55 57 59 71 67 63 
24.0 69 56 57 62 65 54 50 86 77 49 48 52 61 79 68 63 
30.0 62 63 68 57 62 63 61 74 70 57 57 65 66 69 61 61 




Table A2.3. Mean resting heart rate (beats/minute) after 
placebo and atenolol administration in the black and white 
groups (n=8 in each group). 
AVERAGE RESTING HEART RATE 
TIME (beats/minute) 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 66.2 71 .6 69.8 69.4 
0.5 80.5 76.5 76.4 57.5 
1.0 80.4 76.5 70.0 64.5 
1 .5 75.9 70.1 68.5 63.3 
2.0 78.2 68.5 74.9 64.8 
3.0 77.4 65.4 72.3 60.6 
4.0 71 .6 64.3 67.8 57.1 
5.0 67.6 61 .6 68.1 58.0 
6.0 68.4 63.3 72.3 63.9 
8.0 68.0 63.3 67.4 62.6 
10.0 62.5 59.0 66.9 57.3 
12.0 63.9 60.9 69.9 62.0 
24.0 68.0 62.4 65.4 62.1 
30.0 67.9 63.8 72.9 63.3 
36.0 67.0 61 .6 71 .4 67.5 
A9 
Table A2.4. Area under the Curve (AUC) for resting heart rate 
from 0 to 12 hours (beats/minute.hr) after placebo and atenolol 
and the difference between placebo and atenolol. 
Subjects AUC (0-12 hours) (bpm.hr) 
Blacks Placebo Atenolol Difference 
MN 797.00 669.55 127.45 
CM 864.40 716.20 148.20 
VL 742.00 828.85 -86.85 
AP 802.80 737.00 65.80 
ZN 822.40 766.50 55.90 
DS 844.50 802.00 42.50 
NM 861.75 767.75 94.00 
AK 971 .00 898.30 72.70 
Whites 
NV 970.40 782.45 187.95 
HA 791.00 694.25 96.75 
BB 785.45 712.45 73.00 
ACA 756.25 673.20 83.05 
NF 806.25 726.65 79.60 
JFI 861.60 817.25 44.35 
JFO 852.50 687.80 164.70 
ACL 861.45 797.15 64.30 
Table A2.5. Exercise heart rate in black and white individuals after placebo administration . 
-
EXERCISE HEART RATE AFTER PLACEBO (beats/minute) 
TIME 
BLACKS WHITES (hours) 
NM CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 146 151 134 129 142 146 136 140 138 140 136 125 161 124 133 126 
0.2 N/A 155 137 140 149 154 140 140 139 138 133 133 145 129 134 132 
0.4 N/A N/A 140 145 147 159 142 150 N/A N/A 141 N/A 160 129 129 137 
0.5 148 146 138 142 149 163 152 146 138 144 152 141 164 123 132 129 
0.8 N/A N/A 143 138 150 165 146 150 N/A N/A N/A 139 N/A 125 131 135 
1 . 0 141 152 144 152 152 168 144 152 135 146 144 143 162 129 130 128 
1 . 5 146 150 144 155 155 169 152 151 140 142 144 139 162 115 131 128 
2 . 0 144 150 143 150 155 173 150 157 142 144 147 147 166 125 134 133 
3.0 140 150 137 149 155 162 154 155 136 146 144 140 161 133 136 133 
4 . 0 140 153 136 151 152 159 158 151 140 147 144 133 159 129 148 131 
5.0 136 152 135 155 150 153 140 155 140 140 143 130 160 133 128 134 
6.0 140 154 133 155 153 155 140 157 140 146 147 131 165 137 133 133 
8.0 140 152 132 1 51 144 140 140 155 139 142 143 133 156 135 136 132 
10 . 0 140 149 137 150 138 146 142 150 140 140 144 128 155 138 128 143 
12.0 148 160 136 158 151 146 146 150 137 140 144 138 155 136 128 132 
24.0 132 152 136 140 143 150 140 163 140 144 146 129 154 134 139 126 
30.0 136 147 135 148 141 155 151 144 136 152 140 145 159 127 132 129 




Table A2.6. Exercise heart rate in black and white individuals after atenolol administration. 
TIME 
EXERCISE HEART RATE AFTER ATENOLOL (beats/minute) 
(hours) BLACKS WHITES 
NM CM VL AP ZN DS NM AK NV HA 'BB ACA NF JFI JFO ACL 
0.0 130 160 125 136 152 138 142 157 138 150 129 131 158 133 140 134 
0.2 111 111 99 112 111 116 113 120 98 111 96 101 113 100 103 100 
0.4 N/A N/A 100 115 113 121 115 124 N/A 115 N/A N/A N/A 105 100 N/A 
0.5 109 115 103 110 115 121 116 126 104 120 105 101 116 107 101 105 
0.8 112 N/A 106 113 116 126 115 128 N/A N/A 105 105 116 109 102 105 
~ 
-> 
1 .0 110 11 5 106 115 115 127 115 130 105 115 108 103 116 108 103 107 -> 
1 .5 118 114 110 121 121 129 116 130 106 115 109 105 116 107 104 107 
2.0 117 118 109 122 124 129 117 133 108 120 109 107 120 108 103 113 
3.0 118 11 6 111 124 119 136 120 133 108 120 108 110 122 106 108 111 
4.0 11 5 116 111 126 122 132 118 133 109 120 108 111 121 103 108 115 
5.0 119 116 110 126 122 133 123 130 109 123 111 112 123 115 106 121 
6.0 127 118 11 2 132 125 143 124 131 112 124 115 111 131 115 110 125 
8.0 128 128 11 3 130 124 142 119 135 114 127 117 110 130 117 112 123 
I 
10.0 125 128 11 5 131 128 145 118 139 116 122 119 114 140 122 111 130 ' 
12.0 125 135 122 136 129 138 130 147 124 125 125 116 140 127 119 128 
24.0 140 144 126 136 141 142 129 148 127 123 124 117 142 133 128 128 
30.0 148 134 132 136 140 . 161 144 154 133 132 130 141 149 132 130 150 
36.0 145 151 135 152 149 144 140 155 140 136 135 141 148 138 143 144 
A12 
Table A2.7. Mean exercise heart rate (beats/minute) after 
placebo and atenolol administration in the black and white 
groups (n=8 in each group). 
AVERAGE EXERCISE HEART RATE 
(beats/minute) 
TIME 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 140.5 142.5 135.4 139.1 
0.2 145.0 111 .6 135.4 102.8 
0.4 147.2 114.7 139.2 106 . 7 
0.5 148.0 114.4 140.4 107.4 
0.8 150.6 116.6 132.5 107.0 
1.0 150.6 116.6 139.6 108.1 
1 .5 152.8 119.9 137.6 108.6 
2.0 152.8 121 . 1 142.3 111 .0 
3.0 150.3 122.1 141 . 1 111 .6 
4.0 150.0 121 .6 141 .4 111 .9 
5.0 147.0 122.4 138.5 115.0 
6.0 148.4 126.5 141 .5 117.9 
8.0 144.3 127.4 139.5 121 .8 
10.0 144.0 128.6 139.5 118.8 
12.0 149.4 132.8 138.8 125.5 
24.0 144.5 138.3 139.0 127.8 
30.0 144.6 143.6 140.0 137 . 1 
36.0 147.0 146.4 145.0 140.0 
A13 
Table A2.8. Area under the curve (AUC) for exercise heart rate 
from 0 to 12 hours (beats/minute.hr) after placebo and atenolol 
and the difference between placebo and atenolol. 
Subjects AUC (0-12 hours) (bpm.hr) 
Blacks Placebo Atenolol Difference 
MN 1696.00 1460.20 235.80 
CM 1823.75 1464.75 359.00 
VL 1636.30 1346.25 290.05 
AP 1816.25 1527.75 288.50 
ZN 1781.80 1483.60 298.20 
DS 1840.65 1644.05 196.60 
NM 1740.70 1443.00 297.70 
AK 1834.15 1613.25 220.90 
Whites 
NV 1668.75 1344.40 324.35 
HA 1714.10 1467.45 246 . 65 
BB 1730.70 1365.20 365.50 
ACA 1612.10 1327.20 284.90 
NF 1909.30 1538.95 370.35 
JFI 1592.30 1371.50 220.80 
JFO 1597.60 1312.60 285.00 
ACL 1607.15 1440.35 166.80 
Table A2.9. Erect systolic blood pressure for black and white individuals after placebo 
administration. 
- _ . _-- - ---
ERECT SYSTOLIC BP AFTER PLACEBO (mm Hg) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 120 115 140 105 100 105 115 105 118 120 125 106 110 120 95 105 
0.5 120 110 125 110 100 100 110 110 120 118 115 105 110 120 110 100 
I 
I 1 .0 110 110 11 0 110 100 90 120 105 110 110 120 105 100 120 110 100 
I 
1 .5 120 105 120 110 95 100 115 115 110 120 120 107 105 125 105 105 ~ 
-> 
2.0 120 110 105 110 100 100 115 110 118 125 120 110 110 120 105 110 *'" 
3.0 120 110 125 105 105 100 115 110 110 125 105 114 110 120 110 120 
4.0 115 105 125 100 90 105 115 100 115 100 120 114 115 120 120 100 
5.0 120 115 122 110 95 100 110 95 110 100 120 106 115 115 105 110 
, 
6.0 120 110 125 110 95 105 11 5 120 100 105 120 113 115 120 120 110 ' 
8.0 110 11 5 125 120 100 110 120 105 110 118 120 105 110 120 120 110 
10.0 120 118 140 11 5 100 110 110 105 120 110 115 109 110 120 110 11 5 
12.0 120 115 125 110 110 120 120 110 110 118 120 119 110 130 110 120 
24.0 115 115 115 105 95 100 120 110 110 105 110 111 110 110 120 110 
30.0 120 115 130 100 100 100 120 11 0 110 118 120 115 110 110 115 11 0 
36.0 130 105 125 110 100 110 120 120 120 110 120 111 115 125 120 115 
Table A2.10. Erect systolic blood pressure in black and white individuals after atenolol 
administration. 
ERECT SYSTOLIC BP AFTER ATENOLOL (mm Hg) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 120 120 120 100 105 100 115 105 118 100 115 110 122 120 110 100 
0.5 125 115 110 105 100 95 115 105 105 105 110 100 120 110 110 95 
1 .0 115 105 105 110 90 100 110 105 100 105 105 100 118 110 95 105 
1 . 5 120 105 115 105 85 105 110 105 105 100 105 85 114 110 100 100 :x>' 
-1 
I 2.0 120 105 110 100 90 100 105 90 105 95 100 90 120 110 100 100 U1 
3.0 125 110 110 105 90 95 115 100 105 100 100 90 116 105 100 100 
4.0 120 110 115 100 85 95 110 95 100 95 105 95 120 105 100 100 
5.0 120 105 105 105 85 105 110 100 100 105 107 90 120 110 100 95 
6.0 120 110 120 105 90 110 110 100 110 90 N/A 105 122 110 110 105 
! 
8.0 118 100 120 105 105 115 100 105 100 100 117 95 118 115 105 100 
10.0 130 120 115 105 105 110 100 105 105 100 117 100 122 120 110 95 
12.0 130 118 140 110 115 120 120 105 110 105 N/A 105 124 120 120 105 
24.0 120 105 120 100 100 110 115 115 110 100 116 100 112 125 120 100 
30.0 130 120 120 95 105 110 120 110 105 95 121 120 120 115 110 105 
36.0 125 110 120 120 105 105 120 115 125 120 122 115 124 120 120 105 
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Table A2. 11. Mean erect systolic blood pressure (mm Hg) 
after placebo and atenolol administration in the black and 
white groups (n=8 in each group). 
ERECT SYSTOLIC BLOOD PRESSURE 
(mm Hg) 
TIME 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 113. 1 11 0.6 112.4 111 .9 
0.5 11 0.6 108.9 112.3 106.9 
1.0 106.9 105.0 109.4 104.8 
1.5 110.0 106.3 11 2 . 1 102.4 
2.0 108.8 102.5 114.8 102.5 
3.0 111 .3 106.3 114.3 102.0 
4.0 106.9 103.8 113.0 102.5 
5.0 108.4 104.4 11 0.1 103.4 
6.0 112.5 108. 1 112.9 107.4 
8.0 11 3 . 1 108.5 114. 1 106.3 
10.0 114.8 111 .3 113.6 108.6 
12.0 116.3 119.8 117. 1 112. 7 
24.0 109.4 11 0.6 110.4 11 0.8 
30.0 111 .9 113.8 113.5 111 .4 
36.0 115.0 115.0 117 . 0 118.9 
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Table A2.12. Area under the curve (AUC) for erect systolic blood 
pressure from 0 to 1 2 hours(mm Hg.hr) for placebo and atenolol 
and the difference between placebo and atenolol. 
Subjects AUC (0-12 hours)(mm Hg.hr) 
Blacks Placebo Atenolol Difference 
MN 1410.00 1471.00 61 .00 
CM 1349.75 1319.25 30.50 
VL 1505.75 1397.50 108.25 
AP 1333.75 1262.50 71 .25 
ZN 1190.00 1161.25 28.75 
DS 1268.75 1280.00 -11 .25 
NM 1380.00 1295.00 85.00 . 
AK 1288.75 1221.25 67.50 
Whites 
NV 1343.00 1253.25 89.75 
HA 1354.25 1191.25 163.00 
BB 1413.75 1092.25 321 .50 
ACA 1318.00 1165.00 153.00 
NF 1330.00 1439.50 -109.50 
JFI 1447.50 1352.50 95.00 
JFO 1350.00 1270.00 80.00 
ACL 1326.25 1197.50 128.75 
Table A2.13. Erect diastolic blood pressure in black and white individuals after placebo 
administration. 
ERECT DIASTOLIC BP AFTER PLACEBO (mm Hg) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 78 80 80 80 65 60 75 75 65 65 80 71 70 60 65 60 
0.5 78 80 65 85 65 70 80 70 80 75 75 67 70 60 70 60 
1 .0 70 80 70 80 60 65 80 75 65 80 75 67 70 70 70 70 
1 . 5 70 70 80 75 50 60 80 75 65 80 70 63 70 65 70 65 
2.0 62 75 60 75 55 60 80 70 75 85 65 67 75 55 70 65 
3.0 70 75 75 70 60 60 80 65 65 85 75 66 80 70 70 70 
4.0 68 75 75 75 60 75 80 70 75 70 75 66 80 70 75 60 
5.0 80 80 80 75 55 60 65 65 70 70 75 63 75 70 70 65 
6.0 80 70 75 70 55 70 70 75 70 70 70 60 70 70 65 60 
8.0 80 80 85 80 65 70 80 80 75 85 70 60 75 60 70 65 
10.0 80 80 80 80 65 80 80 75 75 80 70 67 75 70 70 70 
12.0 80 65 75 80 60 95 80 80 70 80 75 60 80 65 70 65 
24.0 80 75 80 75 60 70 70 75 65 75 70 67 75 70 70 70 
30.0 75 70 65 80 55 65 70 70 70 70 70 60 75 55 70 60 
I 36.0 75 70 75 80 55 75 70 80 70 75 70 54 80 55 75 75 
~ ..... 
CD 
Table A2.14. Erect diastolic blood pressure in black and white individuals after atenolol 
administration. 
ERECT DIASTOLIC BP AFTER ATENOLOL (mm Hg) 
TIME BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 90 90 70 80 65 70 75 70 70 70 75 70 84 65 80 60 
0.5 90 85 65 60 60 70 75 65 75 75 70 70 78 60 80 70 
1 .0 90 80 65 80 50 65 70 65 65 70 65 60 84 60 75 70 
1 .5 85 75 65 75 55 70 80 65 65 80 65 60 80 60 70 70 
2.0 90 70 70 70 55 60 75 65 65 70 65 65 84 55 75 70 
3.0 85 70 60 75 60 65 70 60 75 70 65 60 78 55 75 60 
4.0 90 80 60 65 55 75 80 60 60 70 70 65 82 65 75 65 
5.0 90 80 65 70 55 75 75 60 60 60 72 60 70 60 70 65 
6.0 75 80 75 65 55 75 65 60 65 60 N/A 60 78 65 65 65 
8.0 85 70 75 70 60 70 60 75 70 65 66 60 70 55 70 60 
, 
10.0 95 80 70 70 65 80 60 70 85 65 72 60 72 70 80 55 ! 
12.0 85 50 80 65 70 70 60 70 70 70 N/A 65 76 70 80 60 
24.0 80 70 75 70 55 70 85 80 70 65 59 65 65 70 70 65 
30.0 85 75 75 70 55 60 75 80 75 60 62 75 72 65 75 65 





Table A2.15. Mean erect diastolic blood pressure (mm Hg) 
after placebo and atenolol administration in the black and 
white groups (n=8 in each group). 
ERECT DIASTOLIC BLOOD PRESSURE 
(rom Hg) 
TIME 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 74. 1 76.3 67.0 71 .8 
0.5 74.0 71 .3 69.6 72.3 
1.0 72.5 70.6 70.9 68.6 
1.5 70.0 71 .3 68.5 68.8 
2.0 67.1 69.4 69.6 68.6 
3.0 69.4 68. 1 72.6 67.3 
4.0 72.3 70.6 71 .4 69.0 
5.0 70.0 71 .3 69.8 64.6 
6.0 70.6 68.8 66.9 65.4 
8.0 77.5 70.6 70.0 64.5 
10.0 77.5 73.8 72. 1 69.9 
12.0 76.9 68.8 70.6 70. 1 
24.0 73. 1 73.1 70.3 66.1 
30.0 68.8 71 .9 66.3 68.6 
36.0 72.5 71 .9 69.3 73.5 
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Table A2.16. Area under the curve (AUC) for erect diastolic blood 
pressure from 0 to 12 hours (mm hg.hr) for atenolol and placebo 
and the difference between atenolol and placebo. 
Subjects AUC (0-12 hours)(mm Hg.hr) 
Blacks Placebo Atenolol Difference 
MN 913.00 1045.00 -132.00 
CM 911. 25 895.00 16.25 
VL 920.00 835.00 85.00 
AP 921 .25 832.50 88.75 
ZN 722.50 712.50 10.00 
DS 852.50 862.50 -10.00 
NM 928.75 810.00 118.75 
AK 883.75 793.75 90.00 
Whites 
NV 862.50 841.25 21 .25 
HA 937.50 802.50 135.00 
BB 863.75 683.50 180.25 
ACA 765.50 741.25 24.25 
NF 898.75 912.00 -13.25 
JFI 793.75 745.00 48.75 
JFO 836.25 886.25 -50.00 
ACL 781.25 750.00 31 .25 
Table A2.17. Supine systolic blood pressure in black and white individuals after placebo 
administration. 
SUPINE SYSTOLIC BP AFTER PLACEBO (mm H9) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 140 110 120 100 95 100 110 100 100 105 120 105 110 120 95 105 
0 . 4 120 105 120 105 95 100 120 105 118 110 110 109 100 120 110 110 
0 . 9 120 102 120 110 95 105 115 110 114 105 110 114 95 120 110 105 
1 .4 120 100 120 110 95 95 115 110 110 110 115 106 110 120 105 100 
2.0 118 105 110 110 100 100 115 110 105 110 120 112 110 120 110 110 
3.0 120 105 120 110 100 100 115 100 100 110 115 118 110 120 100 100 
4 . 0 118 100 118 100 95 100 105 100 110 105 115 107 110 115 110 105 
5.0 118 105 120 105 100 90 110 90 100 110 105 109 110 110 105 105 
6.0 120 105 125 120 95 95 110 105 100 90 120 108 115 120 110 110 
8.0 120 110 122 110 95 100 110 105 110 105 110 107 105 120 105 100 
10.0 120 110 130 110 95 105 110 100 110 110 120 112 110 130 105 115 
12.0 120 105 125 110 105 110 120 105 110 110 120 116 110 125 110 105 
24 . 0 120 105 110 105 100 110 110 105 100 100 110 104 105 105 105 110 
30.0 120 105 125 105 90 100 120 105 110 110 115 124 105 110 110 110 




Table A2. 18. Supine systolic blood pressure in black and white individuals after atenolol 
administration. 
SUPINE SYSTOLIC BP AFTER ATENOLOL (mm 8g) 
TIME 
BLACKS WHITES (hours) 
NM CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 120 133 120 105 105 95 110 110 110 115 110 115 122 115 110 105 
0.4 130 120 125 110 100 110 120 110 110 118 105 105 120 110 110 100 
0.9 120 100 120 105 100 100 110 105 100 108 105 100 118 110 100 110 
1 .4 120 105 115 105 85 105 110 95 105 110 110 90 110 105 105 100 
2.0 120 100 110 108 90 100 110 95 100 100 100 90 116 110 100 100 
3.0 125 100 115 110 90 95 110 100 100 100 100 95 112 105 105 100 
4.0 120 100 110 105 90 90 105 95 100 100 99 95 10B 105 95 100 
5.0 120 105 110 105 90 105 120 100 105 100 113 90 10B 115 100 100 
6 . 0 120 105 120 110 90 95 110 105 105 90 115 100 110 115 100 100 
, B.O 115 100 120 105 100 100 110 100 95 95 115 95 10B 115 100 100 
, 
10.0 130 110 120 105 100 95 110 105 95 95 107 105 106 110 100 105 : 
12.0 125 110 130 105 110 100 110 105 110 100 120 100 120 120 100 100 
24.0 120 110 120 105 100 95 105 105 105 95 10B 95 110 115 110 110 
30.0 120 105 125 105 95 100 110 105 100 100 117 110 110 110 110 100 





Table A2.19. Mean supine systolic blood pressure (mm Hg) 
after placebo and atenolol administration in the black and 
white groups (n=8 in each group). 
SUPINE SYSTOLIC BLOOD PRESSURE 
(nun Hg) 
TIME 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 109.4 112.3 107.5 112.8 
0.4 108.8 115.6 110.9 109.8 
0.9 109.6 107.5 109.1 106.4 
1 .4 108. 1 105.0 109.5 104.4 
2.0 108.5 104. 1 11 2 . 1 102.0 
3.0 108.7 105.6 109.1 102. 1 
4.0 104.5 101 .9 109.6 100.3 
5.0 106.9 104.8 106.8 103.9 
6.0 109.4 106.9 109.1 104.4 
8.0 109.0 106.3 107.8 102.9 
10.0 110.0 109.4 114.0 102.9 
12.0 112.5 111. 9 113.3 108.8 
24.0 108. 1 107.5 104.9 106.0 
30.0 108.8 108. 1 111. 8 107 . 1 
36.0 113. 1 111 .9 113.8 115.9 
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Table A2.20. Area under the curve (AUC) for supine systolic blood 
pressure from 0 to 12 hours (mm hg.hr) for placebo and atenolol 
and the difference between placebo and atenolol. 
Subjects AUC (0-12 hours)(mm Hg.hr) 
Blacks Placebo Atenolol Difference 
MN 1438.40 1464.50 -26.10 
CM 1271.75 1260.85 10.90 
VL 1466.50 1416.50 50.00 
AP 1315.75 1277.15 38.60 
ZN 1164.00 1149.75 14.25 
DS 1202.25 1178.75 23.50 
NM 1343.75 1329.50 14.25 
AK 1233.25 1219.75 13.50 
Whites 
NV 1284.60 1211.75 72.85 
HA 1271.50 1185.60 85.90 
BB 1382.75 1310 . 75 72.00 
ACA 1324.95 1171.75 153.20 
NF 1305.50 1331.70 -26.20 
JFI 1450.00 1340.75 109.25 
JFO 1279.25 1203.50 75.75 
ACL 1276.00 1216.00 60.00 
Table A2.21. Supine diastolic blood pressure in black and white individuals after placebo 
administration. 
SUPINE DIASTOLIC BP AFTER PLACEBO (mm H9) 
TIME 
BLACKS WHITES (hours) 
NM CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 90 65 75 65 55 65 65 60 60 65 70 61 65 55 60 65 
0.4 70 65 50 65 50 60 60 60 60 60 60 55 60 60 60 60 
0.9 60 60 80 65 45 60 60 65 68 60 65 50 60 60 65 60 
1 . 4 68 50 70 55 45 60 70 65 58 55 65 55 70 60 55 65 
2.0 58 60 60 60 45 60 70 60 55 70 60 52 65 60 60 55 
3.0 58 60 65 60 50 60 70 55 60 75 65 55 65 60 55 60 
4.0 58 60 75 60 50 60 60 60 70 55 65 50 65 60 55 60 
5.0 58 70 65 
I 
65 45 60 60 55 60 55 65 55 65 70 65 55 
6.0 70 70 65 70 50 55 60 65 55 55 60 50 65 55 60 65 
8.0 70 70 70 70 50 60 60 65 55 60 60 50 65 60 60 60 
10.0 65 70 70 75 55 65 65 60 60 70 70 55 70 70 65 60 
12.0 70 55 65 70 55 60 60 65 60 65 70 55 70 70 70 60 
24.0 60 60 60 65 50 70 60 65 55 60 70 55 60 65 70 60 
30 . 0 60 65 65 65 50 60 60 65 55 60 55 50 65 60 60 60 




Table A2. 22. Supine diastolic blood pressure in black and white individuals after atenolol 
administration. 
SUPINE DIASTOLIC BP AFTER ATENOLOL (mm H9) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN DS NM AK NV HA BB ACA NF JFI JFO ACL 
0.0 75 65 60 70 50 60 65 60 60 60 75 70 76 70 65 60 
0.4 75 70 45 55 45 60 65 65 55 55 65 55 65 60 65 60 
0.9 75 70 55 75 40 60 65 55 50 60 60 55 68 60 65 60 
1 .4 70 60 55 70 40 65 70 60 55 65 60 50 68 65 65 60 
2.0 80 60 60 65 45 60 75 60 50 60 60 55 70 60 65 60 
3.0 75 60 55 65 45 60 60 60 60 55 60 50 64 55 60 55 
4 . 0 75 60 55 60 45 60 65 55 60 60 54 55 64 60 60 55 
5.0 75 70 60 65 40 65 70 55 55 55 66 50 64 70 60 55 
6.0 70 70 55 65 40 55 55 60 50 50 50 50 66 60 50 60 
8.0 75 58 55 65 50 60 60 55 60 50 57 50 62 60 55 60 
10 . 0 80 70 60 55 55 60 70 65 65 50 65 55 66 60 65 60 
12.0 75 70 65 60 60 60 60 65 55 55 57 60 70 60 60 60 
24.0 70 60 60 60 45 60 60 60 55 50 55 55 62 60 55 60 
30.0 75 70 55 60 45 60 65 60 50 50 52 55 60 55 60 60 





Table A2.23. Mean supine diastolic blood pressure (mm Hg) 
after placebo and atenolol administration in the black and 
white groups (n=8 in each group). 
SUPINE DIASTOLIC BLOOD PRESSURE 
(mm H9) 
TIME 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 67.5 63.1 62.6 67.0 
0.4 60.0 60.0 59.4 60.0 
0.9 61. 9 61.9 61 .0 59.8 
1 .4 60.4 61 .3 60.4 61 .0 
2.0 59.1 63.1 59.6 60.0 
3.0 59.8 60.0 61 .9 57.4 
4.0 60.4 59.4 60.0 58.5 
5.0 62.5 59.8 61 .3 59.4 
6.0 63.1 58.8 58. 1 54.5 
8.0 64.4 59.8 58.8 56.8 
10.0 65.6 64.4 65.0 60.8 
12.0 62.5 64.4 65.0 59.6 
24.0 61 .3 59.4 61 .9 56.5 
30.0 61.3 61.3 58. 1 55.3 
36.0 62.5 63.1 60.6 61 .4 
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Table A2.24. Area under the curve (AUC) for supine diastolic 
blood pressure from 0 to 12 hours (mm hg.hr) for placebo and 
atenolol and the difference between placebo and atenolol. 
Subjects AUC (0-12 hours)(mm Hg.hr) 
Blacks Placebo Atenolol Difference 
MN 782.30 903.75 -121.45 
CM 777.75 781 .50 -4.00 
VL 811. 50 685.50 126.00 
AP 803.00 754.25 48.50 
ZN 601.75 568.25 33.50 
DS 723.50 720.25 3.25 
NM 754.50 770.75 -16.25 
AK 743.25 714.75 28.50 
Whites 
NY 711 .40 687.00 24.40 
HA 748.75 650.50 98.25 
BB 772.25 711 .25 61 .00 
ACA 633.80 637.75 -3.95 
NF 793.00 788.85 4.15 
JFI 751.50 729.75 21 .75 
JFO 734.75 717.50 17.25 
ACL 722.25 705.00 17.25 
Table A2.25. Plasma renin activity in black and white individuals after placebo administration. 
TIME PLASMA RENIN ACTIVITY AFTER PLACEBO (ng/ml/hr) 
(hours) 
BLACKS WHITES 
MN CM VL AP ZN NV HA BB ACA NF 
0.0 O. 11 3.23 0.70 3.91 2.56 7.03 3.48 5.01 6.62 2.28 
O. 1 0.84 2.68 1 .04 2.31 1 .55 4.98 4.48 4.23 8.21 1 .92 
0.2 0.67 3.45 0.95 1 .89 4.30 4.82 6.54 5.17 10.26 2.64 
0.3 4.37 6.90 0.57 2.81 3.55 3.57 8.46 5.28 10.33 2.48 
0.5 1 .09 5.44 0.99 2.50 3.01 5.91 3.10 7.35 10.51 1 .83 
0.8 1 .07 3.81 0.62 2. 14 3.37 4.68 3.46 7.43 10.61 2.22 
1 . 0 3.06 4.27 0.51 1 . 77 2.77 3.42 3.64 4.43 7.92 1 .66 
1 .5 1 .72 2.74 0.60 3.05 3.12 4.62 4.58 5.10 11 .06 1 .65 
2.0 0.65 3.10 0.56 3.84 3.86 3.23 2.67 5.83 10.08 2.27 
3.0 0.77 2.18 0.79 1 .98 2.86 2.62 2.49 4.72 5.47 1 .75 
4.0 0.78 2.23 0.37 1 .42 4.80 1 .89 2.43 4.01 5.40 1 . 71 
5.0 0.95 2.39 0.83 1 .04 2.21 2.69 6.17 4.64 3.24 1 .31 
6.0 0.56 5.05 0.80 7.82 4.07 2.87 4.17 4.36 3.72 1 .72 
8.0 0.87 2.42 0.51 0.66 1 .90 1 . 77 5.58 2.07 3.95 1 .13 
10.0 0.91 N/A 0.59 4.88 1 .91 1 .83 2.04 1 .72 4.37 5.60 
12.0 0.64 2.48 0.23 0.60 1 .67 1 .99 3.76 1 .72 5.76 0.78 
24.0 0.36 N/A 0.78 1 .40 2.29 3.13 2.08 2.57 2.70 1 .90 




Table A2.26. Plasma renin activity in black and white individuals after atenolol administration. 
PLASMA RENIN ACTIVITY AFTER ATENOLOL (ng/ml/hr) 
TIME 
BLACKS WHITES (hours) 
MN CM VL AP ZN NV HA BB ACA NF 
0.0 0.27 1 .80 8.45 2.67 3.31 5.87 1 .36 2.73 5.00 1 .70 
o . 1 0 . 76 2 . 25 7 . 75 1 . 10 2 . 30 3.28 2.72 3.92 4.03 2.35 
0.2 0.14 1 .52 0.99 2.48 2.57 2.54 1 .14 1 .63 5.11 4.62 
0.3 N/A 1 .68 1 .07 1 .70 5.91 3.09 2.27 1 .42 4.87 1 .26 
0.5 0.59 0.85 3.27 3.68 2.33 N/A 2.51 1 .87 4.47 4.77 
0.8 0.35 3.15 0.78 4.97 3.58 2.98 1 .17 1 .32 2.94 1 .16 
1 . 0 0.39 2.04 0.66 1 .95 4.81 2.45 1 .43 1 .13 2.93 4. 18 
1 . 5 7.43 0.73 2.01 2.81 1 .83 1 .53 0.84 4.43 1 .41 4.03 
2.0 0.52 0.65 1 .94 4.71 1 .75 3.03 2.46 5.04 2.45 1 .90 
3.0 1 .28 1 .48 1 .27 3.22 3.02 9.56 2.23 4.80 1 .92 1 .79, 
4.0 0.56 0.84 0.64 4.33 1 .40 1 .93 0.93 0.80 1 .60 3.66 
5.0 2.92 1 .17 0.87 0.86 1 .81 1 .08 2.10 6. 11 1 .09 3.44 
6.0 2.16 1 .34 0.53 1 .17 1 .66 1 .13 2.20 0.54 0.89 2.22 
8.0 1 .53 1 .17 1 .57 1 .05 0.88 1 .20 2.08 0.68 0.31 2.72 
10.0 1 .61 2.18 0.51 1 .29 0.59 2.62 4.76 1 . 51 1 . 71 2.38 
12.0 0.43 1 .75 0.72 5.81 0.65 0.82 1 .60 4.34 0.46 0.68 
24.0 N/A 1 .40 0.73 1 .22 2.23 1 .54 1 .75 3.44 2.23 0.85 





Table A2.27. Mean plasma renin activity (ng/ml/hr) after 
placebo and atenolol administration in the black and white 
groups (n=5 in each group). 
PLASMA RENIN ACTIVITY 
(ng/ml/hr) 
TIME 
(hours) BLACKS WHITES 
Placebo Atenolol Placebo Atenolol 
0.0 2. 1 3.3 4.9 3.3 
0.1 1 . 7 2.9 4.8 3.3 
0.2 2.3 1 .5 5.9 3.0 
0.3 3.7 2.6# 6.0 2.6 
0.5 2.6 2.2 5.7 3.4# 
0.8 2.2 2.6 5.7 1.9 
1 .0 2.5 2.0 4.2 2.4 
1 .5 2.2 2.9 5.4 2.4 
2.0 2.4 1 .9 4.8 3.0 
3.0 1 . 7 2. 1 3.4 4.1 
4.0 1.9 1 .5 3. 1 1 .8 
5.0 1 .5 1 .5 3.6 2.8 
6.0 3.7 1.4 3.4 1 .4 
8.0 1 .3 1 .3 2.9 1 .4 
10.0 2.1# 1 .2 3. 1 2.8# 
12.0 1 . 1 1 .9 2.8 1 .6 
24.0 1. 2# 1 .4# 2.4 2.0 
30.0 2.6# 2.3# 2.0# 2.3# 
# Missing values 
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Table A2.28. Area under the curve (AUC) from 0 to 12 hours for 
PRA (ng Ang./ml) after placebo and atenolol and the difference 
in AUC between placebo and atenolol. 
Subjects AUC (0-12 Hours) (ng Ang./ml) 
Blacks Placebo Atenolol Difference 
MN 11 .31 19.33 -8.02 
CM 35.91 17.24 18.67 
VL 7.24 13.62 -6.38 
AP 34.80 29.18 5.62 
ZN 33.53 19.24 14.29 
Whites 
NV 31 . 14 29 . 47 1 .67 
HA 46.10 28.32 17.78 
BB 43.36 29.33 14.03 
ACA 66.96 17.76 '"49.20 
NF 26.65 30.46 -3.81 
A34 
Table A2.29. Individual maximum changes (Emax) in heart rate and 
the time to maximum effects (T ) for atenolol. max 
I I 
Resting Heart Rate Exercise Heart Rate 
Emax (bpm) Tmax (hr) Emax (bpm) Tmax (hr) 
BLACKS 
MN 26 3 . 0 39 0.5 
CM 10 4.0 44 0.2 
VL 5 1 . 5 40 0.4 
AP 18 3.0 30 0.4 
ZN 1 1 4.0 38 0.2 
DS 23 4.0 42 0.5 
NM 1 1 2.0 36 0.5 
AK 14 2.0 26 0.4 
WHITES 
NV 22 3.0 41 0.2 
HA 20 2.0 27 0.2 
BB 20 3.0 37 0.2 
ACA 16 5.0 40 0.5 
NF 23 2.0 48 0.5 
JFI 1 1 1 .5 29 0.2 
JFO 29 6.0 31 0.2 
ACL 18 3.0 32 0.2 
Table A2. 30. Individual maximum BP changes (Emax) (mm Hg) and time 
to maximum (Tm~) (hours) effects after atenolol. 
ERECT BP SUPINE BP 
Systolic Diastolic Systolic Diastolic 
Emax Tmax Emax Tmax Emax Tmax Emax Tmax 
BLACKS 
MN 0 - 5 6.0 5 8.0 0 -
CM 15 8.0 15 12.0 10 8.0 12 8.0 
VL 17 5.0 15 4.0 10 5.0 20 4.0 
AP 15 8.0 15 12.0 10 6.0 20 10 . 0 
ZN 15 3.0 5 8.0 10 1 .4 10 6.0 
DS 10 4.0 25 12.0 10 4.0 10 24.0 
NM 20 8.0 20 8.0 10 12 . 0 10 3.0 
AK 20 2.0 15 6.0 15 1 .4 10 8.0 
WHITES 
NV 15 10.0 15 4.0 15 0.9 18 0.9 
HA 30 2.0 20 8.0 15 10.0 20 3.0 
BB 20 2.0 10 3.0 20 2.0 15 4.0 
ACA 24 3.0 7 10 . 0 23 3.0 5 5.0 
NF 0 - 10 24.0 5 6.0 4 10.0 
JFI 15 1 .5 15 3 . 0 20 10.0 10 10.0 
JFO 20 4.0 0 - 15 4.0 15 24.0 
ACL 20 3.0 15 10.0 10 6.0 5 4.0 
Aa34 
Table A2.31. Twenty four hour urinary elimination of sodium and 
potassium in black and white subjects after placebo and atenolol 
administration. 
SUBJECTS 24 HOUR URINARY EXCRETION (mEq) 
Placebo Atenolol 
Sodium Potassium Sodium Potassium 
BLACKS 
MN 87* 20* - -
CM - - - -
VL 381 74 381 46 
AP 318 39 442 83 
ZN 254 30 383 37 
DS 233 51 289 55 
NM 366 66 360 54 
AK 250 58 350 43 
Mean 300 53 368 53 
Median 286 55 371 50 
SD 64 17 50 16 
CV (%) 21 32 14 30 
WHITES 
NV - - - -
HA 251 72 326 68 
BB 116 31 287 85 
ACA 114 83 192 50 
NF 265 42 470 67 
JFI 229 49 327 89 
JFO 436 117 - -
ACL 401 120 370 146 
Mean 259 73 329 84 
Median 251 72 327 77 
SD 125 36 92 33 
cv (%) 48 49 28 39 
B vs W 
p< 0.4799 0.2234 0.3841 0.0666 
ALL 
Mean 278 64 348 69 
Median 254 58 355 61 
SD 100 29 73 30 
cv (%) 36 45 21 43 
At vs PI 
p< 0 . 0593 0.7018 




Resting HR (bests/minute) 
100rl----~--~----~--~----------------------------_, 




501-····· .. ····_···'c-·-··i .......... -.......... \ ::" ... ,,::: .................................................................... . 
40'~----~--~----~--~----~--~----~----L---~ 
o 4 8 12 16 20 24 
Time (hours) 
Atenolol -+- Placebo 
VL 
28 32 36 
Resting HR (beats/minute) 
100rl--~--~------~--------------------------~ 
90 .... --.--.-... -.-.--._-_ ... -_.-.... --.. --... -.-.---.. --.............. _-...... _.-._-... - .. - ... -.... -.-........... -.-...... - .. 




50 J----... __ .--_ .. _ .... -........................ --....... _ .. -.-._ .... -....... _-... - .. _ ..... -.---... --.-.............. --............... ················ .. ···--.. ·· .. · .. ····· .. ··1 
40~1----~--~----~--~----~----L----L----~--~ 
o 4 8 12 16 20 24 
Time (hours) 
-.-- Atenolol -+- Placebo 
28 32 36 
eM 
Resting HR (beats/minute) 
100rl--~---------------------------------------' 
90 1-... - .... ""_._-" ". 
40'k-----L-----~----~-----L----~----~------L-----~--~ 
o 4 8 12 16 20 24 28 32 36 
Time (hours) , 
Atenolol -+- Placebo 
AP 
Resting HR (beats/minute) 
100., --~~~--------~-----------------------------, 
90 ... --.--.-.-.. -.--.. - ......... - ... -.-.--.-.-..... -._.--.-.. - .. -... - ........ --.... - .----..... - ... - ... - .......... -... ---.-.- .. -_. 
\ .. -.-...... -..... -................ ~:::::::::c.""'"-_o,-,,::-:::::::::::~.-"""::~:::::::::::::::~=::.:::::""--. 
40LI ____ J-____ ~ ____ L-____ L-__ ~ ____ ~ ____ -L ____ -L __ ~ 
o 4 8 12 16 20 24 28 32 36 
Time (hours) 
-_ .•... - Atenolol -+- Placebo 










:: l=-~-'~-=:O ..... ~ -.........==-----::"= i 6) · \V~ •••• ~. ••••••••••••••••• .. ••••••••• •••••••• H 
50 
40 40 
0 4 8 12 16 20 24 28 32 36 0 4 8 12 16 20 24 26 32 36 
Time (hours) Time (hours) 





RestIng HR (beats/minute) Resting HR (beats/minuteO 
100, 100fT' 
90 k1-- ----- - •••••••••••••••••••••••••• H •• H ••• __ •••••••• H· ••••••• H •••••• 90 '! 
80 .- - . -.... .. .-. . - - .............. -.... -........ ••••••••••••••••••• H •• H. __ 80 
I ~ .. 





0 4 8 12 16 20 24 28 32 36 0 4 8 12 16 20 24 26 32 36 
Time (hours) Time (hours) 
- •.. - Atenolol ---t- Placebo . Atenolol ---t- Placebo 
Fig A2.2. Resting heart rates in black individuals. 
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Appendix to Chapter 5 
Table A3.1. Atenolol plasma concentration (ng/ml) versus time (hours after start of infusion) data 
for black volunteers. 
MN CM VL AP 
Time Cone Time Cone Time Cone Time Cone 
hrs ng/ml hrs ng/ml hrs ng/ml hrs ng/ml 
0.00 0 0.00 0 0.00 0 0.00 0 
0.17 1337 0.20 1209 0.20 1429 0.21 1126 
0.26 1055 0.25 1078 0.25 1179 0.27 946 
0.32 783 0.32 878 0.34 867 0.37 737 
0.37 698 0.41 725 0.41 683 0.43 604 
0.50 618 0.70 446 0.63 N/A 0.74 472 
0.89 418 0.89 482 0.90 436 0.89 390 
1 . 11 369 1 .16 363 1 .16 370 1 .14 355 
1 .64 314 1 .70 298 1 .67 300 1 .74 285 
2. 11 302 2.14 270 2.17 260 2.24 225 
3. 11 193 3.02 227 3.17 214 3.34 199 
4.21 154 4.04 196 4.14 N/A 4.14 166 
5.29 146 5.14 176 5.14 N/A 5.14 155 
6.07 113 6.12 157 6.17 114 6.24 N/A 
8.16 81 8.06 124 8.17 105 7.94 128 
10.2 N/A 10.2 103 10.2 50 10.0 64 
12.0 47 12. 1 88 1 2 . 0 41 11 . 7 68 
23.4 20 23.6 17 24.0 N/A 24.0 N/A 
29.0 14 28.6 12 30.0 <10 30.0 20 
36.0 < 10 36.0 <10 36.0 <10 36.0 16 
N/A No sample. 
<10 less than 10 ng/ml, below assay sensitivity. 
ZN 
Time Cone Time 
hrs ng/ml hrs 
0.00 0 0.00 
O. 18 1519 O. 19 
0.22 1487 0.23 
0.32 1001 0.33 
0.39 849 0.40 
0.64 661 0.65 
0.99 424 0.88 
1 .24 448 1 .20 
1 .64 398 1 .85 
2.24 338 2.23 
3.14 258 3.15 
4.09 N/A 4.15 
5. 14 156 5.10 
6. 14 136 6.25 
8.14 96 8.20 
10.0 64 10.2 
12. 1 64 11 .9 
25.0 N/A 25.7 
31 .0 22 29. 1 












486 1 .14 








92 12. 1 
N/A 25.4 




























Table A3.2. Atenolol plasma concentration (ng/ml) versus time (hours after start of infusion) data 
for white volunteers. 
--
NV BB ACA NF 
Time Cone Time Cone Time Cone Time Cone 
hrs ng/ml hrs ng/ml hrs ng/ml hrs ng/ml 
0.00 0 0.00 0 0.00 0 0.00 0 
0.18 1335 0.16 1139 0.16 1071 0.20 976 
0.23 1037 0.20 1100 0.23 996 0.26 784 
0.30 802 0.32 858 0.31 935 0.29 625 
0.39 686 0.42 718 0.38 840 0.39 571 
0.64 443 0.62 599 0.62 524 0.62 446 
0.88 408 0.89 522 0.91 495 0.81 330 
1 .10 357 1 .12 465 1 .13 399 1 .14 272 
1 .68 293 1 .62 401 1 .73 345 1 .64 263 
2.12 235 2.12 371 2.13 283 2.36 234 
3. 11 170 3.12 247 3.23 245 3.14 191 
4.46 161 4.22 241 4.23 243 4.24 153 
5.15 142 5.12 207 5.33 209 5.24 118 
6. 11 143 6.12 164 6.23 166 6.14 90 
8.08 97 8.22 124 8.13 136 8.14 77 
10.4 75 10.2 92 10. 1 64 10. 1 60 
12.4 N/A 12. 1 68 12.0 62 12.2 40 
24. 1 14 23.7 10 24.1 46 24.4 <10 
30.0 N/A 30.0 <10 29.8 N/A 30.3 <10 
36.0 12 36.2 <10 36.0 < 1 0 36.0 < 10 
N/A No sample. 
<10 less than 10 ng/ml, below assay sensitivity. 
JFI JFO 
Time Cone Time Cone 
hrs ng/ml hrs ng/m 
0.00 0 0.00 0 
0.18 956 O. 18 980 
0.23 N/A 0.25 831 
0.31 704 0.37 810 
0.39 662 0.40 751 
0.66 440 0.62 N/A 
0.90 318 0.89 N/A 
1 .23 294 1 .14 405 
1 .63 261 1 .69 338 
2.13 185 2.14 249 
3.23 169 3.14 222 
4.23 172 4. 14 207 
5.33 130 5.24 137 
6. 13 120 6.14 131 
8.13 81 8.14 123 
10.2 67 10.0 54 
11 .8 52 11 .9 N/A 
25.2 14 25.2 12 
30.4 1 1 30.0 <10 










1 .07 N/A 
1 .34 363 








11 .8 37 
25.1 <10 
30.0 < 10 




Table A3.3. Intermediate model independent pharmacokinetic parameters for blacks and whites. 
Cn tn ).. (r2) AUCO_tn AUCo_ .. AUMCO_tn AUMCo_ .. MRTINF MRT1V 
(ug/L) (hr) (hr-1 ) (ug/L.hr) (ug/L.hr) 
Blacks 
MN 1 4 29.0 0.097(.968) 2640 2784 15572 21246 7.63 7.56 
CM 12 28.6 0.119(.994) 3169 3270 20396 24127 7.38 7.31 
VL 41 12.0 0.196(.910) 2231 2440 7410 10987 4.50 4.43 
AP 1 6 36 . 0 0.073(.949) 3108 3327 24949 35841 10.77 10.70 
ZN 10 36.0 0.078(.955) 3054 3182 25049 31308 9.84 9.74 
DS 92 11 .9 0.121(.842) 2947 3707 10334 25666 6.92 6.85 
NM 20 30 . 6 0.080( . 973) 2794 3044 20613 31388 10.31 10.24 
Whites 
NV 1 2 36.0 0.090( . 934) 2808 2941 19075 25356 8.62 8.55 
BB 1 0 23.7 0.162(.999) 3168 3230 16637 18481 5.72 5.65 
ACA 46 24.1 0.084(.729) 3264 3812 21022 40739 10.68 10.61 
NF 40 12.2 0.155(.971) 1824 2082 6634 11447 5.50 5.43 
JFI 11 30.4 0 . 103(.977) 2400 2507 15261 19545 7.80 7.73 
JFO 12 25.2 0.129(.956) 2718 2811 13468 16533 5.88 5.81 





Fig A 3.1a. MN: Plasma concentration-
time plot. 
Concentration of atenolol (ng/ml) 
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Fig A3.1b. MN: Log Plasma 
concentration-time plot. 
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Fig A3.2a. CM: Plasma concentration-
time plot. 
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concentration-time plot. 
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Fig A3.3a. VL: Plasma concentration-
time plot. 
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Fig A3.3b. VL: Log Plasma 
concentration-time plot. 
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Fig A3.4a. AP: Plasma concentration-
time plot. 
Concentration of atenolol (ng/ml) 
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Fig A3.4b. AP: Log Plasma 
concentration-time plot. 
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Fig A3.5a. ZN: Plasma concentration-
time plot. 
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3 Compartment Model 
Fig A3.5b. ZN: Log Plasma 
concentration-time plot. 
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Fig A3.6a. DS: Plasma concentration-
time plot. 
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2 Compartment Model 
Fig A3.6b. DS: Log Plasma 
concentration-time plot. 
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Fig A3.7a. NM: Plasma concentration-
time plot. 
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1600~---------------------------------------' 
1400 ...... _ .... _ ............... T ..... Measured .. Values ............ ::::::=: .. .T.heoreUcaL.CUI.lIe .. _ .... -.. -.-.-.-.. -....... . 
1200 
1000 
__________ • _____ • ______ • ___ • ___ H ______ • ____ • ___ • ___ ••• H ••• _. _________ •• ____ ·_· __ 
800 





o 4 8 12 16 20 24 28 32 36 
Time (Hours after start of infusion) 
3 Compartment 
Fig A3.7b. NM: Log Plasma 
concentration-time plot. 
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Fig A3.8a. NV: Plasma concentration-
time plot. 
Concentration of atenolol (ng/ml) 
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Fig A3.8b. NV: Log Plasma 
concentration-time plot. 
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Fig A3.9a. BB: Plasma concentration-
time plot. 
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Fig A3.9a. BB: Log Plasma 
concentration-time plot. 
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Fig A3.10a. ACA: Plasma concentration-
time plot. 
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Fig A3.10b. ACA: Log Plasma 
concentration time plot. 
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Fig A3.11a. NF: Plasma concentration-
time plot. 
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Fig A3.11b. NF: Log Plasma 
concentration time plot. 
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Fig A3.12a. JFI: Plasma concentration-
time plot. 
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Fig A3.12b. JFI: Log Plasma 
concentration-time plot. 
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Fig A3.13a. JFO: Plasma concentration-
time plot. 
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Fig A3.13b. JFO: Log Plasma 
concentration time plot. 
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Fig A3.14a . . ACL: Plasma concentration-
time plot. 
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APPENDIX 4 
Appendix to Chapter 6 
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Table A4.1. ELS estimation of parameter (S) and standard error 
of the estimate (SEE) for the linear effect model for each 
individual together with MOF and random deviation in the effect 




PARAMETER MOF °e 
S (SEE) (cv %) 
MN (B) 0.122 (0.02) 195.4 63 
CM (B) 0.349 (0.10) 254.5 138 
VL (B) Terminated with rounding errors 
AP (B) 0.150 (0.03) 225.2 109 
ZN (B) 0.112 (0.01 ) 222.7 56 
DS (B) 0.128 (0.03) 269.2 52 
NM (B) 0.184 (0.03) 226.8 69 
NV (w) 0.232 (0.04) 230.6 88 
BB (w) 0.843 (0.30) 295.0 197 
ACA (W) 0.126 (0.02) 221 .3 68 
NF (W) 1 .25 (0.50) 293.6 195 
JFI (W) 0.096 (0.01) 184.2 64 
JFO ( W) 0.267 (0.30) 311 .2 109 
ACL (W) 0.593 (0.40) 269.4 169 
Table A4.2. Individuals ELS parameter estimates (S and I) for the log-linear model with (SEE), 













JFI ( W) 
JFO (W) 
ACL (W) 
PARAMETER MOF °e 
S (SEE) I (SEE) 
(CV %) 
Terminated with rounding errors dominating. 
14.0 (0.83) -1 .60 (1.17) 181 .2 20 
10.8 (0.41) 3.09 (0.16) 156.2 15 
10.9 (2.1) -0.95 ( 3 . 5 ) 185.9 35 
Terminated with rounding errors dominating 
Terminated with rounding errors dominating 
18.0 (1.23) -10.4 (1 .50) 178.0 20 
Terminated with rounding errors. 
11 .2 (0.50) 6.26 (0.53) 170.5 15 
Terminated with rounding errors. 
12.3 (0.87) 7.39 (0.49) 187.9 24 
Terminated with rounding errors. 
Terminated with rounding errors. 













Table A4. 3. ELS parameter estimates with standard error or the estimate (SEE) for the Emax 






MN (B) 37.4 (3.6) 124.0 (38.2) 
CM (B) 34.7 (2.0) 18.9 (5.1) 
VL (B) 24.8 (3.4) 2.2 (4.5) 
AP (B) 28.4 (3.1) 27.4 (5.7) 
ZN (B) 50.3 (7.8) 234 (92.1) 
DS (B) 30.8 (3.6) 47.4 (17.8) 
NM (B) 36.2 (2.7) 61.6 (8.9) 
NV (W) 35.5 (2.5) 45.6 (13.1) 
BB (W) 34.3 (2.5) 5.4 (3.0) 
ACA (W) 35.5 (2.2) 86.0 (23.6) 
NF (W) 36.7 (3.5) 4.7 (2.8) 
JFI (W) 42.7 (8.3) 252 (121) 
JFO (w) 36.9 (1.8) 30.8 (3.0) 





































Table A4.4. ELS parameter estimates (E , ICso ' n) together with standard errors of the estimates 
(SEE) for Sigmoid E model with MOF, CV(%) for the random deviation of the measured from predicted 
m~x 
effect and correlat1on. 
SUBJECTS PARAMETERS (SEE) MOF o£ CORRELATION 
Emax ICso Slope 
(CV %) 
Emax & Emax & ICso & 
(bpm) (ng/ml) n ICso n n 
MN(B) 52.1 (11.8) 300* (150) 0.722 (0.15) 175.8 32 0.979 -0.837 -0.839 
CM(B) 70.0* (37.3) 319 (679) 0.495 (0.17) 177. 1 17 0.997 -0.954 -0.962 
VL(B) 67.6 (13.3) 1000*(422) 0.340 (0.40) 189.5 42 0.880 0.495 0.251 
AP(B) 36.8 (7.7) 59.9 (48.2) 0.566 (0.18) 185.8 35 0.927 -0.731 -0.786 
ZN(B) 34.9 ( 2 .5 ) 95.4 (9.3) 1.86 (0.15) 195.8 30 0.461 -0.614 -0.627 
DS(B) 70.0* (19.9) 902 (887) 0.552 (0.08) 224.8 50 0.933 -0.664 -0.686 
NM(B) 34.4 (4.1) 53.6 (18.5) 1.10 (0.22) 179.0 19 0.932 -0.834 -0.954 
NV(W) 41.2 (8.3) 71.7 (3.6) 0.807 (0.23) 193.0 9 0.937 -0.932 -0.896 
BB(W) 45.4 (16.9) 30.1 (65.3) 0.500 (0.22) 172. 1 16 0.997 -0.986 -0.990 
ACA(W) 49.7 (28.3) 225 (392) 0.598 (0.37) . 201 .1 
, 
38 0.995 -0.992 -0.987 I 
NF 70.0* (17.1) 157 (17.1) 0.444 (0.04) 182.9 21 0.972 -0.891 -0.952 
JFI 61 . 1 ( 3 . 2 ) 488 (112) 5.00* ( 111) 137.3 50 1 .000 -1.000 -1.000 
JFO 38.3 (3.2) 34.8 (6.5) 0.918 (0.11) 251 .2 75 0.662 -0.866 -0.851 
ACL 46.3 (8.4) 1000* (252) 0.392 (0.01) 157.0 51 0.782 -0.920 -0.728 
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